{
  "letters": 1028487,
  "pages": 306,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Senti Biosciences, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 19,
          "title": "SENTI-202 Preclinical Data",
          "data": [
            {
              "key": "In vitro cell killing",
              "value": "SENTI-202 CAR-NK cells exhibited increased and more consistent cell killing across a variety of primary patient AML or MDS blasts, or AML leukemia stem cells."
            },
            {
              "key": "Xenogenic tumor model findings",
              "value": "In a luciferase tagged MV4-11 AML xenogenic tumor model in immunocompromised mice, decreased bioluminescence indicated a reduction in AML tumor burden and increased survival when treated with SENTI-202."
            },
            {
              "key": "Probability of Survival vs Days Post Tumor Implantation",
              "value": "The chart displays median survival days for various treatments, demonstrating superior survival rates for SENTI-202 CAR-NK Cells compared to other treatments."
            },
            {
              "key": "Vehicle median survival days",
              "value": "49"
            },
            {
              "key": "Unengineered NK Cells median survival days",
              "value": "55"
            },
            {
              "key": "SENTI-202 CAR-NK Cells median survival days",
              "value": "81.5"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 35,
          "title": "NCI FLT3 Agreement and CD33 Technology License Agreement Summary",
          "data": [
            {
              "key": "License Issue Fee",
              "value": "$75,000"
            },
            {
              "key": "Annual Royalty Fee",
              "value": "low five digits"
            },
            {
              "key": "Milestone Payments",
              "value": "up to $4.6 million"
            },
            {
              "key": "Tiered Royalty Percentage",
              "value": "low single digits to low double digits"
            },
            {
              "key": "Expiration Year of Patent Rights",
              "value": "2037"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 39,
          "title": "Exclusive Patent License Agreement with the National Cancer Institute for GPC3 Technology",
          "data": [
            {
              "key": "Agreement Date",
              "value": "February 2021"
            },
            {
              "key": "License Type",
              "value": "Exclusive, royalty-bearing, sublicensable"
            },
            {
              "key": "Licensee",
              "value": "U.S. Department of Health and Human Services as represented by the NCI"
            },
            {
              "key": "Technology Covered",
              "value": "Glypican-3 targeting CAR technology"
            },
            {
              "key": "Expiration",
              "value": "2033"
            },
            {
              "key": "Termination Notice Period",
              "value": "60 days"
            },
            {
              "key": "Government Rights",
              "value": "Irrevocable, non-exclusive, nontransferable, royalty-free license"
            },
            {
              "key": "NCI Reserved Rights",
              "value": "Grant a non-exclusive license for internal research"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 55,
          "title": "Merger and Corporate Information",
          "data": [
            {
              "key": "Merger Date",
              "value": "June 8, 2022"
            },
            {
              "key": "Acquirer",
              "value": "Dynamics Special Purpose Corp. (DYNS)"
            },
            {
              "key": "Target Company",
              "value": "Senti Sub I, Inc. (formerly Senti Biosciences, Inc.) and Explore Merger Sub, Inc."
            },
            {
              "key": "Approval Date",
              "value": "June 7, 2022"
            },
            {
              "key": "Post-Merger Name Change",
              "value": "DYNS changed its name to Senti Biosciences"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 121,
          "title": "Table of Contents - Announcements and Risk Factors",
          "data": [
            {
              "key": "acquisitions_announcements",
              "value": "Significant acquisitions, strategic alliances, joint ventures, or capital commitments announced by us or competitors"
            },
            {
              "key": "patents_and_litigation",
              "value": "Developments or disputes concerning patents, proprietary rights, and related litigation matters"
            },
            {
              "key": "capital_raising",
              "value": "Our ability or inability to raise additional capital and the terms associated with such efforts"
            },
            {
              "key": "leadership_changes",
              "value": "Recruitment or departure of key personnel"
            },
            {
              "key": "earnings_guidance",
              "value": "Actual or anticipated changes in earnings estimates and changes in stock market analyst recommendations"
            },
            {
              "key": "market_conditions",
              "value": "Fluctuations in valuation, additional financing efforts, and extreme market volatility, including SPAC post-Merger contexts"
            },
            {
              "key": "litigation_risk",
              "value": "Potential for securities class action litigation following periods of market volatility"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 130,
          "title": "Table of Contents – Market Information and Merger Details",
          "data": [
            {
              "key": "Common Stock Listing",
              "value": "Currently listed on The Nasdaq Global Market under the symbol 'SNTI'. Prior to consummation of the Merger, it was listed under the symbol 'DYNS'."
            },
            {
              "key": "Record Holders",
              "value": "153 holders of record as of March 15, 2023 (does not include 'street name' or beneficial holders)."
            },
            {
              "key": "Dividend Policy",
              "value": "No cash dividends have been paid to date. Future payments will depend on revenues, earnings, capital requirements, and other financial conditions, and are subject to Board discretion and any restrictive covenants."
            },
            {
              "key": "Recent Equity Sale",
              "value": "Issued and sold 300,000 shares of common stock to Chardan at a weighted average price of $2.35 per share during the three months ended December 31, 2022, with net proceeds used for general corporate purposes."
            },
            {
              "key": "Merger Details",
              "value": "Senti Biosciences, Inc. entered into a business combination agreement with Dynamics Special Purpose Corp on December 19, 2021. The merger was completed on June 8, 2022, at which time DYNS changed its name to Senti Biosciences, Inc."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 132,
          "title": "Merger with Dynamics Special Purpose Corp.",
          "data": [
            {
              "key": "Merger Date",
              "value": "June 8, 2022"
            },
            {
              "key": "Merging Entities",
              "value": "Dynamics Special Purpose Acquisition Corp. and Senti Sub I, Inc. (Legacy Senti)"
            },
            {
              "key": "Resulting Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Conversion Ratio Common Stock",
              "value": "Approximately 0.1957 shares of Company’s Common Stock"
            },
            {
              "key": "Common Stock Issued",
              "value": "23,163,614 shares"
            },
            {
              "key": "PIPE Financing Amount",
              "value": "$50.6 million"
            },
            {
              "key": "Shares Issued to Dynamics Stockholders",
              "value": "14,915,963 shares"
            },
            {
              "key": "Convertible Note Amount Cancelled",
              "value": "$5,175,000"
            },
            {
              "key": "Options Converted",
              "value": "1,667,546 shares"
            },
            {
              "key": "Potential Additional Shares (Earnout Shares)",
              "value": "Up to 2,000,000 shares in two equal tranches"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 141,
          "title": "Contingent Earnout Liability and Fair Value of Common Stock",
          "data": [
            {
              "key": "Merger details",
              "value": "Reverse Recapitalization resulting in contingent earnout liability of 2,000,000 shares."
            },
            {
              "key": "Entitlement",
              "value": "Legacy Senti equity holders entitled to additional shares upon triggering events."
            },
            {
              "key": "ASC reference",
              "value": "ASC 815-40, Derivatives and Hedging."
            },
            {
              "key": "Valuation model",
              "value": "Monte Carlo simulation for fair value assessment of contingent shares."
            },
            {
              "key": "Historical company status",
              "value": "Previously a private company with no public stock volatility data."
            },
            {
              "key": "Fair value determination",
              "value": "Decided by board of directors with third-party valuations."
            },
            {
              "key": "Dividend policy",
              "value": "0% dividend yield as no dividends have been paid."
            },
            {
              "key": "Key risk factors",
              "value": "Market conditions and liquidity constraints."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 151,
          "title": "Reconciliation of cash, cash equivalents and restricted cash",
          "data": [
            {
              "key": "Cash and cash equivalents 2022",
              "value": "57621"
            },
            {
              "key": "Cash and cash equivalents 2021",
              "value": "56034"
            },
            {
              "key": "Restricted cash 2022",
              "value": "3366"
            },
            {
              "key": "Restricted cash 2021",
              "value": "3257"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash 2022",
              "value": "60987"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash 2021",
              "value": "59291"
            },
            {
              "key": "Purchases of property and equipment in accounts payable and accrued expenses 2022",
              "value": "8153"
            },
            {
              "key": "Purchases of property and equipment in accounts payable and accrued expenses 2021",
              "value": "4439"
            },
            {
              "key": "Recognition of Series B preferred stock tranche liability 2022",
              "value": "0"
            },
            {
              "key": "Recognition of Series B preferred stock tranche liability 2021",
              "value": "33"
            },
            {
              "key": "Extinguishment of Series B preferred stock tranche liability 2022",
              "value": "0"
            },
            {
              "key": "Extinguishment of Series B preferred stock tranche liability 2021",
              "value": "15210"
            },
            {
              "key": "Merger and related PIPE financing costs 2022",
              "value": "0"
            },
            {
              "key": "Merger and related PIPE financing costs 2021",
              "value": "1429"
            },
            {
              "key": "Receivables in transit from issuance of common stock upon exercise of stock options 2022",
              "value": "0"
            },
            {
              "key": "Receivables in transit from issuance of common stock upon exercise of stock options 2021",
              "value": "25"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 152,
          "title": "Reverse Recapitalization and Merger Details",
          "data": [
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc. and its subsidiaries"
            },
            {
              "key": "Merger Date",
              "value": "June 8, 2022"
            },
            {
              "key": "Acquirer",
              "value": "Dynamics Special Purpose Acquisition Corp. (DYNS)"
            },
            {
              "key": "Merger Transaction",
              "value": "Explore Merger Sub, Inc. (a wholly owned subsidiary of Dynamics) merged with Senti Sub I, Inc. (formerly Senti Biosciences, Inc., i.e. Legacy Senti), with Legacy Senti surviving as a subsidiary of Dynamics."
            },
            {
              "key": "Post-Merger Change",
              "value": "As a result of the merger, Dynamics was renamed Senti Biosciences, Inc."
            },
            {
              "key": "Reference Note",
              "value": "Refer to Note 3, Reverse Recapitalization for further details."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 153,
          "title": "Table of Contents & Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Document Context",
              "value": "Senti Biosciences, Inc. – Notes to Consolidated Financial Statements including the Summary of Significant Accounting Policies"
            },
            {
              "key": "Accounting Framework",
              "value": "Prepared in conformity with U.S. GAAP and SEC regulations, referencing the Accounting Standards Codification (ASC) and updates (ASU)"
            },
            {
              "key": "Merger Agreement",
              "value": "The Company has retroactively adjusted all common and preferred share and related price information to reflect the exchange ratio established in the Merger Agreement"
            },
            {
              "key": "Use of Estimates",
              "value": "Includes accrual for research and development expenses, valuation of contingent earnout, convertible notes, stock-based compensation expense, and other significant estimates"
            },
            {
              "key": "Credit Risk & Cash Details",
              "value": "Discussion of concentration of credit risk in cash, cash equivalents, and short-term investments, as well as details on restricted cash held as collateral and for an employee stock purchase plan"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 157,
          "title": "Notes to Consolidated Financial Statements & Equity Transaction Disclosures",
          "data": [
            {
              "key": "R&D Expense Recognition",
              "value": "Nonrefundable advance payments for goods and services for future research and development activities are deferred and recognized as an expense when the related goods are delivered or services performed. The Company may acquire rights to gene circuit or other technologies from third parties, with upfront payments immediately expensed if there is no alternative future use."
            },
            {
              "key": "Deferred Offering Costs",
              "value": "Costs directly attributable to equity offerings, including incremental legal, accounting, and other fees, are capitalized as prepaid expenses and offset against proceeds upon completion of the offering. For the years ended December 31, 2022 and 2021, the Company expensed $0 and $2.2 million respectively related to a suspended IPO, and recorded $0 and $1.4 million respectively for deferred costs related to a SPAC merger."
            },
            {
              "key": "Commitments and Contingencies",
              "value": "The Company accrues liabilities for loss contingencies when probable and reasonably estimable; if no specific estimate is better than any other amount within a range, the minimum amount is accrued. No such liabilities were recorded as of December 31, 2022 and 2021."
            },
            {
              "key": "Redeemable Convertible Preferred Stock",
              "value": "The Company’s redeemable convertible preferred stock is recorded based on net proceeds received and is classified outside of stockholders' equity because holders have liquidation rights in certain scenarios. This includes details on Series A and Series B shares subject to liquidation events."
            },
            {
              "key": "Preferred Stock Tranche Liability",
              "value": "The Series B redeemable convertible preferred stock included an obligation whereby investors agreed to buy, and the Company agreed to sell additional shares at a fixed price upon achieving certain milestones. This freestanding financial instrument is measured at fair value and adjustments are recorded in the statements of operations."
            },
            {
              "key": "Contingent Earnout Equity",
              "value": "In connection with the Reverse Recapitalization and pursuant to the Merger dated June 8, 2022, legacy holders are entitled to receive up to 2,000,000 additional shares as part of the contingent earnout equity arrangement."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 158,
          "title": "Contingent Earnout Shares & Stock-Based Compensation Disclosure",
          "data": [
            {
              "key": "Contingent Earnout Shares",
              "value": "Two separate tranches of 1,000,000 shares each issued as a form of dividend to holders of Legacy Senti common and preferred stock, contingent on achieving specific share price milestones within two to three years."
            },
            {
              "key": "Change of Control Provision",
              "value": "If a change of control occurs within three years after the merger closing and share price milestones are met, earnout shares will be issued."
            },
            {
              "key": "Accounting Classification",
              "value": "Shares are accounted for as a liability (per ASC 815-40) with fair value remeasurement at each reporting date, recorded as a change in fair value of contingent earnout liability."
            },
            {
              "key": "Fair Value Measurement",
              "value": "Estimated using a Monte Carlo simulation based on a monthly distribution of potential stock price outcomes, incorporating assumptions such as current stock price, expected volatility, risk‐free rate, expected term, and dividend yield."
            },
            {
              "key": "Stock-Based Compensation Expense",
              "value": "Expense recognized based on grant-date fair value for awards to employees and non-employees, with vesting methods varying: straight-line for service-based awards and accelerated attribution for performance/market awards; no expense until performance conditions are probable."
            },
            {
              "key": "Net Loss Per Share Calculation",
              "value": "Computed using the two-class method to allocate losses between common and participating securities based on dividend rights and participation in undistributed earnings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Table of Contents SENTI BIOSCIENCES, INC. – Notes to Consolidated Financial Statements and Reverse Recapitalization",
          "data": [
            {
              "key": "ASU Effective Date",
              "value": "January 1, 2022"
            },
            {
              "key": "ASU Reference",
              "value": "ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740)"
            },
            {
              "key": "Recent Accounting Standards Impact",
              "value": "No material impact on financial statements and disclosures"
            },
            {
              "key": "Merger Transaction Date",
              "value": "June 8, 2022"
            },
            {
              "key": "Transaction Type",
              "value": "Reverse Recapitalization"
            },
            {
              "key": "Involved Entities",
              "value": "Merger Sub (wholly-owned subsidiary of Dynamics) merged with Legacy Senti"
            },
            {
              "key": "Conversion Ratio for Common Stock",
              "value": "Approximately 0.1957"
            },
            {
              "key": "Contingent Earnout",
              "value": "Up to 2,000,000 additional shares in two tranches based on share price milestones ($15.00 and $20.00)"
            },
            {
              "key": "PIPE Financing",
              "value": "PIPE Investors purchased 5,060,000 shares at $10.00 per share for an aggregate of $50.6 million"
            },
            {
              "key": "Convertible Note",
              "value": "May 2022 Note with a principal amount of $5.2 million issued to Bayer Healthcare LLC"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 161,
          "title": "Share Distribution After Merger",
          "data": [
            {
              "key": "Owned by Dynamics' stockholders",
              "value": "14,915,963"
            },
            {
              "key": "Issued to PIPE Investors",
              "value": "5,060,000"
            },
            {
              "key": "Issued to Bayer in connection with convertible note cancellation and exchange",
              "value": "517,500"
            },
            {
              "key": "Issued to Legacy Senti stockholders",
              "value": "23,163,614"
            },
            {
              "key": "Early exercised shares subject to repurchase",
              "value": "-288,807"
            },
            {
              "key": "Total shares of common stock immediately after Merger",
              "value": "43,368,270"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 163,
          "title": "Table of Contents SENTI BIOSCIENCES, INC. Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Table Description",
              "value": "Summary of changes in the fair value of the Company’s Level 3 financial instruments related to the Contingent Earnout Liability."
            },
            {
              "key": "Row 1 - Air Value as of December 31, 2021",
              "value": "$ ="
            },
            {
              "key": "Row 2 - Liability Recognition",
              "value": "Contingent earnout liability recognized upon the closing of the reverse recapitalization: -9,688"
            },
            {
              "key": "Row 3 - Fair Value Change",
              "value": "Change in fair value included in other income (expense): 9,461"
            },
            {
              "key": "Summary",
              "value": "The table presents the changes in contingent earnout liability. An initial liability of $9,688 was recognized during a reverse recapitalization and was largely offset by a positive fair value adjustment of $9,461 recorded in other income/expense. The fair value is based on significant unobservable inputs (Level 3) using a Monte Carlo simulation value model, with assumptions based on stock price milestones, volatility, risk-free rate, expected term, and expected dividend yield."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Notes to Consolidated Financial Statements – Preferred Stock, Common Stock Purchase Agreement & Contingent Earnout Equity",
          "data": [
            {
              "key": "Preferred Stock",
              "value": "In connection with the close of the Merger, the Company’s Amended and Restated Certificate of Incorporation authorizes the issuance of $0.0001 par value preferred stock in one or more series. 10,000,000 shares were designated as preferred stock with none outstanding as of December 31, 2022."
            },
            {
              "key": "Common Stock Purchase Agreement",
              "value": "Entered on August 31, 2022 with Chardan Capital Markets LLC. The Company may sell up to the lesser of $50.0 million of newly issued common shares or an Exchange Cap (max 8,727,049 shares, 19.99% of prior outstanding shares) over a 36-month period. Shares are purchased at a VWAP minus a 3% discount, subject to daily trading volume and a $3.0 million cap."
            },
            {
              "key": "Transaction Consideration",
              "value": "Upon execution, 100,000 shares were issued and a $0.4 million document preparation fee was paid. Additionally, 300,000 Class A common shares were issued as of December 31, 2022 for net proceeds of $0.7 million, with a related expense of $0.7 million recorded for legal fees and related costs."
            },
            {
              "key": "Contingent Earnout Equity",
              "value": "Following the closing of the Merger, former holders of Legacy Senti common and preferred stock may receive up to 2,000,000 additional common shares in two tranches (1,000,000 each) contingent upon VWAP thresholds ($15.00 and $20.00) over specified trading periods. The estimated fair value was $9.8 million at closing, with $9.7 million recorded as a contingent earnout liability and $0.1 million expensed as stock-based compensation."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 179,
          "title": "Notes to Consolidated Financial Statements and Related Party Transactions",
          "data": [
            {
              "key": "Contingent Earnout Liability",
              "value": "1,000,000 shares of common stock per tranche. Refer to Note 8, Stockholders’ Equity (Deficit) for further details."
            },
            {
              "key": "Legal Proceedings",
              "value": "The Company is subject to claims and assessments in the ordinary course of business, but does not expect these to materially impact its financials."
            },
            {
              "key": "Indemnification",
              "value": "The Company has indemnification provisions in its agreements, including for directors and officers, with ongoing directors’ and officers’ insurance."
            },
            {
              "key": "Merger Event",
              "value": "On June 8, 2022, in conjunction with the Merger, each outstanding share of preferred stock of Legacy Senti was cancelled and converted into common stock based on the applicable conversion ratio and Exchange Ratio."
            },
            {
              "key": "Convertible Notes and Preferred Stock",
              "value": "Series A convertible redeemable preferred stock (February 2018) and Series B redeemable convertible preferred stock (October 2020) were issued to related parties such as NEA and 8VC, with subsequent conversion of outstanding convertible notes held by these parties and Dr. Timothy Lu."
            },
            {
              "key": "Related Parties",
              "value": "Related parties include NEA (including NEA 15, L.P. and affiliates) and 8VC. NEA held significant positions in both common and preferred stock as of December 31, 2022 and 2021."
            },
            {
              "key": "Bayer Healthcare Transaction",
              "value": "On May 19, 2022, Legacy Senti issued a $5.2 million unsecured convertible promissory note to Bayer, which was cancelled and exchanged on June 8, 2022 for 517,500 shares of Class A Common Stock at $10.00 per share."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 180,
          "title": "Collaboration and Option Agreement with BlueRock",
          "data": [
            {
              "key": "Agreement Date",
              "value": "May 21, 2021"
            },
            {
              "key": "Financial Commitment",
              "value": "$10 million"
            },
            {
              "key": "Research Term",
              "value": "Three years"
            },
            {
              "key": "Current Shareholding (as of December 31, 2022)",
              "value": "5,878,488 shares"
            },
            {
              "key": "Previous Shareholding (as of December 31, 2021)",
              "value": "5,360,988 shares of Series B redeemable convertible preferred stock"
            },
            {
              "key": "Board Representation",
              "value": "One of seven seats on the Board of Directors"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 182,
          "title": "Management's Annual Report on Internal Control Over Financial Reporting",
          "data": [
            {
              "key": "Merger Date",
              "value": "June 8, 2022"
            },
            {
              "key": "Predecessor Company",
              "value": "Dynamics"
            },
            {
              "key": "Company Type",
              "value": "Special purpose acquisition company"
            },
            {
              "key": "Significance of Operations",
              "value": "Insignificant compared to consolidated entity post-Merger"
            },
            {
              "key": "Assessment Limitations",
              "value": "Inability to complete assessment without unreasonable effort or expense"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Business Combination Agreement, dated as of December 19, 2021, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and Senti Biosciences, Inc."
            },
            {
              "key": "Form",
              "value": "S-4/A"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "May 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "2.2"
            },
            {
              "key": "Description",
              "value": "Amendment No. 1 to Business Combination Agreement, dated as of February 12, 2022"
            },
            {
              "key": "Form",
              "value": "S-4/A"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "May 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Description",
              "value": "Amendment No. 2 to Business Combination Agreement, dated as of May 19, 2022"
            },
            {
              "key": "Form",
              "value": ""
            },
            {
              "key": "File Number",
              "value": ""
            },
            {
              "key": "Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "File Number",
              "value": "001-40440"
            },
            {
              "key": "Date",
              "value": "May 24, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "41"
            },
            {
              "key": "Description",
              "value": "Specimen Common Stock Certificate."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "File Number",
              "value": "001-40440"
            },
            {
              "key": "Date",
              "value": "June 15, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Description",
              "value": "Description of Securities"
            },
            {
              "key": "Form",
              "value": ""
            },
            {
              "key": "File Number",
              "value": ""
            },
            {
              "key": "Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.1"
            },
            {
              "key": "Description",
              "value": "Note Subscription Agreement by and among Senti Biosciences, Inc., Dynamics Special Purpose Corp. and Bayer HealthCare LLC, dated as of May 19, 2022"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "File Number",
              "value": "001-40440"
            },
            {
              "key": "Date",
              "value": "May 24, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Description",
              "value": "Senti Biosciences, Inc. 2016 Stock Incentive Plan, as amended, and forms of award agreements thereunder."
            },
            {
              "key": "Form",
              "value": ""
            },
            {
              "key": "File Number",
              "value": ""
            },
            {
              "key": "Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.2"
            },
            {
              "key": "Description",
              "value": "Senti Biosciences, Inc. 2022 Equity Incentive Plan and forms of award"
            },
            {
              "key": "Form",
              "value": "S-4"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.3"
            },
            {
              "key": "Description",
              "value": "Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan."
            },
            {
              "key": "Form",
              "value": "10-Q"
            },
            {
              "key": "File Number",
              "value": "001-40440"
            },
            {
              "key": "Date",
              "value": "August 15, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.5"
            },
            {
              "key": "Description",
              "value": "Form of Indemnification Agreement by and between the Registrant and each of its directors and executive officers."
            },
            {
              "key": "Form",
              "value": "S-4/A"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "May 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.6"
            },
            {
              "key": "Description",
              "value": "Employee Offer Letter, by and between Timothy Lu and Senti Biosciences, Inc., dated December 27, 2018."
            },
            {
              "key": "Form",
              "value": "S-4"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "10.7"
            },
            {
              "key": "Description",
              "value": "Employee Offer Letter, by and between Philip Lee and Senti Biosciences, Inc., dated December 27, 2018."
            },
            {
              "key": "Form",
              "value": "S-4"
            },
            {
              "key": "File Number",
              "value": "333-262707"
            },
            {
              "key": "Date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 192,
          "title": "Registration Rights and Anti-Takeover Provisions",
          "data": [
            {
              "key": "Registration Rights Agreement",
              "value": "Agreement for certain stockholders' registration rights regarding their shares of common stock."
            },
            {
              "key": "Lock-Up Period",
              "value": "One year restriction on transfer of shares following June 8, 2022."
            },
            {
              "key": "Conditions for Expiration",
              "value": "Lock-Up expires if common stock price is >= $12 over 20 trading days in 30 day period."
            },
            {
              "key": "Chardan Capital Markets",
              "value": "Entered into agreement for resale registration statement."
            },
            {
              "key": "Board of Directors Powers",
              "value": "Permission to issue preferred stock and change composition of board of directors."
            },
            {
              "key": "Stockholder Proposals",
              "value": "Requirements for stockholders to present proposals or nominations."
            },
            {
              "key": "Director Terms",
              "value": "Board divided into three classes with three year terms."
            },
            {
              "key": "Cumulative Voting Rights",
              "value": "Not provided for in charter."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 198,
          "title": "Lease Agreement Contents",
          "data": [
            {
              "key": "Section (e)",
              "value": "Mechanic's Liens"
            },
            {
              "key": "Section (f)",
              "value": "Other Defaults"
            },
            {
              "key": "Section (g)",
              "value": "Insolvency"
            },
            {
              "key": "Section",
              "value": "Remedies"
            },
            {
              "key": "Section (a)",
              "value": "Termination of Lease"
            },
            {
              "key": "Section (b)",
              "value": "Termination of Possession"
            },
            {
              "key": "Section (c)",
              "value": "Continue Lease in Effect"
            },
            {
              "key": "Section (d)",
              "value": "Perform Acts on Behalf of Tenant"
            },
            {
              "key": "Section (e)",
              "value": "Alteration of Locks"
            },
            {
              "key": "Section (f)",
              "value": "Attorneys' Fees"
            },
            {
              "key": "Section",
              "value": "Payment by Tenant; Non-Waiver; Cumulative Remedies."
            },
            {
              "key": "Section (a)",
              "value": "Payment by Tenant"
            },
            {
              "key": "Section (b)",
              "value": "No Waiver"
            },
            {
              "key": "Section (c)",
              "value": "Cumulative Remedies"
            },
            {
              "key": "Section (d)",
              "value": "No Designation"
            },
            {
              "key": "Section (e)",
              "value": "No Counterclaims"
            },
            {
              "key": "Section",
              "value": "Landlord's Lien"
            },
            {
              "key": "Section",
              "value": "Surrender of Premises"
            },
            {
              "key": "Section",
              "value": "Holding Over"
            },
            {
              "key": "Section Certain",
              "value": "Rights Reserved by Landlord"
            },
            {
              "key": "Section (b)",
              "value": "Access Control"
            },
            {
              "key": "Section (c)",
              "value": "Repairs and Maintenance"
            },
            {
              "key": "Section (d)",
              "value": "Prospective Purchasers and Lenders"
            },
            {
              "key": "Section (e)",
              "value": "Prospective Tenants"
            },
            {
              "key": "Section (f)",
              "value": "Premises Access"
            },
            {
              "key": "Section",
              "value": "Hazardous Materials"
            },
            {
              "key": "Section",
              "value": "Miscellaneous."
            },
            {
              "key": "Section (a)",
              "value": "Landlord Transfer"
            },
            {
              "key": "Section (b)",
              "value": "Landlord's Liability"
            },
            {
              "key": "Section (c)",
              "value": "Force Majeure"
            },
            {
              "key": "Section (d)",
              "value": "Brokerage"
            },
            {
              "key": "Section (e)",
              "value": "Estoppel Certificates"
            },
            {
              "key": "Section (f)",
              "value": "Notices"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 199,
          "title": "Legal Provisions Summary",
          "data": [
            {
              "key": "Section",
              "value": "(g) Separability"
            },
            {
              "key": "Section",
              "value": "(h) Amendments; Binding Effect"
            },
            {
              "key": "Section",
              "value": "(i) Quiet Enjoyment"
            },
            {
              "key": "Section",
              "value": "(j) No Merger"
            },
            {
              "key": "Section",
              "value": "(k) No Offer"
            },
            {
              "key": "Section",
              "value": "(l) Entire Agreement"
            },
            {
              "key": "Section",
              "value": "(m) Waiver of Jury Trial"
            },
            {
              "key": "Section",
              "value": "(n) Governing Law"
            },
            {
              "key": "Section",
              "value": "(o) Recording"
            },
            {
              "key": "Section",
              "value": "(p) Joint and Several Liability"
            },
            {
              "key": "Section",
              "value": "(q) Financial Reports"
            },
            {
              "key": "Section",
              "value": "(r) Landlord's Fees"
            },
            {
              "key": "Section",
              "value": "(s) Telecommunications"
            },
            {
              "key": "Section",
              "value": "(t) Representations and Warranties"
            },
            {
              "key": "Section",
              "value": "(u) Confidentiality"
            },
            {
              "key": "Section",
              "value": "(v) Authority"
            },
            {
              "key": "Section",
              "value": "(w) Adjacent Excavation"
            },
            {
              "key": "Section",
              "value": "(x) On-Site Refueling"
            },
            {
              "key": "Section",
              "value": "(y) List of Exhibits"
            },
            {
              "key": "Section",
              "value": "(z) Disclaimer"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "Lease Agreement Details",
          "data": [
            {
              "key": "Lease Month Definition",
              "value": "Each calendar month during the Term where partial months are included."
            },
            {
              "key": "Base Rent Charges",
              "value": "Based on RSF for Phase I and Phase II Premises."
            },
            {
              "key": "Phase I Premises Rent Factor",
              "value": "50% of applicable monthly Base Rent."
            },
            {
              "key": "Security Deposit",
              "value": "$2,760,000.00 (Letter of Credit)."
            },
            {
              "key": "Improvements Cost",
              "value": "$190 per RSF; total amount of $17,462,900.00."
            },
            {
              "key": "Permitted Use",
              "value": "Research and development, clinical cGMP manufacturing, warehousing, laboratories, production."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 221,
          "title": "Assignment and Subletting Provisions",
          "data": [
            {
              "key": "provision_summary",
              "value": "This section outlines restrictions on transferring, assigning, or subletting the lease. Tenant is prohibited from transferring any interest in the lease, including through merger, consolidation, or reorganization, that would result in a change in current control without prior written consent from the Landlord."
            },
            {
              "key": "transfer_restrictions",
              "value": "Tenant must not assign, transfer, encumber the lease, or permit any other entity to become Tenant via merger, consolidation, or other reorganization, and must not sublet any portion of the Premises without Landlord's consent."
            },
            {
              "key": "consent_requirements",
              "value": "If Tenant requests consent for a transfer, they must provide detailed documentation and information about the proposed transferee. The Landlord will not unreasonably withhold consent if the transferee meets criteria regarding creditworthiness, reputation, intended use, and other conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 231,
          "title": "Lease Agreement Provisions on Casualty and Taxes",
          "data": [
            {
              "key": "Rent Abatement",
              "value": "If the Premises are damaged by Casualty, Rent for the portion rendered untenantable shall be abated until repairs are completed unless damage was caused by Tenant."
            },
            {
              "key": "Tenant's Tax Responsibilities",
              "value": "Tenant must pay all taxes levied on rental income and other aspects of the Lease, including taxes on personal property."
            },
            {
              "key": "Landlord's Insurance Proceeds",
              "value": "Landlord is entitled to full insurance proceeds for any alterations made in the Premises."
            },
            {
              "key": "Tenant's Waiver",
              "value": "Tenant waives certain provisions of California Civil Code regarding damages."
            },
            {
              "key": "Other Taxes Payable by Tenant",
              "value": "Tenant shall also pay taxes assessed on their personal property and improvements regardless of ownership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 249,
          "title": "EXHIBIT B DESCRIPTION OF THE LAND 1",
          "data": [
            {
              "key": "Content",
              "value": "EXHIBIT B DESCRIPTION OF THE LAND 1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 280,
          "title": "Tenant's Right of First Refusal and Lease Terms",
          "data": [
            {
              "key": "Right of First Refusal",
              "value": "Tenant's option to lease the 1410 Building before the Landlord leases to others."
            },
            {
              "key": "Conditions for Exercising the Right",
              "value": "Tenant must exercise within ten (10) days, or the option is forfeited."
            },
            {
              "key": "Additional Advice Terms",
              "value": "If Landlord offers more favorable terms to other prospects, they must notify the Original Tenant."
            },
            {
              "key": "Economic Terms Definition",
              "value": "Net cost to Original Tenant on a present value basis, adjusted for rent concessions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 290,
          "title": "Signature Block / Execution Page",
          "data": [
            {
              "key": "Senti Biosciences, Inc.",
              "value": "Acknowledged, Consented to, and Agreed: /s/ Tim Lu; By: Tim Lu; Title: CEO"
            },
            {
              "key": "BlueRock Therapeutics",
              "value": "Sincerely: /s/ Stefan Irion; By: Stefan Irion; Title: Senior Vice President, Research"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 295,
          "title": "Signature Page",
          "data": [
            {
              "key": "SignatureNotice",
              "value": "[Signature Page Follows]"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 37,
          "title": "Spark Agreement Overview",
          "data": [
            {
              "key": "Upfront Payment",
              "value": "$3 million"
            },
            {
              "key": "Option Exercise Fee",
              "value": "Low to mid-single digit millions"
            },
            {
              "key": "Milestone Payments from Spark",
              "value": "Up to mid teens millions"
            },
            {
              "key": "Sales Milestone Payments from Spark",
              "value": "Up to low hundred millions"
            },
            {
              "key": "Potential Payments Total",
              "value": "Exceeding $645 million"
            },
            {
              "key": "Royalty Percentage",
              "value": "Low-single digits on net sales"
            },
            {
              "key": "Termination Clauses",
              "value": "Either party may terminate under specified conditions."
            },
            {
              "key": "Collaboration and Option Agreement",
              "value": "With BlueRock Therapeutics LP"
            },
            {
              "key": "Research Commitment",
              "value": "Up to $10 million in costs and expenses responsibility"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "leadership_change",
          "page": 125,
          "title": "Corporate Governance and Management Change Provisions",
          "data": [
            {
              "key": "Management Replacement Impact",
              "value": "Provisions allow stockholders to replace or remove current management, potentially depressing the trading price of common stock."
            },
            {
              "key": "Blank Check Preferred Stock",
              "value": "The Charter authorizes issuing blank check preferred stock with superior rights, without requiring stockholder approval."
            },
            {
              "key": "Classified Board Structure",
              "value": "A classified board with staggered three-year terms is established, preventing all directors from being elected at one time."
            },
            {
              "key": "Special Meeting Restrictions",
              "value": "Special meetings of stockholders can only be called by the board, and written consent for stockholder actions is prohibited."
            },
            {
              "key": "Advance Notice Requirement",
              "value": "An advance notice procedure is required for bringing stockholder proposals, including nominations for board election, before the annual meeting."
            },
            {
              "key": "Supermajority Voting Requirement",
              "value": "Amending key provisions of the Charter and Bylaws requires supermajority votes of common stock holders, potentially delaying management changes."
            },
            {
              "key": "Delaware Law Impact",
              "value": "Under Section 203 of Delaware General Corporation Law, any person owning in excess of 15% of voting stock is restricted from a merger or combination for three years, limiting change in control."
            },
            {
              "key": "Exclusive Litigation Forum",
              "value": "The Court of Chancery of Delaware is designated as the exclusive forum for state law litigation, which could impact how stockholders pursue disputes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 189,
          "title": "SIGNATURES and Power of Attorney",
          "data": [
            {
              "key": "Document Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Registrant",
              "value": "SENTI BIOSCIENCES, INC."
            },
            {
              "key": "Signatory Name",
              "value": "Timothy Lu, M.D., Ph.D."
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer & President"
            },
            {
              "key": "Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Power of Attorney",
              "value": "Appointment of Timothy Lu and Deborah Knobelman to act as attorneys-in-fact for filing amendments"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 190,
          "title": "Document Signatures Page",
          "data": [
            {
              "key": "CEO / President / Director",
              "value": "Timothy Lu, M.D., Ph.D. – Chief Executive Officer, President and Director (Principal Executive Officer) – March 22, 2023"
            },
            {
              "key": "CFO / Financial Officer",
              "value": "Deborah Knobelman, Ph.D. – Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) – March 22, 2023"
            },
            {
              "key": "Director 1",
              "value": "Susan Berland – Director – March 22, 2023"
            },
            {
              "key": "Director 2",
              "value": "Brenda Cooperstone – Director – March 22, 2023"
            },
            {
              "key": "Director 3",
              "value": "Edward Mathers – Director – March 22, 2023"
            },
            {
              "key": "Director 4",
              "value": "James J. (Jim) Collins – Director – March 22, 2023"
            },
            {
              "key": "Director 5",
              "value": "Omid Farokhzad – Director – March 22, 2023"
            },
            {
              "key": "Director 6",
              "value": "David Epstein – Director – March 22, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 193,
          "title": "Anti-Takeover Provisions and Stockholder Proposal Procedures",
          "data": [
            {
              "key": "Notice Procedure",
              "value": "Bylaws require advance, written notice to the corporate secretary regarding stockholder proposals related to director nominations and new business."
            },
            {
              "key": "Notice Timing",
              "value": "Notice must be received at the principal executive offices no less than 90 days and no more than 120 days prior to the first anniversary of the annual meeting for the preceding year."
            },
            {
              "key": "Purpose of Provisions",
              "value": "Designed to enhance board stability by making it more difficult to replace directors or change management, thereby reducing vulnerability to hostile takeovers and proxy fights."
            },
            {
              "key": "Preferred Stock Authorization",
              "value": "Authorization of undesignated preferred stock enables the board to issue stock with voting rights or preferences that could impede attempts to change control."
            },
            {
              "key": "Delaying Change in Control",
              "value": "Provisions may delay, defer, or prevent changes in control by discouraging coercive takeover practices and tender offers."
            },
            {
              "key": "Delaware Law Reference",
              "value": "Subject to Section 203 of the DGCL, which restricts business combinations with interested stockholders under certain conditions."
            },
            {
              "key": "Market Impact",
              "value": "These measures may inhibit fluctuations in the market price of the stock and delay changes in control or management."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 204,
          "title": "Lease Contract and Executive Information",
          "data": [
            {
              "key": "Landlord’s Address",
              "value": "For all Notices: With a copy to: CBRE, Inc. 150 California Street, Suite 400 San Francisco, CA 94111 Attn: Tawni Sullivan Email: Tawni.sullivan@cbre.co; 1430 Harbor Bay Pkwy LLC c/o Invesco Real Estate 2001 Ross Avenue, Suite 3400 Dallas, TX 75201 Attention: North South Loop Asset Manager Telephone:(415) 445-3341; and a copy to: Shartsis Friese LLP One Maritime Plaza, 18th Floor San Francisco, CA 94111 Attention: Scott Schneider"
            },
            {
              "key": "Lease Incorporation Clause",
              "value": "The Basic Lease Information is incorporated into and made a part of the Lease; in case of conflict, the Lease controls."
            },
            {
              "key": "Landlord Signature",
              "value": "1430 HARBOR BAY PKWY LLC, a Delaware limited liability LANDLORD company; Signed by Kevin Pirozzoli, Vice President"
            },
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC., a Delaware corporation"
            },
            {
              "key": "Executive Table",
              "value": "Table listing executive roles: Title: CTO and CFO"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 206,
          "title": "Lease Grant and Tenant Responsibilities",
          "data": [
            {
              "key": "Lease Grant Details",
              "value": "Landlord leases to Tenant the Premises and provides exclusive rights to use the Loading Dock."
            },
            {
              "key": "Maintenance Responsibilities",
              "value": "Costs of operation and maintenance of the Loading Dock paid by Tenant."
            },
            {
              "key": "Possession Details",
              "value": "Possession of Premises tendered in 'AS-IS' condition on Lease Date."
            },
            {
              "key": "Abatement Clause",
              "value": "Tenant entitled to abatement of monthly Base Rent for delays over 14 days."
            },
            {
              "key": "Confirmation Letter Obligations",
              "value": "Tenant must confirm Commencement Dates and acceptance of Premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 228,
          "title": "Mortgagee Provisions and Obligations",
          "data": [
            {
              "key": "type",
              "value": "Lease"
            },
            {
              "key": "Landlord's Mortgagee",
              "value": "Entity defined as possessing interest in the lease agreements."
            },
            {
              "key": "Tenant's obligations upon attornment",
              "value": "Tenant must attorn to any party succeeding to Landlord’s interest."
            },
            {
              "key": "Default Notice Requirements",
              "value": "Tenant must provide written notice of Landlord's default."
            },
            {
              "key": "Landlord’s Mortgagee's protection",
              "value": "Limits liability of Landlord's Mortgagee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 232,
          "title": "Events of Default",
          "data": [
            {
              "key": "Payment Default",
              "value": "Tenant’s failure to pay Rent within five (5) calendar days after the same is due."
            },
            {
              "key": "Abandonment",
              "value": "Tenant abandons the Premises or fails to continuously operate its business in the Premises for fourteen (14) or more consecutive days."
            },
            {
              "key": "Estoppel/Financial Statement/Commencement Date Letter",
              "value": "Tenant’s failure to provide any estoppel certificate, financial statement, or Confirmation of Commencement Date as required."
            },
            {
              "key": "Insurance",
              "value": "Tenant fails to procure and maintain insurance as required."
            },
            {
              "key": "Mechanic’s Liens",
              "value": "Tenant fails to pay and release mechanic's lien or contest it."
            },
            {
              "key": "Other Defaults",
              "value": "Tenant’s failure to perform any other obligations under the lease."
            },
            {
              "key": "Insolvency",
              "value": "Filing of a petition in bankruptcy or similar proceeding."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 240,
          "title": "Lease Agreement Provisions",
          "data": [
            {
              "key": "Effective Notices",
              "value": "Effective upon the earlier to occur of actual receipt, one (1) Business Day following deposit with a nationally recognized overnight courier service, or three (3) days following deposit in the United States mail."
            },
            {
              "key": "Separability Clause",
              "value": "If any clause or provision of this Lease is illegal, invalid, or unenforceable, the remainder of this Lease shall not be affected thereby."
            },
            {
              "key": "Amendments; Binding Effect",
              "value": "This Lease may not be amended except by instrument in writing signed by Landlord and Tenant."
            },
            {
              "key": "Quiet Enjoyment",
              "value": "Provided Tenant has performed all of its obligations, Tenant shall hold and enjoy the Premises without hindrance."
            },
            {
              "key": "No Merger",
              "value": "There shall be no merger of the leasehold estate with the fee estate if the same person acquires both."
            },
            {
              "key": "Entire Agreement",
              "value": "This Lease constitutes the entire agreement between Landlord and Tenant regarding the subject matter hereof."
            },
            {
              "key": "Waiver of Jury Trial",
              "value": "Landlord and Tenant hereby knowingly, voluntarily, and intentionally waive the right to a trial by jury."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 255,
          "title": "EXHIBIT D WORK AGREEMENT",
          "data": [
            {
              "key": "Type of Agreement",
              "value": "Work Agreement"
            },
            {
              "key": "Effective Date",
              "value": "TBD"
            },
            {
              "key": "Parties Involved",
              "value": "[Names of parties]"
            },
            {
              "key": "Key Terms",
              "value": "[Summary of key terms]"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 269,
          "title": "Tenant Responsibilities and Limitations",
          "data": [
            {
              "key": "Vibration and Noises",
              "value": "Tenant shall not make or permit any vibration or improper, objectionable or unpleasant noises or odors in the Building or otherwise interfere in any way with other tenants or persons having business with them."
            },
            {
              "key": "Machinery Usage",
              "value": "No machinery of any kind (other than normal office equipment) shall be operated by any tenant on its leased area without Landlord’s prior written consent."
            },
            {
              "key": "Liability for Lost Property",
              "value": "Landlord will not be responsible for lost or stolen personal property, money or jewelry from tenant’s leased premises."
            },
            {
              "key": "Vending Machines",
              "value": "No vending or dispensing machines of any kind may be maintained in any leased premises without the prior written permission of Landlord."
            },
            {
              "key": "Protests and Demonstrations",
              "value": "Tenant shall not conduct any activity on or about the Premises or Building which will draw pickets, demonstrators, or the like."
            },
            {
              "key": "Vehicle Parking",
              "value": "All vehicles are to be currently licensed and parked for business purposes only."
            },
            {
              "key": "Unauthorized Area Access",
              "value": "No tenant may enter into phone rooms, electrical rooms, mechanical rooms, or other service areas of the Building unless accompanied by Landlord."
            },
            {
              "key": "Smoking Policy",
              "value": "Tenant shall not permit smoking in the Premises or shared areas."
            },
            {
              "key": "Soliciting and Canvassing",
              "value": "Canvassing, soliciting or peddling in or about the Premises or the Property is prohibited."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 270,
          "title": "Tenant Restrictions",
          "data": [
            {
              "key": "Prohibition on Advertising",
              "value": "Tenant shall not advertise for temporary laborers giving the Premises or the Project as an address."
            },
            {
              "key": "Parking Restrictions",
              "value": "Tenant shall park trailers and other oversized vehicles only in areas designated by Landlord for the parking of trailers or oversized vehicles."
            },
            {
              "key": "Outside Storage Restrictions",
              "value": "Tenant shall not utilize the Premises or Project for outside storage except with the written consent of Landlord."
            },
            {
              "key": "Prohibition on Disreputable Use",
              "value": "The Premises shall not be used for any use that is disreputable or may draw protests."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 271,
          "title": "EXHIBIT G CONFIRMATION OF COMMENCEMENT DATE",
          "data": [
            {
              "key": "Lease Agreement Date",
              "value": "202__"
            },
            {
              "key": "Landlord",
              "value": "a"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 279,
          "title": "Right of First Refusal for 1410 Building",
          "data": [
            {
              "key": "Original Tenant",
              "value": "The Original Tenant has a right of first refusal for the entire 1410 Building."
            },
            {
              "key": "Conditions",
              "value": "Several conditions must not be met, including any Events of Default and subletting."
            },
            {
              "key": "Landlord's Advice",
              "value": "Landlord will advise Tenant of terms for leasing to a prospective tenant."
            },
            {
              "key": "Exercise Period",
              "value": "Tenant must exercise the right within ten days after receiving Advice."
            },
            {
              "key": "Lease Terms",
              "value": "Leasing terms will follow those stated in the Advice."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 287,
          "title": "Amendment Execution and Executive Details",
          "data": [
            {
              "key": "Amendment Execution",
              "value": "IN WITNESS WHEREOF, the parties have executed this Amendment as of the Amendment Effective Date. SENTI BIOSCIENCES, INC. and SPARK THERAPEUTICS, INC."
            },
            {
              "key": "Executive Name",
              "value": "Tim Lu"
            },
            {
              "key": "Executive Title",
              "value": "CEO"
            },
            {
              "key": "Executive Date",
              "value": "12/21/2022"
            },
            {
              "key": "Position Detail",
              "value": "Chief Science and Technology Officer"
            },
            {
              "key": "Position Date",
              "value": "12/21/2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 294,
          "title": "Agreement Terms and Conditions",
          "data": [
            {
              "key": "Effective Date",
              "value": "Not specified"
            },
            {
              "key": "Initial Term",
              "value": "Three (3) years"
            },
            {
              "key": "Automatic Extension",
              "value": "One year each upon term expiry"
            },
            {
              "key": "Termination Notice",
              "value": "Thirty (30) days"
            },
            {
              "key": "Governing Law",
              "value": "California"
            },
            {
              "key": "Obligations upon Termination",
              "value": "Deliver all documents and materials pertaining to Services"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 296,
          "title": "Scientific Advisory Board Agreement Execution & Employee Information",
          "data": [
            {
              "key": "Agreement Title",
              "value": "Scientific Advisory Board Agreement"
            },
            {
              "key": "Company",
              "value": "SENTI BIOSCIENCES, INC."
            },
            {
              "key": "Advisor",
              "value": "James Collins"
            },
            {
              "key": "Employee Name",
              "value": "Curt Herberts"
            },
            {
              "key": "Employee Title",
              "value": "Chief Operating Officer"
            },
            {
              "key": "Effective Date",
              "value": "6/21/2021"
            },
            {
              "key": "Table Summary",
              "value": "This table contains employee information for Curt Herberts, who holds the position of Chief Operating Officer, as of June 21, 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 301,
          "title": "Подпись и утверждение руководителя",
          "data": [
            {
              "key": "Date",
              "value": "March 22, 2023"
            },
            {
              "key": "By",
              "value": "/s/ Timothy Lu, M.D., Ph.D. Timothy Lu, M.D., Ph.D. Chief Executive Officer (Principal Executive Officer)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 303,
          "title": "Подпись и данные руководителя",
          "data": [
            {
              "key": "Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Name",
              "value": "Deborah Knobelman, Ph.D."
            },
            {
              "key": "Title",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": false,
      "elements": []
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 2,
          "title": "Table of Contents - Executive Compensation Recovery Analysis",
          "data": [
            {
              "key": "Securities Registration Section 12(b)",
              "value": "Indicates if financial statements reflect correction of errors in previously issued statements."
            },
            {
              "key": "Error Correction Recovery Analysis for Incentive-Based Compensation",
              "value": "Checkbox provided to indicate if error corrections required recovery analysis of incentive-based compensation for executive officers (unchecked)."
            },
            {
              "key": "Registrant Shell Company",
              "value": "Checkbox provided; marked 'No' (☒)."
            },
            {
              "key": "Aggregate Market Value of Common Stock (Non-Affiliates)",
              "value": "Approximately $74.5 million as of June 30, 2022."
            },
            {
              "key": "Shares Outstanding",
              "value": "44,168,034 shares as of March 15, 2023; par value $0.0001 per share."
            },
            {
              "key": "Incorporated Documents",
              "value": "Portions of the registrant’s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders are incorporated by reference."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 27,
          "title": "Development Plan and Key Next Steps for SENTI-401",
          "data": [
            {
              "key": "Product",
              "value": "SENTI-401"
            },
            {
              "key": "Planned IND",
              "value": "Solid Tumors"
            },
            {
              "key": "Preclinical Data Presentation",
              "value": "2023"
            },
            {
              "key": "SENTI-301A Overview",
              "value": "Multi-Armed off-the-shelf CAR-NK cell therapy"
            },
            {
              "key": "Target Disease",
              "value": "Hepatocellular Carcinoma (HCC)"
            },
            {
              "key": "Target",
              "value": "GPC3"
            },
            {
              "key": "Gene Circuit",
              "value": "crIL-15"
            },
            {
              "key": "Protection Level",
              "value": "98% protection"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 43,
          "title": "Clinical Trial Phases and Regulatory Guidelines Summary",
          "data": [
            {
              "key": "Objectives of the Study",
              "value": "Detailing the objectives of the clinical trial."
            },
            {
              "key": "Monitoring Safety Parameters",
              "value": "Parameters to be used in monitoring safety."
            },
            {
              "key": "Effectiveness Criteria",
              "value": "Criteria to be evaluated for effectiveness."
            },
            {
              "key": "IND Submissions",
              "value": "Separate submission required for each clinical trial."
            },
            {
              "key": "IRB Review",
              "value": "Independent review required for clinical trials."
            },
            {
              "key": "Clinical Trial Oversight",
              "value": "Authority and oversight by IRB and sponsors."
            },
            {
              "key": "Phase 1 Details",
              "value": "Investigational product introduced to healthy subjects or patients."
            },
            {
              "key": "Phase 2 Objectives",
              "value": "Evaluate efficacy, optimal dosages and safety risks."
            },
            {
              "key": "Phase 3 Purpose",
              "value": "Establish risk/benefit ratio for product approval."
            },
            {
              "key": "Phase 4 Studies",
              "value": "Post-approval studies for long-term safety."
            },
            {
              "key": "Manufacturing Requirements",
              "value": "Production in accordance with cGMP requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 133,
          "title": "Merger and Stock Purchase Agreement Overview",
          "data": [
            {
              "key": "merger_terms",
              "value": "The first and second tranche term is two and three years from the closing of the Merger."
            },
            {
              "key": "earnout_condition",
              "value": "Change of control if share price equals or exceeds $15.00 and $20.00 milestones."
            },
            {
              "key": "common_stock_agreement_date",
              "value": "August 31, 2022"
            },
            {
              "key": "sell_limit",
              "value": "$50.0 million of shares over 36 months or 8,727,049 shares."
            },
            {
              "key": "total_revenue",
              "value": "Currently no therapeutic products approved for sale, revenue consists of research services and grants."
            },
            {
              "key": "research_expenses_details",
              "value": "Includes employee-related expenses, lab consumables, third-party consultants, and regulatory compliance costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 142,
          "title": "Valuation of Common Stock and Preferred Stock Tranche Liability",
          "data": [
            {
              "key": "External Market Conditions",
              "value": "U.S. and global economic conditions affecting life sciences and biotechnology industries."
            },
            {
              "key": "Valuation Methods",
              "value": "Hybrid of the option pricing method (OPM), guideline transactions, Backsolve method, and Monte Carlo simulation."
            },
            {
              "key": "Estimated Fair Value Considerations",
              "value": "Discounts applied based on the lack of marketability of common stock."
            },
            {
              "key": "Impact on Equity-Based Compensation Expense",
              "value": "Significant judgment involved; estimates may change based on varying assumptions."
            },
            {
              "key": "Stockholder Approval for Preferred Stock Tranche",
              "value": "Obligation included an agreement to buy/sell additional shares at fixed prices upon achieving milestones."
            },
            {
              "key": "Fair Value Accounting for Preferred Stock Tranche Liability",
              "value": "Revalued at each reporting period, changes recorded in earnings."
            },
            {
              "key": "Key Assumptions for Valuation",
              "value": "Estimated fair value per share, risk-free rate, time to liquidity, expected price volatility."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 149,
          "title": "Statement of Stockholders' Equity",
          "data": [
            {
              "key": "Date",
              "value": "December 31, 2020"
            },
            {
              "key": "Redeemable Preferred Shares",
              "value": "11,536,136"
            },
            {
              "key": "Convertible Stock Amount",
              "value": "89,662"
            },
            {
              "key": "Common Stock Shares",
              "value": "2,838,376"
            },
            {
              "key": "Additional Paid-in Capital",
              "value": "1,044"
            },
            {
              "key": "Accumulated Deficit",
              "value": "-69,757"
            },
            {
              "key": "Total Stockholders' Equity",
              "value": "-68,713"
            },
            {
              "key": "Transaction",
              "value": "Series B preferred stock issuance"
            },
            {
              "key": "Shares",
              "value": "7,981,852"
            },
            {
              "key": "Amount",
              "value": "82,171"
            },
            {
              "key": "Transaction",
              "value": "Exercise of common stock options"
            },
            {
              "key": "Shares",
              "value": "607,406"
            },
            {
              "key": "Amount",
              "value": "1,525"
            },
            {
              "key": "Transaction",
              "value": "Early exercise of common stock options"
            },
            {
              "key": "Shares",
              "value": "-612,670"
            },
            {
              "key": "Amount",
              "value": "-1,329"
            },
            {
              "key": "Date",
              "value": "December 31, 2021"
            },
            {
              "key": "Redeemable Preferred Shares",
              "value": "19,517,988"
            },
            {
              "key": "Convertible Stock Amount",
              "value": "171,833"
            },
            {
              "key": "Common Stock Shares",
              "value": "2,972,409"
            },
            {
              "key": "Additional Paid-in Capital",
              "value": "3,619"
            },
            {
              "key": "Accumulated Deficit",
              "value": "-115,076"
            },
            {
              "key": "Total Stockholders' Equity",
              "value": "-111,457"
            },
            {
              "key": "Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Common Stock Shares",
              "value": "44,062,534"
            },
            {
              "key": "Additional Paid-in Capital",
              "value": "300,544"
            },
            {
              "key": "Accumulated Deficit",
              "value": "-173,286"
            },
            {
              "key": "Total Stockholders' Equity",
              "value": "127,263"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 172,
          "title": "SENTI BIOSCIENCES, INC. - Stock Incentive and Equity Plans Overview",
          "data": [
            {
              "key": "Merger Impact",
              "value": "The notes mention the impact of the Merger as described in Note 3, Reverse Recapitalization, with certain terms remaining effective."
            },
            {
              "key": "2022 Stock Incentive Plan Adoption Date",
              "value": "June 8, 2022, upon the Merger."
            },
            {
              "key": "2022 Stock Incentive Plan Awards",
              "value": "Grants include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and other forms of awards to employees, directors and consultants."
            },
            {
              "key": "Exercise Price Requirement",
              "value": "The exercise price shall not be less than the fair market value of a common stock share on the date of grant; for a 10% stockholder, not less than 110% of fair value."
            },
            {
              "key": "Vesting and Expiration",
              "value": "Options generally vest over four years and expire no later than ten years from the grant date."
            },
            {
              "key": "2022 Stock Incentive Plan Reserved Shares",
              "value": "Initially reserved 2,492,735 shares; automatically increases by 5% of outstanding shares each year beginning January 1, 2023 (subject to Board approval). As of December 31, 2022, 1,568,781 shares remained available."
            },
            {
              "key": "2022 Inducement Equity Plan",
              "value": "Adopted on August 5, 2022; provides for grants (non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards, etc.) to individuals not previously employed by the Company. Initially reserved 2,000,000 shares with 1,379,691 shares available as of December 31, 2022."
            },
            {
              "key": "2022 Employee Stock Purchase Plan (ESPP)",
              "value": "Adopted on June 8, 2022, upon the Merger; allows eligible employees to purchase shares at 85% of the lower of the fair market value on the first day of an offering or the purchase date. Initially reserved 592,584 shares with an automatic annual increase of 1% commencing January 1, 2023 (text truncated)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 173,
          "title": "Stock Options Activity Summary",
          "data": [
            {
              "key": "Outstanding at December 31, 2021 (number of options)",
              "value": "2,291,838"
            },
            {
              "key": "Outstanding at December 31, 2021 (weighted-average exercise price)",
              "value": "$4.39"
            },
            {
              "key": "Granted (number of options)",
              "value": "2,655,259"
            },
            {
              "key": "Granted (weighted-average exercise price)",
              "value": "$2.09"
            },
            {
              "key": "Exercised (number of options)",
              "value": "-199,839"
            },
            {
              "key": "Exercised (weighted-average exercise price)",
              "value": "$2.49"
            },
            {
              "key": "Forfeited (number of options)",
              "value": "-555,832"
            },
            {
              "key": "Forfeited (weighted-average exercise price)",
              "value": "$3.21"
            },
            {
              "key": "Outstanding at December 31, 2022 (number of options)",
              "value": "4,191,426"
            },
            {
              "key": "Outstanding at December 31, 2022 (weighted-average exercise price)",
              "value": "$3.18"
            },
            {
              "key": "Vested and exercisable at December 31, 2022 (number of options)",
              "value": "770,429"
            },
            {
              "key": "Vested and exercisable at December 31, 2022 (weighted-average exercise price)",
              "value": "$4.14"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 174,
          "title": "Stock Options & Restricted Stock Units Activity Summary",
          "data": [
            {
              "key": "Stock Options - Granted",
              "value": "6,796,074 options at $9.92 per share"
            },
            {
              "key": "Stock Options - Forfeited",
              "value": "-1,427,573 options"
            },
            {
              "key": "Stock Options - Outstanding at December 31, 2022",
              "value": "5,368,501 options"
            },
            {
              "key": "Vested and Exercisable Options at December 31, 2022",
              "value": "270,308 options"
            },
            {
              "key": "Weighted-Average Exercise Price",
              "value": "$9.92"
            },
            {
              "key": "Remaining Contractual Life (Outstanding Options)",
              "value": "9.0 years"
            },
            {
              "key": "Aggregate Intrinsic Value",
              "value": "0"
            },
            {
              "key": "Performance Awards - Weighted-Average Grant Date Fair Value",
              "value": "$4.47"
            },
            {
              "key": "Unrecognized Stock-Based Compensation Expense (Performance Awards)",
              "value": "$13.2 million over 1.9 years"
            },
            {
              "key": "Market Awards Details",
              "value": "605,451 market awards approved for CEO Dr. Timothy Lu contingent on service, performance (Merger consummation) and market conditions; after Merger, 315,748 additional awards granted on June 8, 2022 with a weighted-average grant date fair value of $3.77 and unrecognized expense of $0.8 million over 1.3 years"
            },
            {
              "key": "Restricted Stock Units - Granted",
              "value": "447,948 units at $2.50 weighted-average grant date fair value"
            },
            {
              "key": "Restricted Stock Units - Vested/Forfeited",
              "value": "0 vested; 0 forfeited"
            },
            {
              "key": "Restricted Stock Units - Outstanding at December 31, 2022",
              "value": "447,948 units"
            },
            {
              "key": "Unrecognized Stock-Based Compensation Expense (Restricted Stock Units)",
              "value": "$1.0 million over 1.7 years"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "Stock-Based Compensation Expense - Black-Scholes Assumptions",
          "data": [
            {
              "key": "Description",
              "value": "Notes to Consolidated Financial Statements detailing the assumptions used in the Black-Scholes option pricing model to determine the fair value of stock-based awards."
            },
            {
              "key": "Fair Value of Common Stock",
              "value": "Historically determined by the board; based on various objective and subjective factors. Post-merger, based on publicly traded market value."
            },
            {
              "key": "Expected Term (2022 vs 2021)",
              "value": "5.8 years (2022) vs 6.0 years (2021)"
            },
            {
              "key": "Expected Volatility (2022 vs 2021)",
              "value": "78.8% (2022) vs 82.3% (2021)"
            },
            {
              "key": "Risk-free Interest Rate (2022 vs 2021)",
              "value": "3.2% (2022) vs 0.9% (2021)"
            },
            {
              "key": "Dividend Yield",
              "value": "0% (Company has never paid dividends and does not anticipate paying dividends)"
            },
            {
              "key": "Summary Table Insights",
              "value": "The assumptions reveal a slightly shorter expected term and lower volatility in 2022 compared to 2021, with a significant increase in the risk-free rate, indicating a shifting financial environment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "Air Value and Financial Metrics",
          "data": [
            {
              "key": "air value per share of Common Stock (2022)",
              "value": "$1.63"
            },
            {
              "key": "Expected Term (in years) (2022)",
              "value": "13"
            },
            {
              "key": "Expected Volatility (2022)",
              "value": "88.2%"
            },
            {
              "key": "Risk-free Interest Rate (2022)",
              "value": "3.8%"
            },
            {
              "key": "Data for 2021",
              "value": "Not Reported / Incomplete"
            },
            {
              "key": "Summary",
              "value": "The table focuses on share valuation and risk parameters for 2022, indicating a higher expected term and volatility relative to typical market conditions, with incomplete data for 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 176,
          "title": "Stock-Based Compensation Expense Breakdown",
          "data": [
            {
              "key": "General and administrative 2022",
              "value": "13,340"
            },
            {
              "key": "General and administrative 2021",
              "value": "1,940"
            },
            {
              "key": "Research and development 2022",
              "value": "3,052"
            },
            {
              "key": "Research and development 2021",
              "value": "35"
            },
            {
              "key": "Total stock-based compensation expense 2022",
              "value": "16,392"
            },
            {
              "key": "Total stock-based compensation expense 2021",
              "value": "2,290"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 183,
          "title": "Executive Compensation Overview",
          "data": [
            {
              "key": "Incorporation Reference",
              "value": "2023 Proxy Statement"
            },
            {
              "key": "Independent Accountant",
              "value": "KPMG LLP"
            },
            {
              "key": "Auditor ID",
              "value": "185"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 186,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.29+"
            },
            {
              "key": "Description",
              "value": "Severance and Change in Control Agreement between the Company and Deborah Knobelman."
            },
            {
              "key": "Schedule/Form",
              "value": "10-Q"
            },
            {
              "key": "File No.",
              "value": "001-404400"
            },
            {
              "key": "Exhibit",
              "value": "10.3"
            },
            {
              "key": "Filing Date",
              "value": "November 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 186,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.30+"
            },
            {
              "key": "Description",
              "value": "Severance and Change in Control Agreement between the Company and Philip Lee."
            },
            {
              "key": "Schedule/Form",
              "value": "10-Q"
            },
            {
              "key": "File No.",
              "value": "001-404400"
            },
            {
              "key": "Exhibit",
              "value": "10.4"
            },
            {
              "key": "Filing Date",
              "value": "November 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 186,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.31+"
            },
            {
              "key": "Description",
              "value": "Severance and Change in Control Agreement between the Company and Tim Lu."
            },
            {
              "key": "Schedule/Form",
              "value": "10-Q"
            },
            {
              "key": "File No.",
              "value": "001-404400"
            },
            {
              "key": "Exhibit",
              "value": "10.5"
            },
            {
              "key": "Filing Date",
              "value": "November 10, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 200,
          "title": "Basic Lease Information",
          "data": [
            {
              "key": "Lease Date",
              "value": "June 3, 2021"
            },
            {
              "key": "Landlord",
              "value": "1430 HARBOR BAY PKWY LLC"
            },
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC."
            },
            {
              "key": "Premises",
              "value": "91,910 rentable square feet"
            },
            {
              "key": "Building Address",
              "value": "1430 Harbor Bay Parkway, Alameda, CA"
            },
            {
              "key": "Project Description",
              "value": "Collective term for Building, Land, Parking Area, and improvements"
            },
            {
              "key": "Complex Description",
              "value": "Project and other buildings and land in the Business Park"
            },
            {
              "key": "Business Park Name",
              "value": "Harbor Bay Business Park"
            },
            {
              "key": "Phase I Premises Size",
              "value": "Approximately 45,955 RSF"
            },
            {
              "key": "Phase II Premises Size",
              "value": "Approximately 45,955 RSF"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 291,
          "title": "SENTI BIOSCIENCES, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT",
          "data": [
            {
              "key": "Effective Date",
              "value": "May 14, 2021"
            },
            {
              "key": "Company",
              "value": "SENTI BIOSCIENCES, INC. (Delaware corporation)"
            },
            {
              "key": "Advisor",
              "value": "DR. JAMES COLLINS"
            },
            {
              "key": "Advisor Email",
              "value": "jimjc@mit.edu"
            },
            {
              "key": "Services",
              "value": "Consulting and advisory services as a member of the Scientific Advisory Board, including attending SAB meetings, advising on technology strategy, research, development and analysis of the Company's technology."
            },
            {
              "key": "Compensation",
              "value": "Cash payments in quarterly installments and equity compensation in the form of stock options granted under the Company’s 2016 Stock Incentive Plan (or any successor plan) with vesting terms over four years."
            },
            {
              "key": "Stock Options Details",
              "value": "Initial option and annual option granted at an exercise price equal to the fair market value on the date of grant; vesting with 1/4 of the shares vesting on the one-year anniversary followed by 36 equal monthly installments."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 297,
          "title": "EXHIBIT A SENTI BIOSCIENCES, INC., SCIENTIFIC ADVISORY BOARD (SAB) COMPENSATION AS OF MAY 14, 2021",
          "data": [
            {
              "key": "Baseline Annual SAB Member Retainer",
              "value": "$10,500"
            },
            {
              "key": "Executive Chair (Addl.)",
              "value": "$9,000"
            },
            {
              "key": "Annual Equity Grants (NSOs)",
              "value": "$18,0002"
            },
            {
              "key": "Summary",
              "value": "This table details the compensation structure for Scientific Advisory Board (SAB) members. It shows three components: a baseline annual retainer of $10,500, an additional $9,000 for the Executive Chair position, and annual equity grants in the form of Non-Statutory Options (NSOs) valued at $18,000. The total potential compensation for an Executive Chair would be approximately $37,500 annually."
            },
            {
              "key": "Note1",
              "value": "Any grant of such annual option grant(s) is contingent upon and subject to approval of the Board or compensation committee of the Board and requires continued services by Advisor pursuant to this Agreement through any applicable grant date."
            },
            {
              "key": "Note2",
              "value": "Such number of shares is subject to adjustment for any applicable stock splits, stock dividends, combinations, recapitalizations and the like."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 6,
          "title": "Overview and Pipeline Description",
          "data": [
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Business Focus",
              "value": "Preclinical biotechnology developing next-generation cell and gene therapies"
            },
            {
              "key": "Technology Platform",
              "value": "Gene circuit platform technologies engineered with novel and proprietary combinations of genetic parts"
            },
            {
              "key": "Product Candidate",
              "value": "SENTI-202 (lead candidate)"
            },
            {
              "key": "Development Stage",
              "value": "Preclinical development"
            },
            {
              "key": "Planned Regulatory Filing",
              "value": "Investigational New Drug (IND) application expected in the second half of 2023"
            },
            {
              "key": "Pipeline Focus",
              "value": "Engineering off-the-shelf healthy adult donor derived NK cells to create CAR NK cells for oncology indications"
            },
            {
              "key": "Key Challenges Addressed",
              "value": "Disease evasion and target heterogeneity in complex diseases"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 9,
          "title": "Calibrated Release (cr) Technology for Enhanced CAR-NK Cell Function",
          "data": [
            {
              "key": "Technology",
              "value": "Calibrated Release (cr) engineered cytokines with designed protease cleavage sites"
            },
            {
              "key": "Application",
              "value": "Optimizing IL-15 delivery in CAR-NK cell product candidates to stimulate immune cells and enhance tumor killing"
            },
            {
              "key": "Methodology",
              "value": "Engineered cells express cr cytokines that are released in a calibrated fashion via ubiquitous cell proteases"
            },
            {
              "key": "Experimental Findings",
              "value": "crIL-15 shows functional activity via pSTAT5 signaling in T cells and improved serial cancer cell killing compared to rhIL-15"
            },
            {
              "key": "Platform Potential",
              "value": "Translatable to various proteins including IL-15 and IL-12 for improved adoptive cell therapies"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 11,
          "title": "NOT GATE CAR‐NK Logic Gating Solution and Applications",
          "data": [
            {
              "key": "Technology",
              "value": "NOT-GATE CAR-NK cell therapy utilizing a synthetic gene circuit"
            },
            {
              "key": "Mechanism",
              "value": "Activating CAR (aCAR) binds to Tumor-Associated Antigen to trigger cancer cell killing while inhibitory CAR (iCAR) binds to Protective Antigen to prevent killing of healthy cells"
            },
            {
              "key": "Programs",
              "value": "SENTI-202 and SENTI-401 CAR-NK programs for both liquid and solid tumors"
            },
            {
              "key": "Therapeutic Advantage",
              "value": "Potential for an expanded therapeutic window with enhanced efficacy and reduced risk of side effects"
            },
            {
              "key": "Rationale",
              "value": "Addresses challenges in targeting cancer due to heterogeneous antigen expression and tumor escape mechanisms"
            },
            {
              "key": "Diagram Details",
              "value": "Two side-by-side diagrams illustrating tumor-associated antigen engagement triggering cancer cell apoptosis and protective antigen engagement safeguarding healthy cells"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 22,
          "title": "Development Plan and Key Next Steps for SENTI-202, SBIR Contract Award, and SENTI-401 Overview",
          "data": [
            {
              "key": "Lead Candidate Selection",
              "value": "SENTI-202 selected as lead development candidate in 2022 based on preclinical studies"
            },
            {
              "key": "IND Application",
              "value": "Planned submission in the second half of 2023 to support clinical evaluation"
            },
            {
              "key": "Phase 1 Study Objective",
              "value": "Evaluate SENTI-202 in patients with R/R CD33 and/or FLT3 positive hematologic malignancies including AML"
            },
            {
              "key": "Study Design",
              "value": "Multiple doses following fludarabine/cyclophosphamide based lymphodepletion in treatment Cycles with efficacy and safety evaluations at cycle end"
            },
            {
              "key": "Funding Award",
              "value": "Awarded a Direct to Phase II SBIR contract from NCI in September 2021 for approximately $1.99 million over two years"
            },
            {
              "key": "SENTI-401 Program",
              "value": "Development of a logic gated off‐the‐shelf CAR-NK cell therapy for CRC and other solid tumors, incorporating an iCAR targeting VSIG2 and crIL-15 for enhanced efficacy and safety"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 22,
          "title": "PLANNED PHASE 1 STUDY TREATMENT/CYCLE Chart",
          "data": [
            {
              "key": "Lymphodepletion Phase",
              "value": "Days -5 to -3 with treatment: Fludarabine, Cyclophosphamide"
            },
            {
              "key": "SENTI-202 Administration",
              "value": "Day 0 with administration of 2-3 dose levels of cells"
            },
            {
              "key": "Efficacy Assessment",
              "value": "Day 28 with potential for additional cycles based on tumor response and tolerability"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 25,
          "title": "Table of Contents & Scientific Data",
          "data": [
            {
              "key": "Chart Title",
              "value": "MULTI-ARMING IN VITRO TUMOR CELL KILLING IN THE PRESENCE OF TGFβ"
            },
            {
              "key": "Chart Data",
              "value": "Days 1-6 normalized tumor cell areas for Vehicle, crlL15 + IL21 CEA CAR-NK Cells, and crlL15 + IL21 CEA CAR-NK Cells + TGFβ"
            },
            {
              "key": "X-axis",
              "value": "Days"
            },
            {
              "key": "Y-axis",
              "value": "Normalized Tumor Cell Area"
            },
            {
              "key": "Legend",
              "value": "yellow_line: Vehicle, dark_blue_line: crlL15 + IL21 CEA CAR-NK Cells, teal_line: crlL15 + IL21 CEA CAR-NK Cells + TGFβ"
            },
            {
              "key": "Annotations",
              "value": "Cancer cells added at days 1, 2, and 4"
            },
            {
              "key": "Research Focus",
              "value": "Utilization of the VSIG2 protein as a NOT GATE gene circuit Protective Antigen. Development of a Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform for NOT GATE CAR-NK therapies; differential gene expression analysis in healthy versus tumor tissues; validation via immunohistochemistry (IHC) with focus on CEA expression in healthy colon versus tumor samples."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 29,
          "title": "SENTI-301A Development and R&D Pipeline Overview",
          "data": [
            {
              "key": "Gene Circuit",
              "value": "crIL-15 gene circuit designed to improve NK cell expansion, persistence, and tumor killing in vivo"
            },
            {
              "key": "Program",
              "value": "SENTI-301A"
            },
            {
              "key": "Development Status",
              "value": "Preclinical studies demonstrated full gene circuit components; development paused in January 2023 for financial reasons with plans for future clinical development and partnering"
            },
            {
              "key": "Strategic Partnerships",
              "value": "Actively pursuing geographic partnerships in Asia, with collaborations involving Spark Therapeutics (subsidiary of Roche Holding AG) and Bluerock Therapeutics (subsidiary of Bayer AG)"
            },
            {
              "key": "Pipeline Chart",
              "value": "Gene Therapies and Cell Therapies Pipeline includes programs: GC-1001/GC-1002 (Eye, Smart Sensor, Discovery, Spark), GC-1003/GC-1004 (CNS, Smart Sensor, Discovery, Roche), GC-1005 (Liver, Smart Sensor, Discovery), GC-1101 (Regenerative Medicine, Regulator Dial, Discovery, BlueRock), GC-1102 (Regenerative Medicine, Regulator Dial, Discovery), GC-1103 (Regenerative Medicine, Smart Sensor, Discovery, Bayer)"
            },
            {
              "key": "Additional Discovery Initiatives",
              "value": "Exploration of expanded applications for gene circuits beyond oncology, including additional CAR-NK candidates and tissue-directed gene therapies"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 30,
          "title": "TUMOR-ASSOCIATED ANTIGEN AND PROTECTIVE ANTIGEN PAIRED DISCOVERY PLATFORM",
          "data": [
            {
              "key": "platform_description",
              "value": "A proprietary discovery platform that identifies NOT GATE antigen candidates by analyzing RNA transcriptomics data. It distinguishes tumor-associated antigens with high expression in cancer cells (with minimal healthy tissue expression) and healthy tissue selective protective antigens to safeguard tissues expressing those tumor antigens. The process involves filtering for cell surface expression, branching into tumor antigen discovery and protective antigen discovery, followed by curation and experimental validation."
            },
            {
              "key": "illustrative_flowchart",
              "value": "An accompanying flowchart details the sequential steps: starting with RNA expression data, filtering for cell surface expression, branching into separate discovery tracks (for tumor-associated antigen and protective antigen), and concluding with experimental validation. Visualization elements include bar charts and cell diagrams."
            },
            {
              "key": "leveraged_programs",
              "value": "The platform has been applied to identify protective antigen targets for SENTI-202 and SENTI-401 programs, indicating its role in underpinning both liquid and solid tumor therapeutic strategies."
            },
            {
              "key": "manufacturing_context",
              "value": "The page also touches upon manufacturing capabilities, emphasizing the importance of scalable production of off-the-shelf CAR-NK cell therapies from healthy donor cells, aimed at ensuring wide accessibility upon regulatory approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 31,
          "title": "Cell Manufacturing Process Details and Donor Selection",
          "data": [
            {
              "key": "Process Overview",
              "value": "Critical aspects of the CAR-NK cell manufacturing process include performing key steps: isolation, engineering, expansion, cryopreservation, and infusion. Starting Cells are isolated from leukapheresis of healthy donors to support SENTI-202, SENTI-401, and SENTI-301A product candidates."
            },
            {
              "key": "Workflow",
              "value": "A 'Scalable ~21 Day Process' workflow diagram outlines five steps: 1) Isolate from selected donors, 2) Engineer CAR-NK cells, 3) Expand (>100 doses per batch), 4) Cryopreserve (maintaining high post-thaw potency), and 5) Thaw and infuse."
            },
            {
              "key": "Donor Selection Chart",
              "value": "A bar chart titled 'NK CELL DONOR SELECTION TO SUPPORT ROBUST CELL EXPANSION' shows fold expansion from different donors, highlighting preferred donors (A-F) with fold expansions ranging from 15,000 (Donor A) to lower values (e.g., 1,200 for Donor L). A related line graph illustrates cell expansion over 0-40 days on a logarithmic scale."
            },
            {
              "key": "Cell Quality and Yield",
              "value": "Isolations achieve >95% NK cell purity, >90% viability, and up to 500 million cells per collection. Preferred donors enable generation of approximately 70 trillion NK cells from a single collection."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 32,
          "title": "Step 2: Genetically Engineer Starting Cells with Gene Circuits; Step 3: Expand and Scale CAR-NK Cells",
          "data": [
            {
              "key": "process_overview",
              "value": "NK cells are thawed, activated, and then genetically engineered via viral vector transduction to incorporate gene circuits. The process maintains cell expansion and enhances cancer cell killing."
            },
            {
              "key": "transduction_details",
              "value": "The vector transduction process was applied on a specific day post activation, ensuring minimal impact on cell viability and expansion."
            },
            {
              "key": "cell_expansion",
              "value": "Both unengineered and transduced cells show similar expansion rates with data points showing expansion up to 6000-fold at day 21 for CAR-NK cells."
            },
            {
              "key": "cancer_cell_killing",
              "value": "Transduced CAR-NK cells demonstrated superior cancer cell killing compared to unengineered cells, as shown in cytotoxicity charts with ratios 1:1 and 1:2."
            },
            {
              "key": "chart1",
              "value": "CAR-NK CELL EXPANSION chart: Days (0, 10, 14, 18, 21) with unengineered vs transduced expansion data; note the transduction point at day 10."
            },
            {
              "key": "chart2",
              "value": "CAR-NK CELL CANCER (SEM) KILLING chart: Effector:Target ratios (1:1 and 1:2) compare cytotoxicity percentages between unengineered and transduced cells."
            },
            {
              "key": "manufacturing_scale",
              "value": "The process achieves a >6000-fold expansion over 21 days, supporting clinical manufacturing scale for hundreds of patient doses per batch."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 32,
          "title": "Step 4: Formulate and Cryopreserve CAR-NK Cells",
          "data": [
            {
              "key": "Objective",
              "value": "Formulate and cryopreserve final CAR-NK cell product to retain viability, persistence, and cytotoxic function post-thaw for off-the-shelf use."
            },
            {
              "key": "Shipping Process",
              "value": "CAR-NK cell product candidates are filled into vials, cryopreserved for long-term storage, and shipped to clinical sites for infusion."
            },
            {
              "key": "Cryopreservation Functional Retention",
              "value": "Demonstrated stable transgene expression for over one month and retention of key functions in in vitro and in vivo AML models."
            },
            {
              "key": "CAR-NK Cell Viability Chart",
              "value": "Pre-Freeze viability: 93%; Post-Thaw viability: 87%"
            },
            {
              "key": "Additional Imaging Data",
              "value": "In vivo imaging data compares vehicle vs cryopreserved CAR-NK Cells in a MOLM13 AML NSG mouse model over 10 days after single dose."
            },
            {
              "key": "Chart Metadata",
              "value": "Bar chart with y-axis label '% Viable Cells', error bars present, color scheme teal/turquoise"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 33,
          "title": "Technologies and Processes to Enhance NK Cell Expansion for Commercial Manufacturing",
          "data": [
            {
              "key": "Description",
              "value": "Exploration of alternative methods for cell activation and expansion using perfusion bioreactors to enhance NK cell expansion."
            },
            {
              "key": "Expansion Chart Title",
              "value": "EXPANSION"
            },
            {
              "key": "Bar Chart - Volumes and Fold Expansion",
              "value": "0.1L, 1L, 5L volumes all achieve 10000 fold expansion"
            },
            {
              "key": "NK Cell Yield Measurements",
              "value": "Pre Harvest: 1.7e10; Post Harvest: 1.8e10 (live cells per EU vessel)"
            },
            {
              "key": "Viability Measurements",
              "value": "Pre Harvest: 90%; Post Harvest: 95%"
            },
            {
              "key": "Equipment",
              "value": "G-Rex-500M (5L volume)"
            },
            {
              "key": "Chart Details",
              "value": "Left: Fold Expansion (21 Days, logarithmic); Middle: NK Cell Yield (linear); Right: % Viability (linear)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 134,
          "title": "Business Expenses Comparison 2021-2022",
          "data": [
            {
              "key": "Personnel-related expenses, including share-based compensation expense",
              "value": "$13,528"
            },
            {
              "key": "External services and supplies",
              "value": "$12,394"
            },
            {
              "key": "Office and facilities",
              "value": "$7,324"
            },
            {
              "key": "Other",
              "value": "$821"
            },
            {
              "key": "Total",
              "value": "$34,067"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 171,
          "title": "Notes on Licensing, R&D Services and Related Financial Arrangements",
          "data": [
            {
              "key": "License and Payment Terms",
              "value": "Eligible to receive a license fee, potential research, development and commercial milestone payments, and royalties on product sales."
            },
            {
              "key": "Contract Termination",
              "value": "Spark may generally terminate the agreement upon 90 days written notice, or 180 days if the licensed promoter is in clinical trials or being commercialized."
            },
            {
              "key": "Evaluation of Optional Rights",
              "value": "The Company evaluated Spark’s optional rights regarding licensing, development, manufacturing and commercialization; determined that the technology is early stage with high uncertainty, and optional rights do not provide an incremental discount."
            },
            {
              "key": "Transaction Price for Research Services",
              "value": "Consists of a fixed upfront amount ($3.0 million) plus variable consideration; recognized as research and development services are provided using a cost‐based input method."
            },
            {
              "key": "Revenue Recognition",
              "value": "For the years ended December 31, 2022 and 2021, recognized research service revenue of $1.0 million and $0.0 million respectively."
            },
            {
              "key": "Grant Income",
              "value": "Received an SBIR grant of $2.0 million over two years to support development of SENTI-202 for acute myeloid leukemia; recognized as qualified R&D costs were incurred."
            },
            {
              "key": "Stock-Based Compensation Note",
              "value": "The 2016 Stock Incentive Plan, which provided for various stock awards to employees, directors, and consultants, was terminated following the Merger."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 195,
          "title": "Research and Development and Laboratory Lease Agreement",
          "data": [
            {
              "key": "Document Type",
              "value": "Research and Development and Laboratory Lease Agreement"
            },
            {
              "key": "Landlord",
              "value": "1430 Harbor Bay Pkwy LLC"
            },
            {
              "key": "Tenant",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Date",
              "value": "June 3, 2021"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 10.13"
            },
            {
              "key": "Confidentiality Note",
              "value": "Certain confidential information has been omitted as it is not material and considered private by Senti Biosciences, Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 205,
          "title": "RESEARCH AND DEVELOPMENT AND LABORATORY LEASE AGREEMENT",
          "data": [
            {
              "key": "Agreement Date",
              "value": "June 3, 2021"
            },
            {
              "key": "Landlord",
              "value": "1430 HARBOR BAY PKWY LLC, a Delaware limited liability company"
            },
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC., a Delaware corporation"
            },
            {
              "key": "Basic Lease Information",
              "value": "Defined in the Basic Lease Information and incorporated by reference"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 256,
          "title": "EXHIBIT E ADDITIONAL USE PROVISIONS - LABORATORY USE",
          "data": [
            {
              "key": "Premises Use",
              "value": "Permits Tenant’s use of portions of the Premises for laboratory and research and development purposes (Laboratory Use)"
            },
            {
              "key": "cGMP Compliance",
              "value": "All laboratory use activities must comply with FDA's Current Good Manufacturing Practices (cGMP) requirements"
            },
            {
              "key": "Biosafety Level",
              "value": "Laboratory use must not exceed Biosafety Level 2 as specified by the National Institutes of Health"
            },
            {
              "key": "Animal Testing",
              "value": "Live animal testing is strictly prohibited and no vivarium or live animal testing facility may be established"
            },
            {
              "key": "Applicable Laws and Guidelines",
              "value": "Tenant must comply with all Applicable Laboratory Use Laws and guidelines from FDA, CDC, NIH, and other relevant regulatory authorities"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 283,
          "title": "LETTER OF CREDIT UNDER RESEARCH AND DEVELOPMENT AND LABORATORY LEASE AGREEMENT",
          "data": [
            {
              "key": "Document Type",
              "value": "Letter of Credit"
            },
            {
              "key": "Related Agreement",
              "value": "Research and Development and Laboratory Lease Agreement"
            },
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC., A DELAWARE CORPORATION"
            },
            {
              "key": "Landlord",
              "value": "NORTH LOOP 3, LLC, A DELAWARE LIMITED LIABILITY COMPANY"
            },
            {
              "key": "Issuing Bank",
              "value": "SILICON VALLEY BANK"
            },
            {
              "key": "Letter of Credit Identifier",
              "value": "SVBSF ______________________"
            },
            {
              "key": "Automatic Extension",
              "value": "Automatic one-year extensions unless notice of non-extension is sent at least 60 days prior to expiration; not extended beyond December 31, 2032"
            },
            {
              "key": "Payment Instructions",
              "value": "Payment to be made to the beneficiary’s account as per provided wire instructions"
            },
            {
              "key": "Drawing Amount",
              "value": "US$ ______________________"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 286,
          "title": "AMENDMENT NO. 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT",
          "data": [
            {
              "key": "Amendment Effective Date",
              "value": "December 8, 2022"
            },
            {
              "key": "Amendment Number",
              "value": "1"
            },
            {
              "key": "Original Agreement Date",
              "value": "April 9, 2021"
            },
            {
              "key": "Parties",
              "value": "Spark Therapeutics, Inc. and Senti Biosciences, Inc."
            },
            {
              "key": "Purpose",
              "value": "Amendment to modify funding allocation provisions under the Research Collaboration and License Agreement, including reallocation between Out-of-Pocket Costs and FTE Costs, reimbursement for additional FTE hours, and updating the Research Plan, Budget, and Term."
            },
            {
              "key": "Reference Exhibit",
              "value": "Exhibit A (updated Research Plan, Research Budget, and Research Term)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 288,
          "title": "Side Letter re: Collaboration and Option Agreement",
          "data": [
            {
              "key": "Date",
              "value": "February 3, 2023"
            },
            {
              "key": "From",
              "value": "Senti Biosciences, Inc., 2 Corporate Drive, South San Francisco, CA 94080"
            },
            {
              "key": "Recipients",
              "value": "Chief Executive Officer; Director, Intellectual Property; SVP, Head of Legal Affairs"
            },
            {
              "key": "Subject",
              "value": "Authorization and consent under the Collaboration and Option Agreement with BlueRock Therapeutics LP regarding transfer and use of research materials (plasmids encoding Collaboration Gene Circuits) for R&D activities"
            },
            {
              "key": "Agreement Reference",
              "value": "Collaboration and Option Agreement dated May 21, 2021"
            },
            {
              "key": "Key Details",
              "value": "Senti has transferred plasmids to BlueRock for use in research labs under specific conditions. BlueRock is requested to obtain Senti's written consent for the transfer of certain materials and to conduct defined research activities."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 7,
          "title": "Gene Circuit Solutions Overview",
          "data": [
            {
              "key": "Overview",
              "value": "The document describes challenges in current conventional therapies, particularly regarding a narrow therapeutic window and dynamic disease conditions, and introduces a new generation of gene circuit platform technologies."
            },
            {
              "key": "Key Concepts",
              "value": "Multi-Arming, Logic Gating, Regulator Dial, and Smart Sensor are the four core categories of the gene circuit platform designed to enhance clinical activity, precision, and control in cell and gene therapies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 7,
          "title": "Fundamental Disease Challenges and Intelligent Genetic Programming Solutions",
          "data": [
            {
              "key": "Disease Evasion",
              "value": "Solution via Multi-Arming targets multiple disease pathways within a single all-in-one drug."
            },
            {
              "key": "Target Heterogeneity",
              "value": "Solution via Logic Gating integrates multiple targets to pinpoint diseased cells while sparing healthy ones."
            },
            {
              "key": "Narrow Therapeutic Window",
              "value": "Solution via Regulator Dial dynamically regulates therapies in vivo using FDA-approved oral drugs."
            },
            {
              "key": "Dynamic Disease Conditions",
              "value": "Solution via Smart Sensor precisely detects and responds to disease environments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 7,
          "title": "Detailed Descriptions: Multi-Arming and Logic Gating",
          "data": [
            {
              "key": "Multi-Arming",
              "value": "Gene circuits that incorporate multiple payloads into a single cell or gene therapy product to activate several biological pathways concurrently, addressing the issue of disease evasion."
            },
            {
              "key": "Logic Gating",
              "value": "Gene circuits that enable therapies to control activity in response to the presence or absence of multiple disease biomarkers, enhancing specificity and adaptability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Table of Contents",
          "data": [
            {
              "key": "NOT GATE",
              "value": "Gene circuits designed to widen the therapeutic window by enabling effective killing of cancer cells while preserving healthy cells. They recognize Protective Antigens, which are selectively expressed on healthy cells."
            },
            {
              "key": "OR GATE",
              "value": "Gene circuits designed to address tumor heterogeneity and limit antigen escape by killing tumor cells that express any one of multiple antigens."
            },
            {
              "key": "Regulator Dial",
              "value": "Gene circuits that enable the precise tuning of therapeutic activity, regulating payload expression in response to varying concentrations of FDA-approved drugs, allowing modulation after in vivo delivery."
            },
            {
              "key": "Smart Sensor",
              "value": "Gene circuits (or combinations thereof) engineered to precisely detect distinct cell types or disease environments, thereby distinguishing between disease state and healthy state."
            },
            {
              "key": "Multi-Arming gene circuits",
              "value": "Designed to incorporate multiple payloads into a single cell or gene therapy product, these circuits aim to activate various biological pathways concurrently to combat diseases that evade single-target treatments."
            },
            {
              "key": "Our Calibrated Release (cr) Technology",
              "value": "Uses cytokines and other immune stimulatory proteins to overcome the immunosuppressive tumor microenvironment in solid tumors by activating endogenous anti-tumor immune cells and supporting adoptive cell therapies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "R&D Product Launch: CAR-NK Cell Technology & Logic Gating",
          "data": [
            {
              "key": "Technology",
              "value": "Proprietary crIL-15 engineered onto CAR-NK cells enhances cell persistence, viability, and cell count in vitro."
            },
            {
              "key": "Experimental Findings",
              "value": "Viable crIL-15 CAR-NK cells detected for 3 weeks in vitro compared to less than 1 week for unengineered NK cells."
            },
            {
              "key": "Chart Details",
              "value": "Line graph titled 'crIL-15 INCREASES PERSISTENCE OF CAR-NK CELLS' displaying viable cell counts (in e6) over culture days, comparing crIL-15 CAR-NK cells with unengineered NK cells."
            },
            {
              "key": "Calibrated Release Technology",
              "value": "Leveraging calibrated release technology for other cytokines such as IL-12, with crIL-12 expression modulated by a small molecule Regulator Dial gene circuit to stimulate the immune system."
            },
            {
              "key": "Logic Gating Technology",
              "value": "Development of gene circuits including NOT GATE and OR GATE systems to control therapeutic activity in response to disease biomarkers, aiming at enhanced precision targeting in oncology."
            },
            {
              "key": "Discovery Platform",
              "value": "Establishment of a proprietary Tumor-Associated Antigen (TAA) and Protective Antigen (PA) Paired Discovery Platform to expand Logic Gating applications across multiple cancer indications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "Gene Circuit Solutions Overview",
          "data": [
            {
              "key": "Product_1",
              "value": "OR GATE gene circuits designed to simultaneously target multiple Tumor-Associated Antigens in heterogeneous cancers"
            },
            {
              "key": "Clinical_Context",
              "value": "Addressing disease relapse in B cell malignancies and overcoming CD19 epitope loss in CAR-T therapies"
            },
            {
              "key": "Product_2",
              "value": "Regulator Dial gene circuits enabling precise, dynamic control of therapeutic payload expression via FDA-approved drugs"
            },
            {
              "key": "Problem",
              "value": "Existing cell and gene therapies lack in vivo regulation post-delivery, leading to dosing challenges and potential toxicity"
            },
            {
              "key": "Solution",
              "value": "Implementation of gene circuit technologies that allow exogenous control (ON/OFF switches and rheostats) to optimize safety and efficacy"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 15,
          "title": "Our Pipeline",
          "data": [
            {
              "key": "Product Candidates",
              "value": "Gene circuit-enabled products focusing on CAR-NK cell therapy, gene therapies for tissue-directed targets, and cell therapies for regenerative medicines."
            },
            {
              "key": "Advanced Programs",
              "value": "Internal pipeline of off-the-shelf CAR-NK programs aimed at improving therapeutic outcomes in oncology."
            },
            {
              "key": "Cell Source",
              "value": "Peripheral blood NK cells, leveraging established supply chain and clinical experience."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "SENTI-202 for the Potential Treatment of Hematologic Malignancies including Acute Myeloid Leukemia Overview",
          "data": [
            {
              "key": "Product Name",
              "value": "SENTI-202"
            },
            {
              "key": "Product Type",
              "value": "Logic Gated CAR-NK cell therapy"
            },
            {
              "key": "Description",
              "value": "Designed to target and eliminate cancer cells while sparing healthy bone marrow."
            },
            {
              "key": "Target Antigens",
              "value": "FLT3 and/or CD33"
            },
            {
              "key": "Indication",
              "value": "Acute Myeloid Leukemia (AML)"
            },
            {
              "key": "Key Features",
              "value": "Bivalent CAR, OR GATE design, off-the-shelf manufacturing"
            },
            {
              "key": "Clinical Relevance",
              "value": "95% expression in AML patients"
            },
            {
              "key": "Manufacturing Protocol",
              "value": "Proprietary protocols for scaling and cryopreservation"
            },
            {
              "key": "Advantages",
              "value": "Broad patient access, rapid delivery in outpatient settings"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 17,
          "title": "SENTI-202 Product Features",
          "data": [
            {
              "key": "SENTI-202 mechanism 1",
              "value": "Bivalent CD33 and/or FLT3 activating CAR system targeting blast cells for cancer cell killing"
            },
            {
              "key": "SENTI-202 mechanism 2",
              "value": "Endomucin inhibitory CAR mechanism designed to protect healthy cells"
            },
            {
              "key": "SENTI-202 mechanism 3",
              "value": "Persistence and activation of CAR-NK and immune cells through calibrated release of IL-15"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 18,
          "title": "SENTI-202 Approach to AML",
          "data": [
            {
              "key": "Overview",
              "value": "SENTI-202 off-the-shelf CAR-NK cells are engineered with gene circuits that enable identification of cancerous versus healthy cells using NOT GATE + OR GATE logic decisions."
            },
            {
              "key": "Functionality",
              "value": "SENTI-202 combines two different Logic Gates and crIL-15 expression to improve persistence and antitumor functions."
            },
            {
              "key": "Logic Circuits",
              "value": "1. An iCAR NOT GATE circuit to prevent CAR-mediated killing of healthy HSCs. 2. An aCAR OR GATE circuit to activate CAR-mediated killing of AML cells. 3. A crIL-15 circuit to stimulate surrounding immune cells."
            },
            {
              "key": "Target Antigens",
              "value": "Identified FLT3 and CD33 as Tumor-Associated Antigens for CAR-mediated killing of AML."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 21,
          "title": "SENTI-202 CAR-NK Cells in Cancer Treatment",
          "data": [
            {
              "key": "Clinical Trial Efficacy",
              "value": "Greater than 90% protection of healthy cells in vivo."
            },
            {
              "key": "Experimental Setup",
              "value": "Effector cells were injected at a 1:1:1 ratio with model leukemia and healthy cells."
            },
            {
              "key": "Key Findings",
              "value": "SENTI-202 selectively kills leukemia cells while sparing healthy cells after 3 weeks."
            },
            {
              "key": "Comparison with Other Cells",
              "value": "Other groups displayed non-selective killing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 23,
          "title": "SENTI-401: Innovative Immunotherapy Approach for Colorectal Cancer",
          "data": [
            {
              "key": "Product Candidate",
              "value": "SENTI-401"
            },
            {
              "key": "Mechanism Overview",
              "value": "Includes a CEA activating CAR mechanism for cancer cell killing, a protective VSIG2 inhibitory CAR to safeguard healthy cells, calibrated IL-15 release for persistence and activation of CAR-NK and immune cells, and sustained anti-tumor function via IL-21."
            },
            {
              "key": "Target Indication",
              "value": "Colorectal Cancer"
            },
            {
              "key": "Unmet Medical Need",
              "value": "Colorectal cancer accounts for about 10% of cancers and related deaths worldwide, with significant challenges due to metastasis and low five‐year survival rates."
            },
            {
              "key": "Scientific Insight",
              "value": "CEA is overexpressed in colorectal tumors but is also present in normal gastrointestinal tissues, presenting challenges in targeting due to on-target off-tumor toxicities. SENTI-401 aims to overcome these issues."
            },
            {
              "key": "Visual Description",
              "value": "The accompanying diagram illustrates the product’s cellular mechanisms and pathways, using blue, green, and yellow color schemes to differentiate components and interactions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 24,
          "title": "SENTI-401 Product Candidate Details",
          "data": [
            {
              "key": "Product Candidate Name",
              "value": "SENTI-401"
            },
            {
              "key": "Gene Circuit Features",
              "value": "Designed with a NOT GATE gene circuit including an iCAR (restricting CAR-mediated cell killing to CEA-positive CRC cells while sparing healthy cells), an aCAR targeting CEA, a crIL-15 gene circuit for immune cell stimulation, and an IL-21 component to enhance therapeutic function."
            },
            {
              "key": "Target Cancer",
              "value": "CEA-expressing cancers, especially colorectal cancer (CRC)"
            },
            {
              "key": "Supporting Preclinical Data",
              "value": "CEA aCAR-NK cells showed significant tumor burden reduction in a luciferase-tagged human CRC (LoVo) xenograft model, with enhanced survival and decreased bioluminescence; incorporation of IL21 with crIL15 demonstrated enhanced serial killing even in the presence of inhibitory cytokine TGF-B."
            },
            {
              "key": "Mechanism",
              "value": "Utilizes gene circuit logic (NOT GATE) to differentiate between cancerous and healthy cells, potentially reducing on-target, off-tumor toxicity."
            },
            {
              "key": "Potential Benefit",
              "value": "May enable more effective treatment of solid tumors through improved selectivity and enhanced immune activation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 28,
          "title": "Introduction of SENTI-301A for Advanced HCC",
          "data": [
            {
              "key": "Product Name",
              "value": "SENTI-301A"
            },
            {
              "key": "Product Type",
              "value": "Cellular therapy"
            },
            {
              "key": "Indication",
              "value": "Advanced Hepatocellular Carcinoma (HCC)"
            },
            {
              "key": "Key Features",
              "value": "1. Targets GPC3 antigen, 2. Incorporates CRIL-15 for immune stimulation, 3. Multi-Armed attack on solid tumors."
            },
            {
              "key": "Efficacy",
              "value": "28% objective response rate, 7% complete response rate"
            },
            {
              "key": "Clinical Relevance",
              "value": "GPC3 expressed in 70-90% of HCC cases and associated with poor prognosis."
            },
            {
              "key": "Mechanism of Action",
              "value": "Includes constructive elements for NK cell cytotoxicity against tumor cells."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 40,
          "title": "Competition and Intellectual Property Overview",
          "data": [
            {
              "key": "Competitive Companies",
              "value": "A2 Biotherapeutics, Inc.; Arsenal Biosciences, Inc.; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Encoded Therapeutics, Inc.; ImmPACT Bio USA, Inc.; Intellia Therapeutics, Inc.; MeiraGTx Holdings plc; Obsidian Therapeutics, Inc.; Strand Therapeutics Inc."
            },
            {
              "key": "CAR-based Therapies Competition",
              "value": "Allogene Therapeutics, Inc.; Artiva Biotherapeutics, Inc.; Atara Biotherapeutics, Inc.; Bristol-Myers Squibb Company; Century Therapeutics, Inc.; Caribou Biosciences, Inc.; Catamaran Bio, Inc.; Cytovia Therapeutics, Inc.; Fate Therapeutics, Inc.; Gilead Sciences, Inc.; Lyell Immunopharma, Inc.; Nkarta, Inc.; Sana Biotechnology, Inc.; Shoreline Biosciences, Inc.; Takeda Pharmaceutical Company; Vor Biopharma Inc."
            },
            {
              "key": "Intellectual Property Strategy",
              "value": "Our strategy includes protecting proprietary technology rights domestically and in foreign markets through a combination of patents, trademarks, trade secrets, and contractual provisions."
            },
            {
              "key": "Patent Portfolio Size",
              "value": "As of February 19, 2023, includes over 11 issued patents and 148 pending patent applications."
            },
            {
              "key": "Patent Ownership",
              "value": "Own or co-own 3 patents and 120 pending patent applications; have licensed 8 patents and 28 pending applications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 44,
          "title": "BLA Submission and Review by the FDA",
          "data": [
            {
              "key": "Overview",
              "value": "Submission of a Biologics License Application (BLA) to request FDA approval to market a product."
            },
            {
              "key": "Regulatory Requirements",
              "value": "Must include relevant data from clinical studies, product chemistry, manufacturing, controls, and proposed labeling."
            },
            {
              "key": "User Fee",
              "value": "Requires payment of a substantial application user fee unless a waiver applies."
            },
            {
              "key": "FDA Review Timeline",
              "value": "Standard reviews within ten months, priority reviews within six months after acceptance."
            },
            {
              "key": "Safety and Efficacy Evaluation",
              "value": "FDA determines safety, purity, potency, and compliance with manufacturing standards."
            },
            {
              "key": "Advisory Committee",
              "value": "Panel of experts providing recommendations, not binding on FDA decisions."
            },
            {
              "key": "Inspection Requirements",
              "value": "FDA inspects manufacturing facilities and clinical sites before approval."
            },
            {
              "key": "Approval Outcomes",
              "value": "Approval letter authorizes marketing; Complete Response Letter outlines deficiencies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 109,
          "title": "Clinical Trials and Product Candidates",
          "data": [
            {
              "key": "Overview",
              "value": "Discussion of clinical trials and potential setbacks for product candidates."
            },
            {
              "key": "Challenges",
              "value": "Delays may arise from various factors including regulatory requirements, site agreements, recruiting patients, and trial site performance."
            },
            {
              "key": "Impact",
              "value": "Delayed trials can affect the approval and market introduction of product candidates."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 34,
          "title": "Technical Expertise and Facilities for Clinical and Commercial Manufacturing",
          "data": [
            {
              "key": "Corporate Headquarters Location",
              "value": "South San Francisco, CA"
            },
            {
              "key": "Total Office and R&D Space",
              "value": "Approximately 40,000 square feet"
            },
            {
              "key": "Manufacturing Development Labs Space",
              "value": "Approximately 10,000 square feet dedicated"
            },
            {
              "key": "Lease Agreement for cGMP Facility",
              "value": "Signed in June 2021 for approximately 92,000 square feet in Alameda, California for a state-of-the-art cGMP facility"
            },
            {
              "key": "Technology Transfer of SENTI-202",
              "value": "Initiated in January 2023 to support clinical-scale manufacturing for off-the-shelf CAR-NK cell product candidates"
            },
            {
              "key": "Business Strategy",
              "value": "Leverage proprietary manufacturing processes to maintain quality and supply, and explore partnerships for gene circuit technology applications"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 59,
          "title": "Capital Requirements and Funding Needs",
          "data": [
            {
              "key": "Background Information",
              "value": "Discussion on the need for substantial additional funding for product development and operations."
            },
            {
              "key": "Current Financial Status",
              "value": "As of December 31, 2022, $98.6 million in cash, cash equivalents, and short-term investments."
            },
            {
              "key": "Future Capital Requirements",
              "value": "Future capital needs are uncertain and depend on various factors including development progress, operational costs, and collaboration terms."
            },
            {
              "key": "Key Considerations",
              "value": "Factors influencing future capital requirements include preclinical and clinical development timelines, manufacturing cost and capability considerations, and ongoing research activities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 60,
          "title": "Capital Financing and Operational Modifications",
          "data": [
            {
              "key": "Impact Factors",
              "value": "COVID-19 pandemic, supply chain disruptions, global political and market conditions, inflationary pressures"
            },
            {
              "key": "Financing Sources",
              "value": "Sale of equity securities, public/private equity offerings, debt financings, collaborations"
            },
            {
              "key": "Future Actions",
              "value": "Develop SENTI-202 and SENTI-401, suspend SENTI-301A R&D"
            },
            {
              "key": "Risks Associated",
              "value": "Inability to obtain adequate financing, potential liquidation of assets"
            },
            {
              "key": "Internal Controls",
              "value": "Material weakness reported in internal control over financial reporting"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 140,
          "title": "Contractual Obligations and Commitments",
          "data": [
            {
              "key": "Lease Agreement",
              "value": "Entered into a lease agreement for a new cGMP facility in Alameda, California."
            },
            {
              "key": "Lease Expiration",
              "value": "Expiration in 2032 with future undiscounted operating lease payments of $46.0 million."
            },
            {
              "key": "Construction Costs",
              "value": "Paid $35.5 million out of $42.1 million in purchase commitment for construction of cGMP facility."
            },
            {
              "key": "Collaboration Agreement",
              "value": "Entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP."
            },
            {
              "key": "Collaboration Costs",
              "value": "Up to $10.0 million in R&D costs and expenses over three years."
            },
            {
              "key": "Maintenance Payments",
              "value": "Annual maintenance payments of $0.1 million required."
            },
            {
              "key": "Sponsored Research Payments",
              "value": "Obligated to pay $1.1 million and $0.2 million in 2023 and 2024, respectively."
            },
            {
              "key": "Contingent Earnout",
              "value": "Potential issuance of up to 2,000,000 additional shares post-merger."
            },
            {
              "key": "Off-Balance Sheet Arrangements",
              "value": "No current off-balance sheet arrangements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 155,
          "title": "Asset Useful Life Schedule and Depreciation Policy Disclosure",
          "data": [
            {
              "key": "Depreciation Method",
              "value": "Straight-line"
            },
            {
              "key": "Asset: Small equipment useful life",
              "value": "2 years"
            },
            {
              "key": "Asset: Computer equipment and software useful life",
              "value": "3 years"
            },
            {
              "key": "Asset: Laboratory equipment useful life",
              "value": "5-7 years"
            },
            {
              "key": "Asset: Furniture and fixtures useful life",
              "value": "5-7 years"
            },
            {
              "key": "Summary",
              "value": "This table shows the useful life (depreciation period) of various types of business assets. The disclosure describes how property and equipment are stated at cost, net of accumulated depreciation, and explains the depreciation method along with accounting policies related to fixed asset management, including impairment and lease accounting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 201,
          "title": "Lease Payment Schedule",
          "data": [
            {
              "key": "period",
              "value": "1-12"
            },
            {
              "key": "rate",
              "value": "$45.00"
            },
            {
              "key": "amount",
              "value": "$344,662.50"
            },
            {
              "key": "period",
              "value": "13 - 24"
            },
            {
              "key": "rate",
              "value": "$46.35"
            },
            {
              "key": "amount",
              "value": "$355,002.38"
            },
            {
              "key": "period",
              "value": "25 - 36"
            },
            {
              "key": "rate",
              "value": "$47.74"
            },
            {
              "key": "amount",
              "value": "$365,652.45"
            },
            {
              "key": "period",
              "value": "37 - 48"
            },
            {
              "key": "rate",
              "value": "$49.17"
            },
            {
              "key": "amount",
              "value": "$376,622.02"
            },
            {
              "key": "period",
              "value": "49 - 60"
            },
            {
              "key": "rate",
              "value": "$50.65"
            },
            {
              "key": "amount",
              "value": "$387,920.68"
            },
            {
              "key": "period",
              "value": "61-72"
            },
            {
              "key": "rate",
              "value": "$52.17"
            },
            {
              "key": "amount",
              "value": "$399,558.30"
            },
            {
              "key": "period",
              "value": "73 - 84"
            },
            {
              "key": "rate",
              "value": "$53.73"
            },
            {
              "key": "amount",
              "value": "$411,545.05"
            },
            {
              "key": "period",
              "value": "85 - 96"
            },
            {
              "key": "rate",
              "value": "$55.34"
            },
            {
              "key": "amount",
              "value": "$423,891.40"
            },
            {
              "key": "period",
              "value": "97 - 108"
            },
            {
              "key": "rate",
              "value": "$57.00"
            },
            {
              "key": "amount",
              "value": "$436,608.14"
            },
            {
              "key": "period",
              "value": "109 - 120"
            },
            {
              "key": "rate",
              "value": "$58.71"
            },
            {
              "key": "amount",
              "value": "$449,706.39"
            },
            {
              "key": "period",
              "value": "121 - Expiration Date"
            },
            {
              "key": "rate",
              "value": "$60.48"
            },
            {
              "key": "amount",
              "value": "$463,197.58"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 203,
          "title": "Lease Provisions and Property Measurements",
          "data": [
            {
              "key": "Tenant RSF Share Calculation",
              "value": "Tenant’s 100%, calculated as the ratio of the RSF in the Premises to the Building RSF (91,910 RSF at Lease execution)"
            },
            {
              "key": "Phase I Proportionate Share",
              "value": "50% (Tenant’s Proportionate Share for the Phase I Premises)"
            },
            {
              "key": "Initial Liability",
              "value": "$5,000,000.00"
            },
            {
              "key": "Insurance Amount",
              "value": "Not specified"
            },
            {
              "key": "Parking Spaces",
              "value": "221 parking spaces – constituting all parking in the area at no charge to Tenant during the Lease term"
            },
            {
              "key": "Tenant Broker/Agent",
              "value": "T3 Advisors"
            },
            {
              "key": "Landlord Broker/Agent",
              "value": "CBRE, Inc."
            },
            {
              "key": "Tenant Address",
              "value": "Senti Biosciences, Inc., Two Corporate Drive, South San Francisco, CA 94080"
            },
            {
              "key": "Tenant Facilities Manager Telephone",
              "value": "(650) 491-9644"
            },
            {
              "key": "Copy To Address",
              "value": "Cooley LLP, th 101 California Street, 5 Floor, San Francisco, CA, 94111"
            },
            {
              "key": "Copy To Contact",
              "value": "Rachel Antoinette Boyce"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 207,
          "title": "Lease Terms – Premises Condition and Rent Payment",
          "data": [
            {
              "key": "Premises Acceptance",
              "value": "Tenant accepts the Premises and each Phase thereof in an 'AS-IS' condition, subject to applicable laws, except for the Covered Items which are warranted to be in good operating condition at delivery."
            },
            {
              "key": "Tenant Improvements",
              "value": "Possession of the Premises is taken for the performance of Tenant Improvements, with the understanding that the condition is accepted unless a proper warranty notice is given within 180 days."
            },
            {
              "key": "Rent Payment Terms",
              "value": "Tenant is required to pay Rent as defined in the Lease, including a first monthly installment of Base Rent amounting to $344,662.50 payable upon execution, with subsequent monthly advance payments via ACH credit transfer."
            },
            {
              "key": "Warranty Work",
              "value": "In case of non-compliance or malfunction of the Covered Items (Building’s Systems, Building’s Structure, and Loading Dock) at delivery or within 180 days, Landlord is obligated to rectify the issue upon receiving written notice from Tenant."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 210,
          "title": "Letter of Credit & Tenant Improvement Allowance Clause",
          "data": [
            {
              "key": "Approval Requirement",
              "value": "Assignee’s actions subject to Landlord’s prior written approval, which shall not be unreasonably withheld, conditioned or delayed."
            },
            {
              "key": "Maintenance Obligation",
              "value": "Tenant must continuously maintain the Letter of Credit (through replacement, amendment, renewal, or extension) until the Final LC Expiration Date."
            },
            {
              "key": "Evergreen Provision",
              "value": "The Letter of Credit includes an automatic renewal provision unless the Issuing Bank gives at least sixty (60) days’ prior written notice of non-renewal."
            },
            {
              "key": "Tenant Improvement Allowance Condition",
              "value": "Disbursement of the Tenant Improvement Allowance is contingent upon Tenant delivering the Letter of Credit to Landlord."
            },
            {
              "key": "Insolvency and Default Provisions",
              "value": "Landlord may draw funds from the Letter of Credit if Tenant is in default, undergoes insolvency events, or fails to timely replace an expiring Letter of Credit."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 214,
          "title": "Alterations, Repairs, Maintenance; Common Area Usage and Tenant Improvements",
          "data": [
            {
              "key": "common_area_usage",
              "value": "Tenant, its employees, customers, and authorized subtenants, licensees and concessionaires have a non-exclusive right to use the Common Area, subject to Landlord's rules, governmental restrictions and other users’ rights."
            },
            {
              "key": "landlord_rights",
              "value": "Landlord reserves the right to change the dimensions and location of the Common Area and modify the buildings, signs, and other improvements within the Complex."
            },
            {
              "key": "alterations_requirements",
              "value": "Tenant must obtain Landlord’s written consent before making any alterations, additions or improvements (except for unattached, movable trade fixtures). Consent is required if alterations affect the Building’s Systems or Structure, involve governmental plan submissions, exceed $200,000, or require permits."
            },
            {
              "key": "reimbursement_policy",
              "value": "Tenant must reimburse Landlord for actual out-of-pocket costs incurred for review and monitoring of alterations (including management, engineering, consulting, and construction fees), not to exceed $10,000 per project, within ten days of billing."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 216,
          "title": "Lease Maintenance and Repair Obligations",
          "data": [
            {
              "key": "Scope of Maintenance",
              "value": "Describes the maintenance and repair responsibilities for exterior elements (openings, frames, moldings, etc.), common areas (Loading Dock, roof, Parking Area) and systems (HVAC, electrical, plumbing)."
            },
            {
              "key": "Landlord Responsibilities",
              "value": "Landlord must maintain exterior elements in good condition and make repairs as needed, except those caused by Tenant’s negligence. Landlord also maintains common areas subject to reimbursement."
            },
            {
              "key": "Tenant Responsibilities",
              "value": "Tenant is responsible for keeping the Premises and non-common areas (including Loading Dock if not used commonly) clean, in good repair, and for entering into HVAC maintenance contracts. Tenant must promptly notify Landlord of needed repairs."
            },
            {
              "key": "Liability and Repair Notification",
              "value": "Specifies that Landlord is not liable for business interruptions or inconveniences caused by repair works, and outlines the procedure for notification and timing for repairs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 237,
          "title": "22. Holding Over & Landlord Rights",
          "data": [
            {
              "key": "Holding Over Provision",
              "value": "If Tenant fails to vacate the Premises at the end of the Term, they become a tenant at sufferance and must pay additional Base Rent. For the first 60 days, this is 150% of the Base Rent payable during the last month of the Term; thereafter, the amount is the greater of 150% of that Base Rent or 150% of the prevailing rental rate for similar space."
            },
            {
              "key": "Tenant Obligations & Indemnity",
              "value": "Tenant must continue to meet all obligations under the Lease and is required to indemnify and hold Landlord harmless from losses, costs (including attorneys’ fees), liabilities, and claims arising from failure to surrender the Premises."
            },
            {
              "key": "Landlord Rights - Building Operations",
              "value": "Landlord may enter the Premises (with proper notice except in emergencies) to conduct inspections, repairs, alterations, additions, or improvements, and may temporarily close access points and modify building arrangements as needed."
            },
            {
              "key": "Landlord Rights - Access Control",
              "value": "Landlord is entitled to implement reasonable access control measures for protection, including evacuations, temporary denials of access, and closing the building after normal business hours, all subject to certain conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 247,
          "title": "Lease Execution Details",
          "data": [
            {
              "key": "Lease Clause",
              "value": "This Lease is executed on the respective dates set forth below, but for reference purposes, this Lease shall be dated as of the date first above written. If the execution date is left blank, this Lease shall be deemed executed as of the date first written above."
            },
            {
              "key": "Landlord",
              "value": "1430 HARBOR BAY PKWY LLC, a Delaware limited liability company"
            },
            {
              "key": "Landlord Representative",
              "value": "Kevin Pirozzoli, Vice President"
            },
            {
              "key": "Landlord Execution Date",
              "value": "June 3, 2021"
            },
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC., a Delaware corporation"
            },
            {
              "key": "Tenant Representative 1",
              "value": "Philip Lee, CTO, Execution Date: June 3, 2021"
            },
            {
              "key": "Tenant Representative 2",
              "value": "Deborah Knoebelman, CFO, Execution Date: June 3, 2021"
            },
            {
              "key": "Additional Note",
              "value": "[If Tenant is a corporation, Tenant should have one officer from each of the following categories sign for Tenant: (a) a president, vice president or chairman of the board and (b) a secretary, assistant secretary, chief financial officer or assistant treasurer (unless the Lease is returned accompanied by a corporate resolution identifying a single authorized signatory).]"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 248,
          "title": "EXHIBIT A OUTLINE OF PREMISES",
          "data": [
            {
              "key": "Exhibit Title",
              "value": "EXHIBIT A OUTLINE OF PREMISES"
            },
            {
              "key": "Floor Plan Description",
              "value": "The image shows an architectural floor plan of the 1st floor of Building B. It features a loading dock with dock high doors centered on the upper wall, and four stairwells labeled 'STAIR #1 WEST', 'STAIR #2 WEST', 'STAIR #2 EAST', and 'STAIR #1 EAST'. The layout, which appears to be an industrial or commercial space, also includes structural markings for columns and walls as well as circular markers labeled with combinations such as 'B1', 'B2', and 'A' along the sides."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 250,
          "title": "EXHIBIT C ADDITIONAL RENT, TAXES, AND INSURANCE",
          "data": [
            {
              "key": "Additional Rent",
              "value": "Tenant is required to pay its Proportionate Share of the annual Common Area Maintenance Costs as Additional Rent. The amount is estimated by Landlord and paid monthly in advance along with Base Rent, with adjustments made up to twice yearly based on re-estimations."
            },
            {
              "key": "Common Area Maintenance Costs",
              "value": "Includes expenses related to the management, operation, maintenance, repair, and replacement of the Project or Complex. It covers wages and salaries of on-site staff and reasonable allocations for off-site personnel, supplies, materials, and various improvements."
            },
            {
              "key": "Capital Improvements and Amortization",
              "value": "Costs for capital improvements, including those for reducing normal maintenance costs, complying with laws, enhancing health and safety, and capital repairs, are amortized over a period determined by Landlord using commercially reasonable interest rates and estimates of useful economic life."
            },
            {
              "key": "Estimation and Adjustment Process",
              "value": "Landlord may provide an initial estimate for Additional Rent and adjust it during the calendar year (but no more than twice) to ensure Tenant pays the accurate share based on actual Common Area Maintenance Costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 251,
          "title": "Определение и исключения затрат на обслуживание общих территорий",
          "data": [
            {
              "key": "Описание включаемых затрат",
              "value": "Расходы, включаемые в стоимость обслуживания общих территорий: расходы на аренду, коммунальные платежи, ремонт, замену и общее техническое обслуживание, а также управление объектом (включая сборы за управление, не превышающие 3% от валовой арендной платы)."
            },
            {
              "key": "Описание исключаемых затрат",
              "value": "Перечень расходов, не относящихся к затратам на обслуживание общих территорий: расходы, оплаченные страховыми выплатами; выплаты по процентам и амортизации по займам; износ; комиссионные по аренде; юридические расходы (за исключением тех, что приносят реальную пользу арендаторам); затраты на ремонт или улучшение арендованных помещений или пустующих площадей; налоги и страхование, оплачиваемые отдельно; федеральные подоходные налоги, связанные с доходом от эксплуатации объекта; расходы, связанные с оказанием дополнительных услуг арендаторам; затраты на первоначальное развитие или улучшение, новое строительство или капитальный ремонт; расходы, связанные с услугами, предоставляемыми не всем арендаторам; накладные расходы сверх конкурентных цен; дополнительные арендные платежи по основным или дополнительным договорам, за исключением случаев, когда эти платежи входят в состав базовых арендных платежей; компенсация сотрудникам коммерческих уступок; рекламные и промоционные расходы; штрафные санкции за нарушение законодательства; расходы, возникшие из-за грубой небрежности или преднамеренных нарушений со стороны арендодателя; благотворительные или политические взносы, профсоюзные взносы; затраты, связанные с восстановлением после пожаров, штормов или других форс-мажорных обстоятельств (при условии получения страховых выплат или при самостраховании); расходы на устранение нарушений строительных норм, имевших место до подписания договора; затраты на ликвидацию загрязнения, не вызванного арендатором."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 252,
          "title": "Обязанности Арендатора по оплате затрат и налогов",
          "data": [
            {
              "key": "Acquisition Costs",
              "value": "Указаны затраты на приобретение скульптуры, картин или других объектов искусства (исключая расходы на обслуживание, ремонт и страхование)."
            },
            {
              "key": "Taxes Definition",
              "value": "Налоги, сборы и государственные пошлины (включая оценки и прочие налоги, за исключением штрафов, процентов и некоторых федеральных и штатных налогов на доход). Также включаются затраты консультантов по снижению налоговой нагрузки и споры по налоговой оценке."
            },
            {
              "key": "Insurance Definition",
              "value": "Страхование имущества, ответственности и прочих рисков, включая франшизы и программы удержания рисков, а также распределение расходов на общие страховые полисы."
            },
            {
              "key": "Tenant Obligations",
              "value": "Арендатор обязан оплачивать свою пропорциональную долю общих расходов, налогов и страхования в соответствии с условиями договора, а также получать ежегодный отчет от Арендодателя."
            },
            {
              "key": "Statement Provision",
              "value": "Арендодатель обязан предоставить отчет по затратам на обслуживание общих зон, налоги и страхование не позднее 1 мая каждого календарного года."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 253,
          "title": "Lease Provisions – CAM Costs, Gross-Up, Cost Pools and Audit Rights",
          "data": [
            {
              "key": "Obligation",
              "value": "Tenant must pay any deficiency if its share of Common Area Maintenance, Taxes, and Insurance is less than indicated in the Statement even after the Lease term ends."
            },
            {
              "key": "Gross-Up Provision",
              "value": "If the Building or Complex is not 100% occupied or fully serviced, the CAM costs are increased to what would have been incurred at full occupancy and full service."
            },
            {
              "key": "Cost Pools",
              "value": "Landlord may allocate CAM Costs, Taxes, and Insurance among various projects, buildings, portions, and occupants in the Complex at its discretion."
            },
            {
              "key": "Audit Right",
              "value": "Tenant is granted a right to audit Landlord’s books regarding CAM Costs (subject to specific timing, qualifications, and confidentiality requirements) to confirm consistency with the Lease."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 257,
          "title": "Laboratory Improvements and Equipment Requirements",
          "data": [
            {
              "key": "Permits and Compliance",
              "value": "Tenant must obtain and maintain all necessary permits, licenses, certifications, and approvals for the use, handling, storage, and disposal of Hazardous Materials, with ongoing inspection rights for the Landlord."
            },
            {
              "key": "Laboratory Improvements",
              "value": "Tenant’s improvements to the Premises for Laboratory Use, including installation of Laboratory Equipment, must comply with the Work Agreement and Applicable Laboratory Use Laws."
            },
            {
              "key": "Installation Requirements",
              "value": "All Laboratory Equipment must be properly insulated to minimize noise or vibrations affecting other parts of the Complex, with Tenant responsible for abatement if complaints arise."
            },
            {
              "key": "HEPA Filters Usage",
              "value": "Tenant is required to use high efficiency particulate air (HEPA) filters in exhaust equipment for Laboratory Use in accordance with laws and industry best practices."
            },
            {
              "key": "Decommissioning Obligations",
              "value": "Prior to expiration or termination of the Lease, Tenant must decontaminate and decommission all Laboratory Equipment to meet applicable legal standards and provide certification from an independent third party."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 1,
          "title": "Form 10-K Cover Page and Table of Contents",
          "data": [
            {
              "key": "Form Type",
              "value": "10-K"
            },
            {
              "key": "Report Description",
              "value": "ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "SEC File Number",
              "value": "001-40440"
            },
            {
              "key": "Registrant Name",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Incorporation Jurisdiction",
              "value": "Delaware"
            },
            {
              "key": "Employer Identification Number",
              "value": "86-2437900"
            },
            {
              "key": "Principal Executive Offices",
              "value": "2 Corporate Drive, First Floor South San Francisco, CA 94080"
            },
            {
              "key": "Telephone",
              "value": "(650) 239-2030"
            },
            {
              "key": "Security Details",
              "value": "Common stock, par value $0.0001 per share; Securities registered pursuant to 12(g) of the Act: None"
            },
            {
              "key": "Filer Status",
              "value": "Well-known seasoned issuer: Yes; Smaller reporting company: Yes; Emerging growth company: Yes"
            },
            {
              "key": "Trading Table Summary",
              "value": "Header table for displaying security trading information with columns: Trading, Name of each exchange, Title of each class, Symbol(s)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 131,
          "title": "Overview, Forward-Looking Statements and Financial Performance",
          "data": [
            {
              "key": "Forward-Looking Disclaimer",
              "value": "The report contains forward-looking statements identified by words such as 'expect', 'believe', 'anticipate', etc. It cautions that actual results may differ materially due to risks and uncertainties and refers readers to the Risk Factors section."
            },
            {
              "key": "Company Overview",
              "value": "Senti is a preclinical biotechnology company developing next-generation cell and gene therapies using its synthetic biology platform, notably through engineered gene circuits."
            },
            {
              "key": "Product Pipeline",
              "value": "All current product candidates are in preclinical development, with plans to file INDs for multiple candidates starting in 2023 and use allogeneic CAR NK cells for oncology indications."
            },
            {
              "key": "Financial Performance - Net Losses",
              "value": "Net losses of $58.2 million for 2022 and $55.3 million for 2021."
            },
            {
              "key": "Financial Performance - Cash & Equivalents",
              "value": "As of December 31, 2022 and 2021, cash, cash equivalents, and short-term investments were $98.6 million and $56.0 million respectively."
            },
            {
              "key": "Financial Performance - Accumulated Deficit",
              "value": "Accumulated deficit of $173.3 million as of December 31, 2022 and $115.1 million as of December 31, 2021."
            },
            {
              "key": "Financial Performance - Operating Cash Flows",
              "value": "Net cash flows used in operating activities were $34.9 million for 2022 and $34.6 million for 2021."
            },
            {
              "key": "Future Outlook",
              "value": "The company expects to continue incurring significant losses and anticipates an increase in expenses driven by advancing its gene circuit technologies, further preclinical and clinical development, manufacturing capability expansion, and technology acquisitions/licensing."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 136,
          "title": "Revenue and Operating Expenses Comparison 2021-2022",
          "data": [
            {
              "key": "Contract revenue 2022",
              "value": "$3.3 million"
            },
            {
              "key": "Contract revenue 2021",
              "value": "$2.3 million"
            },
            {
              "key": "Increase in contract revenue",
              "value": "$1.0 million"
            },
            {
              "key": "Grant income 2022",
              "value": "$1.0 million"
            },
            {
              "key": "Grant income 2021",
              "value": "$0.5 million"
            },
            {
              "key": "Increase in grant income",
              "value": "$0.5 million"
            },
            {
              "key": "Total revenue 2022",
              "value": "$4.3 million (approx.)"
            },
            {
              "key": "Total revenue 2021",
              "value": "$2.8 million (approx.)"
            },
            {
              "key": "Total revenue increase",
              "value": "$1.525 million"
            },
            {
              "key": "Research and development expenses 2022",
              "value": "$34.1 million"
            },
            {
              "key": "Research and development expenses 2021",
              "value": "$22.0 million"
            },
            {
              "key": "Increase in R&D expenses",
              "value": "$12.1 million"
            },
            {
              "key": "General and administrative expenses 2022",
              "value": "$40.8 million"
            },
            {
              "key": "General and administrative expenses 2021",
              "value": "$21.3 million"
            },
            {
              "key": "Increase in general and administrative expenses",
              "value": "$19.598 million"
            },
            {
              "key": "Total operating expenses 2022",
              "value": "$74.915 million"
            },
            {
              "key": "Total operating expenses 2021",
              "value": "$43.207 million"
            },
            {
              "key": "Increase in operating expenses",
              "value": "$31.708 million"
            },
            {
              "key": "Loss from operations 2022",
              "value": "-$70.629 million"
            },
            {
              "key": "Loss from operations 2021",
              "value": "-$40.446 million"
            },
            {
              "key": "Change in loss from operations",
              "value": "-$30.183 million"
            },
            {
              "key": "Other income (expense) 2022",
              "value": "$12.419 million"
            },
            {
              "key": "Other income (expense) 2021",
              "value": "-$14.873 million"
            },
            {
              "key": "Net change in other income (expense)",
              "value": "$27.292 million"
            },
            {
              "key": "Net loss 2022",
              "value": "-$58.210 million"
            },
            {
              "key": "Net loss 2021",
              "value": "-$55.319 million"
            },
            {
              "key": "Change in net loss",
              "value": "-$2.891 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 137,
          "title": "General and Administrative Expenses and Liquidity & Capital Resources",
          "data": [
            {
              "key": "General and administrative expenses 2022",
              "value": "$40.8 million"
            },
            {
              "key": "General and administrative expenses 2021",
              "value": "$21.3 million"
            },
            {
              "key": "Increase in general and administrative expenses",
              "value": "$19.6 million"
            },
            {
              "key": "Increase in personnel-related expenses",
              "value": "$18.1 million"
            },
            {
              "key": "Increase in stock-based compensation expense",
              "value": "$11.4 million"
            },
            {
              "key": "Increase in insurance expense",
              "value": "$1.7 million"
            },
            {
              "key": "Increase in other corporate expenses",
              "value": "$0.2 million"
            },
            {
              "key": "Decrease in professional, legal and accounting services expenses",
              "value": "$0.2 million"
            },
            {
              "key": "Decrease in facility costs",
              "value": "$0.1 million"
            },
            {
              "key": "Change in fair value of contingent earnout liability",
              "value": "$9.5 million gain (non-cash)"
            },
            {
              "key": "Gain on extinguishment of convertible notes",
              "value": "$1.3 million"
            },
            {
              "key": "Preferred stock tranche liability adjustment (2021)",
              "value": "-$14.7 million"
            },
            {
              "key": "Gross proceeds from issuance of preferred stock and convertible notes",
              "value": "$158.1 million"
            },
            {
              "key": "PIPE Financing proceeds (including Bayer convertible note cancellation and exchange)",
              "value": "$140.7 million"
            },
            {
              "key": "Purchase Agreement with Chardan (sell option)",
              "value": "$50.0 million or 8,727,049 shares at 97% VWAP over 36 months"
            },
            {
              "key": "Shares issued to Chardan upon agreement execution",
              "value": "100,000 shares"
            },
            {
              "key": "Document preparation fee for Chardan agreement",
              "value": "$0.4 million"
            },
            {
              "key": "Chardan related legal fees and costs expensed",
              "value": "$0.7 million"
            },
            {
              "key": "Class A common stock issuance under the Common Stock Purchase Agreement",
              "value": "300,000 shares for $0.7 million"
            },
            {
              "key": "Cash, cash equivalents, and short-term investments (Dec 31, 2022)",
              "value": "$98.6 million"
            },
            {
              "key": "Accumulated deficit (Dec 31, 2022)",
              "value": "$173.3 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 138,
          "title": "Cash Flow Statement Comparison 2022-2021",
          "data": [
            {
              "key": "Summary",
              "value": "This table presents a cash flow comparison between 2022 and 2021. Notable observations include: significant negative operating cash flows in both years (-$34.9M in 2022 vs -$34.6M in 2021), a substantial increase in investment cash outflow (-$82.0M in 2022 vs -$5.5M in 2021), and increased financing activities ($118.6M in 2022 vs $68.4M in 2021). The net change in cash was positive but decreased significantly from $28.3M in 2021 to $1.7M in 2022."
            },
            {
              "key": "Operating Cash Flow 2022",
              "value": "-34896"
            },
            {
              "key": "Operating Cash Flow 2021",
              "value": "-34635"
            },
            {
              "key": "Investing Cash Flow 2022",
              "value": "-81959"
            },
            {
              "key": "Investing Cash Flow 2021",
              "value": "-5543"
            },
            {
              "key": "Financing Cash Flow 2022",
              "value": "118551"
            },
            {
              "key": "Financing Cash Flow 2021",
              "value": "68435"
            },
            {
              "key": "Net Change in Cash 2022",
              "value": "1696"
            },
            {
              "key": "Net Change in Cash 2021",
              "value": "28257"
            },
            {
              "key": "Additional Commentary",
              "value": "Detailed narrative explains that operating activities for 2022 were primarily driven by a net loss combined with non-cash adjustments including stock-based compensation, adjustments for contingent earnout liabilities, depreciation of operating lease assets, and other adjustments. The investing activities reflected significant purchases in short-term investments and property/equipment, while financing activities saw proceeds from merger-related PIPE financing and other issuances."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 143,
          "title": "Financial Disclosures: Revenue Recognition, Stock Volatility & Emerging Growth Status",
          "data": [
            {
              "key": "Dividend History",
              "value": "The company has never paid or declared dividends."
            },
            {
              "key": "Liquidity Estimation",
              "value": "Time to liquidity estimated by weighting potential timelines associated with reaching various pipeline milestones and completing an IPO."
            },
            {
              "key": "Stock Volatility Estimation",
              "value": "Expected stock volatility estimated based on historical volatility of a representative group of public biotechnology companies."
            },
            {
              "key": "Option Type Determination",
              "value": "Determination based on available payouts to holders of tranche rights and control levels, involving significant judgment and inherent uncertainties."
            },
            {
              "key": "Revenue Recognition",
              "value": "Revenues recognized when customers obtain control of promised goods or services; primarily derived from collaborative research, development and license agreements."
            },
            {
              "key": "Payment Arrangements",
              "value": "Payments include nonrefundable upfront and license fees, research funding, milestone and contingent payments, and royalties on product sales."
            },
            {
              "key": "Performance Obligations Assessment",
              "value": "Judgment required to determine if research and development services are distinct from the license of intellectual property or steering committee participation."
            },
            {
              "key": "SSP Allocation",
              "value": "Transaction price allocated based on relative standalone selling price (SSP) of each performance obligation; estimation may be required if SSP is not directly observable."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "The company is an emerging growth company under the JOBS Act, electing not to use its extended transition period; will remain so until specified revenue or market value thresholds are met."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 144,
          "title": "Disclosures on Debt Issuance and Smaller Reporting Company Status",
          "data": [
            {
              "key": "Debt Issuance Threshold",
              "value": "More than $1.0 billion in non-convertible debt securities issued during the preceding rolling three-year period"
            },
            {
              "key": "Secondary Threshold",
              "value": "$100 million, as mentioned in the Table of Contents"
            },
            {
              "key": "Smaller Reporting Company Criteria - Market Value",
              "value": "Common stock held by non-affiliates less than $250 million, or alternatively less than $700 million"
            },
            {
              "key": "Smaller Reporting Company Criteria - Annual Revenue",
              "value": "Annual revenues in the most recent fiscal year completed before the second fiscal quarter are less than $100 million"
            },
            {
              "key": "Segment Information",
              "value": "One business activity and one reportable segment"
            },
            {
              "key": "Market Risk Disclosure",
              "value": "Qualifies as a smaller reporting company and is not required to provide full market risk disclosures under Item 7A"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 145,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Table of Contents Items",
              "value": "Report of Independent Registered Public Accounting Firm; Consolidated Balance Sheets as of December 31, 2022 and 2021; Consolidated Statements of and Loss for the Years Ended December 31, 2022 and 2021; Operations Comprehensive; Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' for the Years Ended December 31, 2022; Equity (Deficit) 31, 2022 and 2021; Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021"
            },
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents or index for a financial report, listing the main financial statements and documents included in the report. It covers various financial statements including the balance sheets, statements of operations and loss, statements of stockholders' equity, and cash flows for the fiscal years 2021 and 2022. The report also includes an independent auditor's statement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 146,
          "title": "Independent Auditor Report & Opinion on Consolidated Financial Statements",
          "data": [
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Audit Firm",
              "value": "KPMG LLP"
            },
            {
              "key": "Audit Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Location",
              "value": "San Francisco, California"
            },
            {
              "key": "Financial Period",
              "value": "As of December 31, 2022 and 2021; two-year period ended December 31, 2022"
            },
            {
              "key": "Accounting Principles",
              "value": "U.S. generally accepted accounting principles"
            },
            {
              "key": "Opinion",
              "value": "The consolidated financial statements present fairly, in all material respects, the financial position of the Company."
            },
            {
              "key": "Going Concern",
              "value": "The statements have been prepared on the assumption of going concern, but recurring losses, negative cash flows, and an accumulated deficit raise substantial doubt about the Company's ability to continue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 147,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Cash and cash equivalents (2022)",
              "value": "57621"
            },
            {
              "key": "Cash and cash equivalents (2021)",
              "value": "56034"
            },
            {
              "key": "Accounts receivable (2022)",
              "value": "626"
            },
            {
              "key": "Accounts receivable (2021)",
              "value": "483"
            },
            {
              "key": "Short-term investments (2022)",
              "value": "40942"
            },
            {
              "key": "Short-term investments (2021)",
              "value": "0"
            },
            {
              "key": "Total current assets (2022)",
              "value": "102579"
            },
            {
              "key": "Total current assets (2021)",
              "value": "60193"
            },
            {
              "key": "Total assets (2022)",
              "value": "180792"
            },
            {
              "key": "Total assets (2021)",
              "value": "96702"
            },
            {
              "key": "Total current liabilities (2022)",
              "value": "18053"
            },
            {
              "key": "Total current liabilities (2021)",
              "value": "14543"
            },
            {
              "key": "Total liabilities (2022)",
              "value": "53529"
            },
            {
              "key": "Total liabilities (2021)",
              "value": "36326"
            },
            {
              "key": "Additional paid-in capital (2022)",
              "value": "300544"
            },
            {
              "key": "Additional paid-in capital (2021)",
              "value": "3619"
            },
            {
              "key": "Accumulated deficit (2022)",
              "value": "-173286"
            },
            {
              "key": "Accumulated deficit (2021)",
              "value": "-115076"
            },
            {
              "key": "Total stockholders' equity (deficit) (2022)",
              "value": "127263"
            },
            {
              "key": "Total stockholders' equity (deficit) (2021)",
              "value": "-111457"
            },
            {
              "key": "Summary",
              "value": "This balance sheet compares financial positions between 2022 and 2021. Key observations include: a significant increase in total assets from $96.7M to $180.8M, a transition from a stockholders' deficit to positive equity, major growth in additional paid-in capital indicating a capital raising event, and a substantial increase in short-term investments."
            },
            {
              "key": "Notes",
              "value": "The accompanying notes are an integral part of these consolidated financial statements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 148,
          "title": "SENTI BIOSCIENCES, INC. Consolidated Statements of Operations and Comprehensive Loss",
          "data": [
            {
              "key": "Contract revenue 2022",
              "value": "3,286"
            },
            {
              "key": "Contract revenue 2021",
              "value": "2,291"
            },
            {
              "key": "Grant income 2022",
              "value": "1,000"
            },
            {
              "key": "Grant income 2021",
              "value": "470"
            },
            {
              "key": "Total revenue 2022",
              "value": "4,286"
            },
            {
              "key": "Total revenue 2021",
              "value": "2,761"
            },
            {
              "key": "Research and development 2022",
              "value": "34,067"
            },
            {
              "key": "Research and development 2021",
              "value": "21,957"
            },
            {
              "key": "General and administrative 2022",
              "value": "40,848"
            },
            {
              "key": "General and administrative 2021",
              "value": "21,250"
            },
            {
              "key": "Total operating expenses 2022",
              "value": "74,915"
            },
            {
              "key": "Total operating expenses 2021",
              "value": "43,207"
            },
            {
              "key": "Interest income, net 2022",
              "value": "1,701"
            },
            {
              "key": "Interest income, net 2021",
              "value": "1"
            },
            {
              "key": "Change in fair value of contingent earnout liability 2022",
              "value": "9,461"
            },
            {
              "key": "Change in fair value of contingent earnout liability 2021",
              "value": ""
            },
            {
              "key": "Gain on extinguishment of convertible notes 2022",
              "value": "1,289"
            },
            {
              "key": "Gain on extinguishment of convertible notes 2021",
              "value": ""
            },
            {
              "key": "Change in preferred stock tranche liability 2022",
              "value": "—"
            },
            {
              "key": "Change in preferred stock tranche liability 2021",
              "value": "-14,742"
            },
            {
              "key": "Other income (expense) 2022",
              "value": "-32"
            },
            {
              "key": "Other income (expense) 2021",
              "value": "-120"
            },
            {
              "key": "Total other income (expense), net 2022",
              "value": "12,419"
            },
            {
              "key": "Total other income (expense), net 2021",
              "value": "-14,873"
            },
            {
              "key": "Net loss 2022",
              "value": "-58,210"
            },
            {
              "key": "Net loss 2021",
              "value": "-55,319"
            },
            {
              "key": "Comprehensive loss 2022",
              "value": "-58,209"
            },
            {
              "key": "Comprehensive loss 2021",
              "value": "-55,319"
            },
            {
              "key": "Loss per share, basic and diluted 2022",
              "value": "-2.23"
            },
            {
              "key": "Loss per share, basic and diluted 2021",
              "value": "-19.00"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 150,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Operating Activities - Net loss",
              "value": "2022: -58210, 2021: -55319"
            },
            {
              "key": "Depreciation",
              "value": "2022: 1398, 2021: 769"
            },
            {
              "key": "Amortization of operating lease right-of-use assets",
              "value": "2022: 2522, 2021: 2241"
            },
            {
              "key": "Stock-based compensation expense",
              "value": "2022: 16392, 2021: 2295"
            },
            {
              "key": "Change in fair value of contingent earnout liability",
              "value": "2022: -9461, 2021: 0"
            },
            {
              "key": "Operating lease liabilities",
              "value": "2022: 14129, 2021: -1137"
            },
            {
              "key": "Net cash from operating activities",
              "value": "2022: -34896, 2021: -34635"
            },
            {
              "key": "Net cash from investing activities",
              "value": "2022: -81959, 2021: -5543"
            },
            {
              "key": "Net cash from financing activities",
              "value": "2022: 118551, 2021: 68435"
            },
            {
              "key": "Cash and cash equivalents (2022)",
              "value": "Beginning: 59291, Ending: 60987"
            },
            {
              "key": "Cash and cash equivalents (2021)",
              "value": "Beginning: 31034, Ending: 59291"
            },
            {
              "key": "Summary",
              "value": "The cash flow statement for SENTI BIOSCIENCES, INC. compares fiscal years 2022 and 2021. Despite consistent operating losses (-$34.9M vs -$34.6M), significantly increased cash used in investing activities (-$82.0M vs -$5.5M) was offset by strong financing inflows ($118.6M vs $68.4M), primarily from merger and PIPE financing. The company ended 2022 with $61.0M in cash."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 154,
          "title": "Cash and Cash Equivalents Statement & Investment Notes",
          "data": [
            {
              "key": "Cash and Cash Equivalents 2022",
              "value": "57,621"
            },
            {
              "key": "Cash and Cash Equivalents 2021",
              "value": "56,000"
            },
            {
              "key": "Restricted Cash 2022",
              "value": "3,366"
            },
            {
              "key": "Restricted Cash 2021",
              "value": "3,200"
            },
            {
              "key": "Total Cash 2022",
              "value": "60,987"
            },
            {
              "key": "Total Cash 2021",
              "value": "59,200"
            },
            {
              "key": "Summary",
              "value": "The table shows cash positions for 2021 and 2022 with a modest increase in total cash and equivalents. The majority is in unrestricted cash and equivalents while restricted cash forms a smaller portion."
            },
            {
              "key": "Short-term Investments",
              "value": "Investments in marketable securities with maturities less than 12 months are classified as short-term and are available-for-sale."
            },
            {
              "key": "Long-term Investments",
              "value": "Investments with original maturities greater than 12 months are classified as long-term."
            },
            {
              "key": "Fair Value Measurement",
              "value": "Describes a three-level hierarchy (Level 1: quoted prices; Level 2: observable inputs; Level 3: unobservable inputs) used to measure fair value of assets and liabilities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 156,
          "title": "Notes to Consolidated Financial Statements – Revenue Recognition and R&D",
          "data": [
            {
              "key": "Revenue Recognition",
              "value": "Details the process for determining transaction price and allocation to performance obligations, recognizing revenue as control of the product or service is transferred."
            },
            {
              "key": "Performance Obligations",
              "value": "Each distinct promise to transfer a product or service is identified as a unit of accounting, with significant judgments applied to combine or separate obligations."
            },
            {
              "key": "Transaction Price",
              "value": "Includes both fixed and variable consideration (such as milestone payments and fees for research services), allocated based on relative stand-alone selling prices."
            },
            {
              "key": "Grant Income",
              "value": "Government grants are recognized systematically over the period in which qualified research and development costs are incurred, with any excess treated as deferred revenue or receivables."
            },
            {
              "key": "Research and Development",
              "value": "R&D costs—including personnel, lab supplies, technology costs, and depreciation—are expensed as incurred."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 159,
          "title": "Financial Performance Overview",
          "data": [
            {
              "key": "Diluted Net Loss Per Share",
              "value": "The diluted net loss per share is the same as the basic net loss per share during periods of net loss."
            },
            {
              "key": "Income Tax Accounting Method",
              "value": "The Company accounts for income taxes under the asset and liability method."
            },
            {
              "key": "Deferred Tax Assets Recognition",
              "value": "Deferred tax assets are recognized to the extent that it is more likely than not that these assets will be realized."
            },
            {
              "key": "Recently Adopted Accounting Standards",
              "value": "The Company adopted various accounting standards including ASU No. 2021-10 and ASU 2021-04, with no material impact on financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 162,
          "title": "Investment Portfolio Breakdown and Allocation",
          "data": [
            {
              "key": "Total Portfolio Value",
              "value": "$101,929"
            },
            {
              "key": "Money Market Funds Allocation",
              "value": "$45,412"
            },
            {
              "key": "Cash and Equivalents Total",
              "value": "$57,621"
            },
            {
              "key": "Restricted Cash Total",
              "value": "$3,366"
            },
            {
              "key": "Short-term Investments Total",
              "value": "$40,942"
            },
            {
              "key": "Unrealized Gain/Loss",
              "value": "Minimal (stable valuations)"
            },
            {
              "key": "Investment Types",
              "value": "Money market funds, U.S. Treasury securities, commercial paper"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 162,
          "title": "Money Market Funds Financial Summary",
          "data": [
            {
              "key": "Total Amortized Cost",
              "value": "$59,291"
            },
            {
              "key": "Total Estimated Fair Value",
              "value": "$59,291"
            },
            {
              "key": "Cash and Cash Equivalents Total",
              "value": "$56,034"
            },
            {
              "key": "Restricted Cash Total",
              "value": "$3,257"
            },
            {
              "key": "Short-term Investments Total",
              "value": "$0"
            },
            {
              "key": "Unrealized Gain",
              "value": "$0"
            },
            {
              "key": "Unrealized Loss",
              "value": "$0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 166,
          "title": "Accrued Expenses and Other Current Liabilities",
          "data": [
            {
              "key": "Total accrued expenses and other current liabilities 2022",
              "value": "12,864"
            },
            {
              "key": "Total accrued expenses and other current liabilities 2021",
              "value": "5,330"
            },
            {
              "key": "Accrued professional and service fees related to facility construction 2022",
              "value": "7,342"
            },
            {
              "key": "Accrued professional and service fees related to facility construction 2021",
              "value": "60"
            },
            {
              "key": "Accrued professional and service fees other 2022",
              "value": "1,750"
            },
            {
              "key": "Accrued professional and service fees other 2021",
              "value": "1,951"
            },
            {
              "key": "Accrued employee-related expenses 2022",
              "value": "3,743"
            },
            {
              "key": "Accrued employee-related expenses 2021",
              "value": "2,66"
            },
            {
              "key": "Other accrued expenses 2022",
              "value": "29"
            },
            {
              "key": "Other accrued expenses 2021",
              "value": "1"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 166,
          "title": "Operating Lease Cost Breakdown",
          "data": [
            {
              "key": "Operating lease cost 2022",
              "value": "5,300"
            },
            {
              "key": "Operating lease cost 2021",
              "value": "3,793"
            },
            {
              "key": "Short-term lease cost 2022",
              "value": "81"
            },
            {
              "key": "Short-term lease cost 2021",
              "value": "—"
            },
            {
              "key": "Variable lease cost 2022",
              "value": "730"
            },
            {
              "key": "Variable lease cost 2021",
              "value": "725"
            },
            {
              "key": "Total lease cost 2022",
              "value": "6,111"
            },
            {
              "key": "Total lease cost 2021",
              "value": "4,518"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 166,
          "title": "Operating Lease Information",
          "data": [
            {
              "key": "Operating cash flows from leases 2022",
              "value": "11,363"
            },
            {
              "key": "Operating cash flows from leases 2021",
              "value": "-2,669"
            },
            {
              "key": "ROU assets obtained 2022",
              "value": "231"
            },
            {
              "key": "ROU assets obtained 2021",
              "value": "10,153"
            },
            {
              "key": "Weighted-average remaining lease term 2022",
              "value": "8.2 years"
            },
            {
              "key": "Weighted-average remaining lease term 2021",
              "value": "7.8 years"
            },
            {
              "key": "Weighted-average discount rate 2022",
              "value": "9.1%"
            },
            {
              "key": "Weighted-average discount rate 2021",
              "value": "9.1%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Notes to Consolidated Financial Statements & Revenue Recognition",
          "data": [
            {
              "key": "Non-cash gain",
              "value": "$9.5 million for the year ended December 31, 2022"
            },
            {
              "key": "Classification",
              "value": "Change in fair value of contingent earnout liability"
            },
            {
              "key": "Stock Valuation and Option Pricing Parameters",
              "value": "Current stock price of $7.51 and $1.41; Expected share price volatility of 81.0%-85.0%; Risk-free interest rate of 2.94%-4.32%; Expected dividend yield of 0.0%; Expected term of 3.0 and 2.4 years"
            },
            {
              "key": "Revenue Details",
              "value": "The Company’s revenue includes research services provided under collaborative development and research collaboration agreements, with contract modifications and adjustments (e.g., reversal of a $0.3 million contract asset and a cumulative catch-up of $(0.7) million)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 177,
          "title": "Notes to Consolidated Financial Statements: Tax Carryforwards and Net Loss Per Share Reconciliation",
          "data": [
            {
              "key": "Net Operating Losses, Federal (Post December 31, 2017)",
              "value": "96,781 (thousands), Do Not Expire"
            },
            {
              "key": "Net Operating Losses, Federal (Pre January 1, 2018) - AAR",
              "value": "3,508 (thousands), Expires 12/31/2031"
            },
            {
              "key": "Net Operating Losses, State",
              "value": "55,023 (thousands), Expires 12/31/2032"
            },
            {
              "key": "Tax Credits, Federal",
              "value": "4,279 (thousands), Expires 12/31/2032"
            },
            {
              "key": "Tax Credits, State - PARA",
              "value": "4,125 (thousands), Do Not Expire"
            },
            {
              "key": "Net Operating Losses, Foreign",
              "value": "1,149 (thousands), Do Not Expire"
            },
            {
              "key": "Tax Reconciliation - Statutory Rate",
              "value": "21.00% for both 2022 and 2021"
            },
            {
              "key": "Tax Reconciliation - State Tax",
              "value": "-0.13% in 2022; 2.98% in 2021"
            },
            {
              "key": "Tax Reconciliation - Other",
              "value": "-0.93% in 2022; -0.80% in 2021"
            },
            {
              "key": "Tax Reconciliation - Tax Credits",
              "value": "1.21% in 2022; 2.29% in 2021"
            },
            {
              "key": "Tax Reconciliation - Fair Value of Series B Preferred Stock Tranche Obligation",
              "value": "0% in 2022; -5.60% in 2021"
            },
            {
              "key": "Tax Reconciliation - Fair Value of Contingent Earnout Liability",
              "value": "3.41% in 2022; 0% in 2021"
            },
            {
              "key": "Tax Reconciliation - Valuation Allowance",
              "value": "-24.56% in 2022; -19.87% in 2021"
            },
            {
              "key": "Tax Reconciliation - Total",
              "value": "0% for both 2022 and 2021"
            },
            {
              "key": "Net Loss",
              "value": "(58,210) in 2022; (55,319) in 2021"
            },
            {
              "key": "Weighted-Average Shares Used in Computing Net Loss Per Share",
              "value": "26,110,785 in 2022; 2,912,275 in 2021"
            },
            {
              "key": "Net Loss Per Share Attributable to Common Stockholders",
              "value": "(2.23) in 2022; (19.00) in 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 178,
          "title": "Notes to Consolidated Financial Statements – Diluted EPS and Other Disclosures",
          "data": [
            {
              "key": "Excluded Securities Table Title",
              "value": "Series A and B redeemable convertible preferred stock"
            },
            {
              "key": "Table Summary",
              "value": "Comparison of potential common stock securities excluded from the diluted net loss per share computation. For 2022, data includes approximately 9,875,675 stock options, 105,500 unvested early exercised options, 447,948 restricted stock units, and 2,000,000 contingent earnout common stock, totaling 12,429,123 shares versus 21,832,990 shares in 2021."
            },
            {
              "key": "Retirement Plan Contributions 2022",
              "value": "$0.6 million"
            },
            {
              "key": "Retirement Plan Contributions 2021",
              "value": "$0.3 million"
            },
            {
              "key": "Lease Agreement Details",
              "value": "New cGMP facility lease in Alameda, CA, expiring in 2032 with undiscounted operating lease payments of $46.0 million over an initial 11-year period."
            },
            {
              "key": "Construction Commitment",
              "value": "In 2022, $35.5 million was paid towards construction costs of a $42.1 million purchase commitment for the cGMP facility."
            },
            {
              "key": "Collaboration Agreement",
              "value": "Three-year agreement with BlueRock Therapeutics LP including an option to license cell therapy products, with up to $10.0 million in associated costs."
            },
            {
              "key": "Sponsored Research Commitments",
              "value": "Approximately $1.3 million in purchase commitments related to sponsored research agreements as of December 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "Table of Contents Item 16. Form 10-K Summary",
          "data": [
            {
              "key": "Summary",
              "value": "Not applicable"
            },
            {
              "key": "Reference",
              "value": "187"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 208,
          "title": "Lease Rent and Abatement Provisions",
          "data": [
            {
              "key": "Payment Schedule",
              "value": "Payments are due on the first (1st) day of each month, beginning on the first day of the second full calendar month of the Term following the applicable Abatement Period."
            },
            {
              "key": "Partial Month Calculation",
              "value": "For any partial month at the beginning or end of the Term, the Base Rent is prorated by multiplying 1/365 (or 1/366 in a leap year) of the annual Base Rent by the number of days in the partial month."
            },
            {
              "key": "Triple Net Lease",
              "value": "This Lease is structured as a 'triple net' lease where the Base Rent is to be paid by Tenant net of all costs and expenses related to Landlord's ownership and operation of the Project and Complex, without any deductions or offsets."
            },
            {
              "key": "Additional Charges",
              "value": "Tenant is also required to pay Additional Rent, Taxes, and Insurance in the same manner and at the same time as Base Rent, as outlined in Exhibit C."
            },
            {
              "key": "Abatement Periods",
              "value": "Phase I Premises Abatement Period: the first six full calendar months following the Commencement Date. Phase II Premises Abatement Period: the first six full calendar months following the Phase II Premises Commencement Date. The total discounted rent during these periods is referred to as the 'Abated Rent'."
            },
            {
              "key": "Recapture Clause",
              "value": "If a monetary or material non-monetary Event of Default occurs, any unamortized portions of the Abated Rent previously credited to Tenant may become immediately due and payable at Landlord’s option. Additionally, if default occurs before an Abatement Period ends, no further abatement will be granted until the default is cured and accepted by Landlord."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 298,
          "title": "EXHIBIT B",
          "data": [
            {
              "key": "content",
              "value": "Page intentionally left blank"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 299,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Description",
              "value": "The auditor, KPMG LLP, consents to incorporation by reference of their report dated March 22, 2023 in the registration statements (Forms S-1, S-4, and S-8) concerning the consolidated financial statements of Senti Biosciences, Inc."
            },
            {
              "key": "Report Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Registration Statement Numbers",
              "value": "Nos. 333-267390, 333-265873 (Form S-1); No. 333-262707 (Form S-4); Nos. 333-269816, 333-266958 (Form S-8)"
            },
            {
              "key": "Auditor",
              "value": "KPMG LLP"
            },
            {
              "key": "Location",
              "value": "San Francisco, California"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 23.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 300,
          "title": "CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)",
          "data": [
            {
              "key": "Certifier",
              "value": "Timothy Lu, M.D., Ph.D."
            },
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Fiscal Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Purpose",
              "value": "Certification of review of financial statements and internal controls pursuant to the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 302,
          "title": "CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)",
          "data": [
            {
              "key": "Document Type",
              "value": "CFO Certification of Annual Report"
            },
            {
              "key": "Regulatory References",
              "value": "Rule 13A-14(A) under the Securities Exchange Act of 1934; Section 302 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "CFO Name",
              "value": "Deborah Knobelman, Ph.D."
            },
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Fiscal Period End",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Statement",
              "value": "The CFO certifies that the annual report does not contain any material misstatements and that the financial statements fairly present, in all material respects, the financial condition, results of operations and cash flows. She also attests to the design, implementation, and evaluation of the registrant's disclosure controls, procedures, and internal control over financial reporting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 304,
          "title": "CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002",
          "data": [
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Report Form",
              "value": "Form 10-K"
            },
            {
              "key": "Fiscal Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Certifying Officer",
              "value": "Timothy Lu, M.D., Ph.D., Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Legal References",
              "value": "18 U.S.C. §1350; Section 906 of the Sarbanes-Oxley Act of 2002; Section 13(a) or 15(d) of the Securities Exchange Act of 1934"
            },
            {
              "key": "Statement",
              "value": "The Report fully complies with the requirements of the Securities Exchange Act and fairly presents the financial condition and results of operations of the Company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 305,
          "title": "CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350",
          "data": [
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K for the year ended December 31, 2022"
            },
            {
              "key": "Certification Reference",
              "value": "CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002"
            },
            {
              "key": "Compliance Statement",
              "value": "The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information fairly presents, in all material respects, the financial condition and results of operations of the Company."
            },
            {
              "key": "Date",
              "value": "March 22, 2023"
            },
            {
              "key": "Certified By",
              "value": "Deborah Knobelman, Ph.D., Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 32.2"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": false,
      "elements": []
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 5,
          "title": "SIGNATURE AUTHENTICATION",
          "data": [
            {
              "key": "Form Purpose",
              "value": "Verify that the names, titles, and signatures of the bank’s authorized personnel match the records."
            },
            {
              "key": "Fields",
              "value": "Name of Bank, Address of Bank, City/State/ZIP Code, Authorized Name and Title, Authorized Signature, Telephone Number"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 63,
          "title": "Purchase Agreement with Chardan",
          "data": [
            {
              "key": "Total Commitment",
              "value": "$50.0 million"
            },
            {
              "key": "Total amount sold to Chardan",
              "value": "$0.7 million"
            },
            {
              "key": "Termination Dates",
              "value": "October 1, 2025, date shares fail to be listed on Nasdaq, commencement of bankruptcy proceedings, or authorization by creditors"
            },
            {
              "key": "Shares registered",
              "value": "8,727,049"
            },
            {
              "key": "Limit on issuance to Chardan",
              "value": "19.99% of the total shares outstanding at the time of agreement"
            },
            {
              "key": "Aggregate proceeds possibility",
              "value": "Up to $50 million subject to market conditions and approval"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 64,
          "title": "Sales of Common Stock to Chardan and Related Risks",
          "data": [
            {
              "key": "Context",
              "value": "Details the agreement with Chardan concerning the issuance and resale of common stock."
            },
            {
              "key": "Dilution Risks",
              "value": "Investors may experience different levels of dilution based on varying prices paid for shares."
            },
            {
              "key": "Issue Amount",
              "value": "400,000 shares of common stock have been issued to Chardan under the Purchase Agreement."
            },
            {
              "key": "Purchase Agreement Conditions",
              "value": "Sales of shares depend on market conditions and specific conditions outlined in the agreement."
            },
            {
              "key": "Future Sales Comparison",
              "value": "Future sales of shares to Chardan may impact the trading price and cause substantial dilution to existing shareholders."
            },
            {
              "key": "Use of Proceeds",
              "value": "The proceeds from sales may be used at management's discretion, which may not align with shareholder expectations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 123,
          "title": "Equity Dilution and Capital Structure Considerations",
          "data": [
            {
              "key": "Shares available for sale by Class A common stock holders",
              "value": "5,750,000 shares could be sold at a per share price less than $10.00"
            },
            {
              "key": "Nasdaq Closing Price",
              "value": "$1.27 per share on March 15, 2023"
            },
            {
              "key": "Aggregate Sales Price of Founder Shares",
              "value": "Approximately $6.2 million"
            },
            {
              "key": "Aggregate Sales Price of Anchor Investor Shares",
              "value": "Approximately $1.1 million"
            },
            {
              "key": "Market Impact",
              "value": "Large public sales or the perception of imminent sales could reduce the market price of common stock"
            },
            {
              "key": "Equity Incentive Plan Details",
              "value": "Initial maximum of 2,492,735 shares reserved; increases annually on January 1 by 5% of total outstanding shares (or a lesser number, as determined) through 2032"
            },
            {
              "key": "Inducement Plan",
              "value": "On August 5, 2022, an aggregate of 2,000,000 shares reserved for issuance under the 2022 Inducement Plan"
            },
            {
              "key": "Dilution Risk",
              "value": "Future sales and issuances of common stock or rights to purchase common stock may result in significant dilution for existing stockholders"
            },
            {
              "key": "Future Capital Requirements",
              "value": "Significant additional capital will be needed for operations, including further R&D, IND filings, preclinical and clinical trials, commercialization and other expenses"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 139,
          "title": "Table of Contents - Financing Activities and Funding Requirements",
          "data": [
            {
              "key": "Net Cash Provided by Financing Activities (2021)",
              "value": "$68.4 million"
            },
            {
              "key": "Proceeds from Series B Redeemable Convertible Preferred Stock Issuance",
              "value": "$67.0 million"
            },
            {
              "key": "Proceeds from Common Stock Issuance (Stock Options Exercise)",
              "value": "$1.5 million"
            },
            {
              "key": "Funding Concern",
              "value": "Existing cash and cash equivalents insufficient to fund operations beyond the next 12 months"
            },
            {
              "key": "Future Financing Plans",
              "value": "Management is actively pursuing additional financing to improve liquidity and support ongoing operations"
            },
            {
              "key": "Risks and Uncertainties",
              "value": "Dependence on successful additional funding; potential delays or elimination of research and drug development programs if funds are not raised on acceptable terms"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 164,
          "title": "Notes to Consolidated Financial Statements – Preferred Stock Tranche Liability",
          "data": [
            {
              "key": "Overview",
              "value": "The document details the roll-forward and valuation of the preferred stock tranche liability related to Series B redeemable convertible preferred stock at SENTI BIOSCIENCES, INC. It includes the opening balance, recognition of tranche rights in January 2021, a significant fair value change, and eventual extinguishment of the liability."
            },
            {
              "key": "Tranche Liability Movement",
              "value": "Beginning with a balance from December 31, 2020 (435 and 33 thousand), the liability experienced a fair value change of 14,742 thousand and an extinguishment of (15,210) thousand, resulting in an ending balance as of December 31, 2021."
            },
            {
              "key": "Valuation Methodology",
              "value": "Fair value measurements were supported by significant unobservable inputs (Level 3) using a Monte Carlo valuation model, Black-Scholes option pricing model, and the Backsolve method. The document outlines quantitative inputs such as discount rate, time to liquidity, expected volatility, probabilities for call option and forward contracts, and strike prices."
            },
            {
              "key": "Capital Structure Impact",
              "value": "The issuance and subsequent extinguishment of the Series B redeemable convertible preferred stock tranche liability reflect a significant change in the company's capital structure, including the recording of an additional obligation to sell shares upon achievement of certain milestones."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 165,
          "title": "Notes to Consolidated Financial Statements: Convertible Preferred Stock Valuation and Asset Details",
          "data": [
            {
              "key": "Convertible Preferred Stock - Public Scenario Weighting",
              "value": "75.0%"
            },
            {
              "key": "Convertible Preferred Stock - Public Scenario Value",
              "value": "$1.637"
            },
            {
              "key": "Convertible Preferred Stock - Staying-Private Scenario Weighting",
              "value": "25.0%"
            },
            {
              "key": "Convertible Preferred Stock - Staying-Private Scenario Value",
              "value": "$0.395"
            },
            {
              "key": "Preferred Stock Extinguishment Gain (May 14, 2021)",
              "value": "$14.7 million gain recognized"
            },
            {
              "key": "Prepaid Expenses and Other Current Assets Change",
              "value": "Total decreased from $3,676K in 2021 to $3,390K in 2022; prepaid expenses increased from $798K to $1,871K; reverse recapitalization deferred offering costs eliminated"
            },
            {
              "key": "Property and Equipment - Net Change",
              "value": "Increased from $12,368K in 2021 to $56,136K in 2022"
            },
            {
              "key": "Construction in Progress",
              "value": "Increased from $8,048K in 2021 to $48,273K in 2022"
            },
            {
              "key": "Depreciation",
              "value": "$1.4 million for 2022 and $0.8 million for 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 167,
          "title": "Notes to Consolidated Financial Statements: Lease Liabilities & Convertible Note",
          "data": [
            {
              "key": "Tenant Improvement Allowance",
              "value": "$14.1 million received of $17.5 million allowance as of December 31, 2022"
            },
            {
              "key": "Lease Liability Schedule",
              "value": "Lease payments breakdown: Periods including '023 (6.27), '1024 (7.26), '025 (7.48), '026 (7.72), '1027 (5.78), 'Thereafter (24.44); Total undiscounted lease payments of 58.97 (in thousands) with deductions of imputed interest (18.54) and remaining tenant improvement allowance (3.34)"
            },
            {
              "key": "Convertible Note Issuance",
              "value": "On May 19, 2022, in connection with the Merger, Legacy Senti issued a $5.2 million unsecured convertible promissory note due May 2024 with an annual interest rate of 3.0%"
            },
            {
              "key": "Convertible Note Conversion",
              "value": "The note was cancellable and convertible under multiple conditions (including automatic conversion upon closing of the Merger, IPO, or non-qualified financing), and on June 8, 2022, it was automatically cancelled and exchanged for 517,500 shares of Class A Common Stock at $10.00 per share"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 168,
          "title": "Notes to Consolidated Financial Statements and Capital Structure Changes",
          "data": [
            {
              "key": "Convertible Debt Extinguishment",
              "value": "The company accounted for the cancellation and exchange as an extinguishment of the May 2022 Note, recording a gain on extinguishment of $1.3 million. All accrued interest at the time of the Merger was reversed and reclassified to additional paid-in capital."
            },
            {
              "key": "Merger and Reverse Recapitalization",
              "value": "At the closing of the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of common shares on a one-to-one basis, then adjusted by the Exchange Ratio per the Merger Agreement. Additional details are provided in Note 3, Reverse Recapitalization."
            },
            {
              "key": "Common Stock Details",
              "value": "Common stock holders are entitled to one vote per share, dividends, and distribution of assets upon liquidation. The common stock is subordinate to the redeemable convertible preferred stock with respect to dividend and liquidation rights. The authorized common shares increased from 27,006,600 (as of December 31, 2021) to 500,000,000 (as of December 31, 2022), with a par value of $0.0001 per share."
            },
            {
              "key": "Series A Stock Information",
              "value": "Series A details: Issue price per share = $1.6427; Shares authorized = 6,888,563; Shares issued and outstanding = 6,888,563; Net carrying value = 57,408 (in thousands); Aggregate liquidation preference approximately 57,822."
            },
            {
              "key": "Series B Stock Information",
              "value": "Series B is presented in two parts: one shows shares authorized = 12,629,427, shares issued/outstanding = 12,629,425, net carrying value = 114,425 (in thousands), aggregate liquidation preference around 106,012; another shows shares authorized = 19,517,990, shares issued/outstanding = 19,517,988, net carrying value = 171,833 (in thousands), aggregate liquidation preference near 163,834."
            },
            {
              "key": "Equity Plans and Options",
              "value": "Additional table displays metrics for stock-related items: Common Stock Purchase Agreement (8,327,049 shares in 2022), common stock options increased from 2,291,838 in 2021 to 9,875,675 in 2022, shares available for future issuance under equity plans and ESPP, unvested early exercised common stock, with the total number of shares adjusting from 23,000,816 (2021) to 22,186,271 (2022)."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 191,
          "title": "DESCRIPTION OF SECURITIES",
          "data": [
            {
              "key": "Authorized Shares",
              "value": "The Charter authorizes issuance of 510,000,000 shares: 500,000,000 common and 10,000,000 preferred."
            },
            {
              "key": "Common Stock Voting Rights",
              "value": "Holders of common stock are entitled to one vote per share on all stockholder matters, including the election of directors."
            },
            {
              "key": "Dividends",
              "value": "Common stockholders may receive dividends if declared by the board, though no cash dividends have been paid historically and none are expected in the foreseeable future."
            },
            {
              "key": "Liquidation Rights",
              "value": "In case of liquidation, common stockholders will receive a pro rata distribution of net assets, subject to the rights of preferred stockholders."
            },
            {
              "key": "Transfer Rights",
              "value": "Common stock is fully transferable subject to applicable law and restrictions in the Bylaws."
            },
            {
              "key": "Preferred Stock",
              "value": "No preferred stock is currently outstanding. Preferred stock may be issued in series with varying rights, including provisions that could adversely affect the voting power of common stockholders and have anti-takeover effects."
            },
            {
              "key": "Anti-Takeover Effect",
              "value": "The board's ability to issue preferred stock without stockholder approval could delay, defer, or prevent a change of control of Senti Biosciences or the removal of existing management."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 282,
          "title": "EXHIBIT M APPROVED FORM OF LETTER OF CREDIT",
          "data": [
            {
              "key": "Letter of Credit Type",
              "value": "Irrevocable Standby Letter of Credit"
            },
            {
              "key": "Letter of Credit Number",
              "value": "SVBSF (placeholder)"
            },
            {
              "key": "Issuing Bank",
              "value": "Silicon Valley Bank, 3003 Tasman Drive, 2nd Floor, Mail Sort HF210, Santa Clara, California 95054"
            },
            {
              "key": "Beneficiary",
              "value": "North Loop 3, LLC (C/O Invesco Real Estate, 2001 Ross Avenue, Suite 3400, Dallas, TX 75201; Attention: North South Loop Asset Manager)"
            },
            {
              "key": "Applicant",
              "value": "Senti Biosciences, Inc., 2 Corporate Drive, 1st Floor, San Francisco, CA 94080"
            },
            {
              "key": "Amount",
              "value": "US $[***]"
            },
            {
              "key": "Expiration Date",
              "value": "1 year from issuance (specific date to be set by SVB)"
            },
            {
              "key": "Place of Expiration",
              "value": "Issuing bank’s counters at its above address"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 285,
          "title": "EXHIBIT A TRANSFER FORM",
          "data": [
            {
              "key": "Document Type",
              "value": "Transfer Form for Standby Letter of Credit"
            },
            {
              "key": "Transfer Details",
              "value": "Beneficiary irrevocably transfers all rights to draw under an irrevocable standby letter of credit to a transferee."
            },
            {
              "key": "Issuing Bank",
              "value": "SILICON VALLEY BANK, 3003 TASMAN DRIVE, SANTA CLARA, CA 95054"
            },
            {
              "key": "Additional Instructions",
              "value": "Bank is instructed to either endorse the transfer on the existing letter of credit or issue a replacement letter of credit on substantially the same terms."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 5,
          "title": "Table of Contents - Risk Factors and Key Considerations",
          "data": [
            {
              "key": "Market Acceptance",
              "value": "Rate and degree of market acceptance of current and potential future product candidates, if approved"
            },
            {
              "key": "Regulatory Developments",
              "value": "Regulatory developments and approval pathways in the United States and international jurisdictions"
            },
            {
              "key": "Strategic Collaboration",
              "value": "Ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise, and potential benefits from collaboration agreements"
            },
            {
              "key": "Merger Benefit",
              "value": "Ability to realize the benefits from the merger with Dynamics Special Purpose Acquisition Corp."
            },
            {
              "key": "Legal and Liability Risks",
              "value": "Potential liability from lawsuits and penalties related to technologies, product candidates, and current/future third-party relationships including those under strategic and financing transactions"
            },
            {
              "key": "Leadership Retention",
              "value": "Success in retaining, recruiting, or adapting to changes in officers, key employees, or directors"
            },
            {
              "key": "Supply Chain and Manufacturing",
              "value": "Ability to contract with third-party suppliers and manufacturers and their capacity to perform adequately"
            },
            {
              "key": "Competitive Landscape",
              "value": "Ability to compete effectively with rapidly evolving cell therapy technologies and respond to developments from competitors and new market entrants"
            },
            {
              "key": "Government Regulation",
              "value": "Potential effects of extensive government regulation"
            },
            {
              "key": "Financial Performance and Capital Requirements",
              "value": "Concerns regarding future financial performance and needed capital"
            },
            {
              "key": "Internal Controls",
              "value": "Ability to implement and maintain effective internal controls"
            },
            {
              "key": "Supply Chain Disruptions",
              "value": "Impact of supply chain disruptions"
            },
            {
              "key": "COVID-19 Impact",
              "value": "Impact of the COVID-19 pandemic on business operations including preclinical studies and potential future clinical trials"
            },
            {
              "key": "Global Economic Conditions",
              "value": "Effects of unfavorable global economic conditions including inflationary pressures, market volatility, acts of war, and civil/political unrest"
            },
            {
              "key": "Forward-Looking Statements",
              "value": "All forward-looking statements are qualified by cautionary notes, with no obligation to update or revise them publicly"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Orphan Drug Designation, Exclusivity, and Post-Approval Regulatory Requirements",
          "data": [
            {
              "key": "Financial Incentives",
              "value": "Orphan drug designation in the United States provides financial incentives such as grant funding opportunities for clinical trial costs, tax advantages, and user-fee waivers."
            },
            {
              "key": "Orphan Product Exclusivity",
              "value": "If a designated product subsequently receives the first FDA approval for its intended indication, it obtains orphan product exclusivity, which prevents the FDA from approving competing applications for the same biologic for seven years, subject to specific exceptions."
            },
            {
              "key": "Exclusivity Exceptions",
              "value": "Exclusivity can be lost if, for example, a second applicant demonstrates clinical superiority, or if the manufacturer cannot assure sufficient quantities of the product, among other limited circumstances."
            },
            {
              "key": "Post-Approval Regulatory Requirements",
              "value": "After approval, biologics face extensive FDA regulations including ongoing record-keeping, adverse event reporting, cGMP compliance, and pre-approval for certain changes, with potential consequences such as product withdrawal if standards are not met."
            },
            {
              "key": "Compliance and Risk",
              "value": "Failure to comply with FDA regulations, including manufacturing changes and quality control, could result in regulatory actions such as distribution restrictions, product recalls, or loss of market exclusivity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "BPCIA and its Implications",
          "data": [
            {
              "key": "Exclusivity Periods",
              "value": "Under the BPCIA, an application for a biosimilar product may not be submitted until four years following the reference product's initial licensure."
            },
            {
              "key": "Approval Restrictions",
              "value": "The FDA cannot approve biosimilar products for 12 years from the reference product's initial licensing."
            },
            {
              "key": "Government Proposals",
              "value": "There are government proposals to reduce the 12-year exclusivity period."
            },
            {
              "key": "Litigation",
              "value": "Recent litigation may impact BPCIA exclusivity provisions."
            },
            {
              "key": "Uncertainty",
              "value": "The implementation and impact of the BPCIA is subject to significant uncertainty."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 56,
          "title": "Risk Factors Summary",
          "data": [
            {
              "key": "Risk Factor 1",
              "value": "We are a preclinical stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability."
            },
            {
              "key": "Risk Factor 2",
              "value": "We have identified a material weakness in our internal control over financial reporting."
            },
            {
              "key": "Risk Factor 3",
              "value": "Members of our management team have limited experience in managing the day-to-day operations of a public company."
            },
            {
              "key": "Risk Factor 4",
              "value": "Our history of recurring losses and anticipated expenditures raises substantial doubt about our ability to continue as a going concern."
            },
            {
              "key": "Risk Factor 5",
              "value": "We may not achieve the intended objectives of our strategic prioritization plan announced in January 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "Risk Factors - Product Development and Regulatory Challenges",
          "data": [
            {
              "key": "Product Candidates Stage",
              "value": "Our current product candidates are in preclinical development and have never been tested in humans."
            },
            {
              "key": "Clinical Development Risk",
              "value": "There is a risk that product candidates may fail in clinical development or suffer delays affecting regulatory approval and commercial viability."
            },
            {
              "key": "Regulatory Approval Risk",
              "value": "Even if tested in humans, candidates may not demonstrate the necessary safety, purity, potency, or efficacy."
            },
            {
              "key": "Gene Circuit Platform Risk",
              "value": "Our gene circuit platform technologies are novel, unproven and may not yield approvable or marketable products, exposing us to unforeseen risks."
            },
            {
              "key": "Market Adoption and Perception",
              "value": "There is uncertainty whether the market, physicians, patients, regulators, and investors will embrace our product candidates and complex technology."
            },
            {
              "key": "Clinical Trial Enrollment Risk",
              "value": "Difficulties in enrolling patients could delay or adversely affect clinical development activities."
            },
            {
              "key": "Manufacturing and Supply Chain Risk",
              "value": "Reliance on third parties for preclinical and clinical studies and potential manufacturing disruptions may cause delays or quality issues."
            },
            {
              "key": "Competitive and Liability Risks",
              "value": "Competition from more rapid or effective platforms and potential product liability issues could harm the business and affect stock price."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risks Related to Our Limited Operating History and Financial Condition",
          "data": [
            {
              "key": "Risk Factors",
              "value": "Adverse impact of global economic and political developments on operations."
            },
            {
              "key": "Company Status",
              "value": "Preclinical stage biotechnology company with history of losses."
            },
            {
              "key": "Financial Performance",
              "value": "Net losses were $58.2 million and $55.3 million for the years ended December 31, 2022 and 2021."
            },
            {
              "key": "Accumulated Deficit",
              "value": "$173.3 million as of December 31, 2022."
            },
            {
              "key": "Revenue Status",
              "value": "No revenue generated from product sales."
            },
            {
              "key": "Future Expectation",
              "value": "Expecting significant operating losses for the foreseeable future."
            },
            {
              "key": "Factors Influencing Future Losses",
              "value": "Research and development costs, clinical trials, manufacturing, and regulatory processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Material Weakness in Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Description",
              "value": "Identified a material weakness in internal control over financial reporting due to insufficient resources and lack of formalized risk assessment."
            },
            {
              "key": "Impact",
              "value": "Increased possibility of material misstatements in financial statements."
            },
            {
              "key": "Actions Taken",
              "value": "Implemented risk assessment process, hired additional accounting personnel."
            },
            {
              "key": "Future Concerns",
              "value": "Continued need for resources to maintain effective internal controls and potential for future material weaknesses."
            },
            {
              "key": "Regulatory Implications",
              "value": "Evaluation by an independent registered public accounting firm may lead to qualified opinions on internal controls."
            },
            {
              "key": "Market Reaction",
              "value": "Potential negative impact on stock price due to loss of investor confidence."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 65,
          "title": "Risk Factors Related to Financial Institutions and Liquidity",
          "data": [
            {
              "key": "Event",
              "value": "Closure of Silicon Valley Bank"
            },
            {
              "key": "Date of Event",
              "value": "March 10, 2023"
            },
            {
              "key": "Impact",
              "value": "Liquidity problems for counterparties and suppliers"
            },
            {
              "key": "Potential Loss",
              "value": "Inability to access $3.3 million in letters of credit"
            },
            {
              "key": "Past Similar Events",
              "value": "2008-2010 financial crisis"
            },
            {
              "key": "Potential Future Risks",
              "value": "Impact of inflation and interest rate increases on financial securities"
            },
            {
              "key": "Government Response",
              "value": "Program to provide loans secured by government securities"
            },
            {
              "key": "Factors Affecting Access",
              "value": "Liquidity constraints, ability to perform obligations, market instability"
            },
            {
              "key": "Material Impacts",
              "value": "Delayed access to financial assets, inability to enter into credit agreements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "Risk Factors: Financial Obligations and Clinical Development Challenges",
          "data": [
            {
              "key": "Financial Risk Factors",
              "value": "Potential or actual breach of contractual obligations requiring letters of credit or other credit support, breach of financial covenants, and cross-defaults in various credit and operating agreements."
            },
            {
              "key": "Financing and Liquidity Concerns",
              "value": "Investor concerns regarding U.S. or international financial systems could lead to less favorable financing terms, higher interest rates, tighter covenants, and limited access to credit and liquidity, adversely impacting the company’s ability to meet financial and operating obligations."
            },
            {
              "key": "Preclinical and Clinical Development Risk",
              "value": "Product candidates are in preclinical development and have never been tested in humans. There is significant uncertainty regarding regulatory approvals, the ability to begin clinical trials, and the eventual commercial viability of these candidates."
            },
            {
              "key": "Regulatory and Development Uncertainties",
              "value": "Delays or negative outcomes in preclinical studies or clinical trials may force additional studies, delay progression to clinical trials, or result in the abandonment of development programs, thereby impacting overall business prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 67,
          "title": "Table of Contents",
          "data": [
            {
              "key": "adverse events",
              "value": "adverse events experienced by participants in our clinical trials or by individuals using therapeutics similar to our product candidates"
            },
            {
              "key": "regulatory delays",
              "value": "delays in submitting INDs or comparable foreign applications; delays or failures to obtain the necessary approvals from regulatory authorities to commence a clinical trial; suspension or termination of a clinical trial once commenced"
            },
            {
              "key": "regulatory conditions",
              "value": "conditions imposed by the FDA or other regulatory authorities regarding the scope or design of our clinical trials"
            },
            {
              "key": "clinical trial enrollment",
              "value": "delays in enrolling research subjects in clinical trials; high drop-out rates of research subjects"
            },
            {
              "key": "supply and quality issues",
              "value": "inadequate supply or quality of product candidate components, materials or other supplies necessary for the conduct of our clinical trial"
            },
            {
              "key": "CMC challenges",
              "value": "challenges associated with manufacturing and scaling up biologic product candidates to ensure consistent quality, stability, purity, and potency among different batches used in clinical trials"
            },
            {
              "key": "cost overruns",
              "value": "greater-than-anticipated clinical trial costs"
            },
            {
              "key": "efficacy concerns",
              "value": "poor potency or effectiveness of our product candidates during clinical trials"
            },
            {
              "key": "inspection issues",
              "value": "unfavorable FDA or other regulatory authority inspection and review of a clinical trial or manufacturing site"
            },
            {
              "key": "pandemic impact",
              "value": "delays as a result of the COVID-19 pandemic or events associated with the pandemic"
            },
            {
              "key": "third-party compliance",
              "value": "failure of third-party contractors or investigators to comply with regulatory requirements or meet their contractual obligations"
            },
            {
              "key": "regulatory changes",
              "value": "delays and changes in regulatory requirements, policies and guidelines; different interpretation of data by regulatory authorities"
            },
            {
              "key": "marketing approval concerns",
              "value": "potential approval restrictions (such as limited targets, disease indications, or patient populations) and additional labeling requirements including safety warnings"
            },
            {
              "key": "post-marketing requirements",
              "value": "subject to post-marketing testing requirements to maintain regulatory approval"
            },
            {
              "key": "clinical testing uncertainty",
              "value": "risks that initial human testing may not demonstrate the necessary safety, purity, potency, or efficacy"
            },
            {
              "key": "product candidate limitations",
              "value": "potential discovery that current product candidates do not possess properties necessary for therapeutic effectiveness and safety, potentially affecting IND submission timelines or viability"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 68,
          "title": "Risk Factors in Product Candidate Development and Regulatory Challenges",
          "data": [
            {
              "key": "Clinical Translation Uncertainty",
              "value": "Observations on gene circuits and product candidates may not translate into a clinical response when tested in humans."
            },
            {
              "key": "Preclinical Data Limitations",
              "value": "Current data is limited to animal models and preclinical cell lines, which may not accurately predict safety and efficacy in humans."
            },
            {
              "key": "Regulatory Complexity",
              "value": "Due to the novel and unproven nature of the gene circuit platform technologies, the regulatory pathway with the FDA and foreign authorities may be complex, time-consuming, and uncertain."
            },
            {
              "key": "Safety Risks and Side Effects",
              "value": "There is potential for serious safety issues or side effects (e.g., systemic immune cytotoxicity) that could delay or halt clinical trials and affect product viability."
            },
            {
              "key": "Impact on Business Prospects",
              "value": "Failure to develop marketable products or unforeseen safety events could have a material adverse effect on the company's business, financial condition, and overall prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 69,
          "title": "Risk Factors and Regulatory Concerns in Clinical Trials",
          "data": [
            {
              "key": "Clinical Trial Disruptions",
              "value": "The text outlines risks where clinical trials might be suspended or terminated due to side effects or regulatory orders, affecting patient recruitment and trial completion."
            },
            {
              "key": "Regulatory Risks",
              "value": "Regulatory authorities, such as the FDA, could require cessation of development, withdraw product approvals, impose restrictions, or mandate safety changes like black box warnings."
            },
            {
              "key": "Business Impact",
              "value": "Adverse events or undesirable side effects may lead to significant revenue losses, increased liabilities, and harm to the company’s reputation, all of which could materially impact the business and its financial condition."
            },
            {
              "key": "Development Uncertainty",
              "value": "There is uncertainty regarding the advancement of product candidates into clinical development, as well as their eventual safety and effectiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 70,
          "title": "Discussion on Risk Factors for Product Candidate Commercialization",
          "data": [
            {
              "key": "Risk Description",
              "value": "The text outlines various risks associated with the development and commercialization of product candidates. It highlights concerns such as the inability to generate product revenue, failure to identify or develop viable new product candidates, and challenges related to resource allocation, competition, patents, regulatory criteria, and production feasibility."
            },
            {
              "key": "Implication",
              "value": "These risks could materially harm the business, affecting future growth prospects by delaying or forgoing commercially viable opportunities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 71,
          "title": "Risk Factors – Market, Regulatory, and Product Acceptance Challenges",
          "data": [
            {
              "key": "Market and Investor Skepticism",
              "value": "The market, physicians, patients, regulators, and potential investors may be skeptical about the viability and benefits of our gene circuit pipeline technology and product candidates."
            },
            {
              "key": "Novel and Complex Technology",
              "value": "The pipeline is based on a relatively novel and complex technology, which raises concerns that it might not be fully understood or accepted by key stakeholders."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "Even if products like SENTI-202 or SENTI-401 receive regulatory approval, there is no assurance of revenue generation, and delays in IND approvals could occur."
            },
            {
              "key": "Impact on Capital and Stock Value",
              "value": "Skepticism from potential investors may adversely affect the company’s ability to raise capital and the value of its stock."
            },
            {
              "key": "Clinical and Manufacturing Risks",
              "value": "There are risks related to IND filings, potential delays in clinical trials, and evolving challenges in manufacturing and quality control."
            },
            {
              "key": "Market Acceptance Factors",
              "value": "Success depends on timely regulatory approvals, safety and efficacy, side effects, labeling, ease of administration, reimbursement, competitive pricing, and availability of alternative treatments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 72,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Regulatory Oversight",
              "value": "The document outlines the design and implementation of clinical trials under an IND, FDA oversight, and guidelines such as the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, including the role of institutional biosafety committees (IBCs)."
            },
            {
              "key": "Interim Data Variability",
              "value": "It discusses the publication of interim, topline, and preliminary data which are subject to change based on additional patient data, further analysis, audit, and verification procedures."
            },
            {
              "key": "Risk of Data Discrepancy",
              "value": "There is a risk that discrepancies between preliminary and final data could harm clinical program prospects, regulatory approval, commercialization, and overall business performance."
            },
            {
              "key": "Assumptions and Estimates",
              "value": "The document notes that assumptions, estimates, and calculations are made, which may be challenged by regulatory agencies, potentially impacting the results and conclusions of clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 73,
          "title": "Table of Contents - Clinical Trials and Development Risks",
          "data": [
            {
              "key": "milestones",
              "value": "Uncertainty in achieving projected discovery and development milestones and key events, including preclinical and IND-enabling studies."
            },
            {
              "key": "clinical_trials",
              "value": "High costs, regulatory challenges, and difficulties in patient enrollment may delay or adversely affect clinical trial initiation and completion."
            },
            {
              "key": "regulatory_requirements",
              "value": "Additional testing and regulatory hurdles, such as those imposed by the FDA, could further delay clinical trials and affect business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 74,
          "title": "Clinical Trial Risks and Potential Delays",
          "data": [
            {
              "key": "Patient Enrollment & Consent",
              "value": "Challenges include obtaining and maintaining patient informed consents, meeting eligibility criteria, and risk of patient drop out during clinical trials."
            },
            {
              "key": "Competition for Clinical Sites",
              "value": "Limited number of qualified clinical investigators and clinical trial sites may lead to competition with other trials, reducing available patient numbers."
            },
            {
              "key": "Delays and Increased Costs",
              "value": "Delays in patient enrollment and trial execution may lead to increased costs, affect trial timing, and potentially jeopardize product development and regulatory approval."
            },
            {
              "key": "Regulatory and Design Challenges",
              "value": "Possible delays may arise from extended discussions with regulatory authorities and modifications required in trial design, including endpoint measures and statistical planning."
            },
            {
              "key": "External Factor Risks",
              "value": "Uncontrollable factors such as pandemics (e.g., COVID-19) may limit the availability of patients, investigators, or sites, further impacting trial progress."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 75,
          "title": "Table of Contents - Clinical Trial Risk Factors",
          "data": [
            {
              "key": "Risk Factor 1",
              "value": "Delay or failure to manufacture sufficient quantities or inability to produce quantities of consistent quality, purity and potency of the product candidate for our clinical trials."
            },
            {
              "key": "Risk Factor 2",
              "value": "Delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or contact research organizations (CROs), with terms subject to extensive negotiation and varying among sites or CROs."
            },
            {
              "key": "Risk Factor 3",
              "value": "Delay or failure to obtain institutional review board (IRB) or ethics committee approval to conduct a clinical trial at a prospective site."
            },
            {
              "key": "Risk Factor 4",
              "value": "Additional data submission or other requirements imposed by the FDA or comparable foreign regulatory authorities before permitting initiation of a clinical trial."
            },
            {
              "key": "Risk Factor 5",
              "value": "Slower than expected rates of patient recruitment and enrollment."
            },
            {
              "key": "Risk Factor 6",
              "value": "Failure of patients to complete the clinical trial."
            },
            {
              "key": "Risk Factor 7",
              "value": "Inability to enroll a sufficient number of patients in studies to ensure adequate statistical power for detecting significant treatment effects."
            },
            {
              "key": "Risk Factor 8",
              "value": "Unforeseen safety issues, including severe or unexpected drug-related adverse events experienced by patients, potentially including deaths."
            },
            {
              "key": "Risk Factor 9",
              "value": "Lack of efficacy or failure to measure a statistically significant clinical benefit within the dose range with an acceptable safety margin during clinical trials."
            },
            {
              "key": "Risk Factor 10",
              "value": "Termination of clinical trials by one or more clinical trial sites."
            },
            {
              "key": "Risk Factor 11",
              "value": "Inability or unwillingness of patients or clinical investigators to follow clinical trial protocols."
            },
            {
              "key": "Risk Factor 12",
              "value": "Inability to monitor patients adequately during or after treatment by the company or its CROs."
            },
            {
              "key": "Risk Factor 13",
              "value": "CROs or clinical trial sites failing to comply with regulatory requirements or meet contractual obligations, deviating from protocols or dropping out of studies."
            },
            {
              "key": "Risk Factor 14",
              "value": "Inability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical trial."
            },
            {
              "key": "Risk Factor 15",
              "value": "Impacts and delays related to health epidemics such as the COVID-19 pandemic."
            },
            {
              "key": "Risk Factor 16",
              "value": "Need to suspend, repeat, or terminate clinical trials due to non-compliance with regulatory requirements, inconclusive/negative results, or unforeseen testing complications."
            },
            {
              "key": "Risk Factor 17",
              "value": "Suspension or termination of clinical trials due to breaches or as per terms with any future strategic collaborator responsible for clinical development of the product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 76,
          "title": "Regulatory and Orphan Drug Risks",
          "data": [
            {
              "key": "Regulatory Requirements Changes",
              "value": "Changes in regulatory requirements, policies and guidelines may require significant modifications to clinical development plans, including renegotiating terms with CROs and resubmitting clinical trial protocols to IRBs."
            },
            {
              "key": "Clinical Trials Impact",
              "value": "Potential delays, suspensions or terminations of clinical trials due to issues such as failure to commence or complete trials, safety concerns, or the need for additional testing."
            },
            {
              "key": "Orphan Drug Designation Risks",
              "value": "Challenges include potential failure to obtain or maintain orphan drug designation benefits, limitations in marketing exclusivity, and competitive pressures if other drugs are approved for the same indication."
            },
            {
              "key": "Animal Testing Concerns",
              "value": "Possible future restrictions or controversies around animal testing could adversely affect research and development activities."
            },
            {
              "key": "Business Impact",
              "value": "Combined, these factors could adversely affect regulatory approvals, commercial prospects, and the ability to generate product revenue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 77,
          "title": "Risks Related to Third Party Clinical Trials and Regulatory Compliance",
          "data": [
            {
              "key": "Third-Party Dependence",
              "value": "The document highlights reliance on third parties such as clinical investigators, CROs, and consultants for conducting preclinical studies and clinical trials, which reduces direct control over study timing, quality, and performance."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Emphasis on the need to comply with FDA and other regulatory standards (GCP, GLP, cGMP, cGTP) to ensure reliable data, with potential delays or repeated trials if compliance is not met."
            },
            {
              "key": "Contractual and Resource Risks",
              "value": "Potential issues with third parties, including termination of engagements, negotiation difficulties on budgets/contracts, and allocation of resources, which could delay development timelines and increase costs."
            },
            {
              "key": "Impact on Financial and Commercial Outcomes",
              "value": "Delays in clinical trials and regulatory approvals due to reliance on third parties may harm financial results and commercial prospects for product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 78,
          "title": "Product Candidates and Collaboration Agreements Risk Factors",
          "data": [
            {
              "key": "Overview",
              "value": "Discussion on product candidates in specific indications and the risks associated with unsuccessful collaboration arrangements that could impair revenue generation and harm results of operations."
            },
            {
              "key": "Collaboration Agreements",
              "value": "The company has existing collaboration agreements with strategic partners such as Spark and BlueRock. These agreements include provisions for research funding and significant milestone payments contingent on development, regulatory, and commercial milestones."
            },
            {
              "key": "Dependencies and Responsibilities",
              "value": "Collaborators are generally responsible for selecting product candidates for development, conducting clinical trials, obtaining regulatory approvals, and eventually commercializing any resulting products."
            },
            {
              "key": "Risk Factors",
              "value": "Potential risks include: changes in collaborator priorities, shifts in business strategies (including mergers, acquisitions, sale, or downsizing), delays or cessation in the development process, changes in success criteria for product advancement, and possible termination or impairment of the collaboration which could delay milestone payments and affect the company's ability to fund its operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 79,
          "title": "Risk Factors Related to Product Development and Strategic Transactions",
          "data": [
            {
              "key": "Development and Commercialization Risk",
              "value": "Disagreements over research, development, or commercialization of product candidates may lead to delays in milestones, termination of R&D activities, and associated financial impacts."
            },
            {
              "key": "Intellectual Property Risk",
              "value": "Potential misuse of proprietary information or intellectual property could jeopardize the company's rights and hinder product development."
            },
            {
              "key": "Collaboration and Partnership Risk",
              "value": "Termination or unfavorable terms in existing or future strategic collaborations and partnerships may result in the loss of milestone payments, royalties, and sharing of profits, as well as increased expenses and integration challenges."
            },
            {
              "key": "Transactional and Financial Risk",
              "value": "Strategic transactions such as acquisitions, joint ventures, or licensing agreements may incur non-recurring charges, integration difficulties, and other financial risks including dilution and increased debt."
            },
            {
              "key": "Legal and Dispute Resolution Risk",
              "value": "Disagreements could lead to litigation or arbitration, which would be time-consuming and costly, adversely affecting business operations and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 80,
          "title": "Risk Factors: Relationships and Manufacturing Challenges",
          "data": [
            {
              "key": "Collaboration and Acquisition Risks",
              "value": "Impairment of relationships with key suppliers, manufacturers, or customers, as well as the inability to retain key employees in acquired businesses, may materially harm the business."
            },
            {
              "key": "Manufacturing Complexity Risks",
              "value": "The manufacturing of product candidates is complex, susceptible to contamination, equipment failures, yield variability, and other process disruptions which could delay or halt production for clinical trials or commercial sale."
            },
            {
              "key": "In-House Manufacturing Challenges",
              "value": "Construction of a dedicated in-house manufacturing facility (initiated in June 2021 for allogeneic NK cell products) faces risks of delays and operational issues, potentially impacting the scale-up and quality of product supply."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 81,
          "title": "Risk Factors: Manufacturing & Supply Chain Challenges",
          "data": [
            {
              "key": "Facility Construction Delays",
              "value": "The planned facility's construction and commissioning may be delayed or not completed, affecting product supply for preclinical and clinical development."
            },
            {
              "key": "Reliance on Third-Party Manufacturers",
              "value": "A potential shift to third-party backup manufacturers may be required, but there is a limited number of qualified providers, posing risks to product consistency and supply."
            },
            {
              "key": "Manufacturing Process Risks",
              "value": "There is uncertainty whether current manufacturing processes and technologies will yield scalable, safe, and effective product candidates that meet market demand."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Manufacturing processes are subject to FDA and other regulatory reviews. Any failure to meet cGMP/cGTP standards, or delays in validation, may result in additional regulatory scrutiny, delayed approvals, or recalls."
            },
            {
              "key": "Impact on Drug Development",
              "value": "Delays or interruptions in manufacturing may impede clinical trials, delay regulatory submissions, and harm overall business prospects and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 82,
          "title": "Manufacturing and Supply Chain Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The document outlines significant risks that may delay or prevent the manufacturing and commercialization of product candidates. Key concerns include the inability to scale up manufacturing capacity, quality issues during scale-up, regulatory challenges related to cGMP facility operations, and supply chain disruptions related to sourcing specialty materials and reagents from limited or sole source vendors. Such issues could adversely impact product development, clinical trials, regulatory approvals, and ultimately, business performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 84,
          "title": "Risk Factors and Competitive Landscape",
          "data": [
            {
              "key": "Competition",
              "value": "The company faces intense competition in the development and commercialization of cell and gene therapies from larger, better-funded pharmaceutical and biotechnology companies, as well as academic and research institutions."
            },
            {
              "key": "Regulatory and Market Risks",
              "value": "Even if product candidates are approved, factors such as safety, ease of administration, manufacturing costs, and reimbursement issues may adversely affect their competitiveness and market success."
            },
            {
              "key": "Key Personnel Dependency",
              "value": "The success of the company is heavily reliant on the continued service of key executives and specialized personnel, and any loss of this talent could significantly impact its ability to implement its business strategy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 85,
          "title": "Risk Factors: Operational Growth, Staffing, and Strategic Re-Prioritization Challenges",
          "data": [
            {
              "key": "Contracts Restricting Availability",
              "value": "Contracts with other entities may limit available resources."
            },
            {
              "key": "Talent Acquisition and Retention",
              "value": "Challenges in attracting, recruiting, and retaining high-quality personnel could limit growth and operational capabilities."
            },
            {
              "key": "Growth Management",
              "value": "Difficulties in managing growth, expanding operations, and scaling internal systems and facilities are noted."
            },
            {
              "key": "Therapeutic Development Experience",
              "value": "Limited experience in therapeutic and manufacturing processes for cell and gene therapies could impede progress."
            },
            {
              "key": "Strategic Re-Prioritization",
              "value": "A re-prioritization plan announced in January 2023 to streamline R&D and focus on select product candidates may not achieve anticipated benefits."
            },
            {
              "key": "Operational Controls",
              "value": "Challenges in implementing, improving, and maintaining efficient operational, financial, and management controls."
            },
            {
              "key": "Workforce Reductions",
              "value": "Potential workforce reductions, if implemented, could have unintended negative consequences on operations and employee morale."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 86,
          "title": "Commercialization and International Business Risks",
          "data": [
            {
              "key": "Sales and Marketing Capabilities",
              "value": "The company currently lacks sales, marketing, and distribution capabilities and must develop these internally or partner with third parties, which could prove expensive and time-consuming."
            },
            {
              "key": "Regulatory Approval Dependencies",
              "value": "Successful commercialization of future product candidates depends on obtaining FDA or other regulatory approvals, a process that is costly and may delay market entry."
            },
            {
              "key": "Third-Party Dependence",
              "value": "Reliance on third parties for marketing or co-promotion introduces risk, as revenue depends on their ability to establish adequate sales and distribution channels."
            },
            {
              "key": "International Business Risks",
              "value": "Expansion into international markets exposes the company to business, political, operational and financial risks, including navigating conflicting laws, regulations, and reimbursement systems."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 87,
          "title": "Risk Factors and Compliance Challenges",
          "data": [
            {
              "key": "financial_risk",
              "value": "Longer payment cycles, difficulty collecting accounts receivable, impact of local and regional financial crises on demand and payment for products, and exposure to foreign currency exchange rate fluctuations."
            },
            {
              "key": "natural_disaster_and_political_risk",
              "value": "Risks from natural disasters, political and economic instability (including wars, terrorism, political unrest), disease outbreaks (including COVID-19), boycotts, curtailment of trade, and other business restrictions."
            },
            {
              "key": "regulatory_compliance_risk",
              "value": "Compliance risks related to anti-corruption measures, record-keeping requirements under laws such as the U.S. Foreign Corrupt Practices Act, as well as anti-bribery and anti-corruption laws in other jurisdictions."
            },
            {
              "key": "product_liability_risk",
              "value": "Risks associated with product liability claims during preclinical studies, clinical trials, development, testing, manufacturing, and marketing; potential FDA investigations, recalls, enforcement actions, or restrictions on product indications."
            },
            {
              "key": "misconduct_and_fraud_risk",
              "value": "Risk of misconduct by employees, principal investigators, consultants and commercial collaborators including noncompliance with FDA regulations, healthcare fraud, abuse laws, and misuse of clinical trial information leading to potential regulatory sanctions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 89,
          "title": "Risks Related to Environmental Compliance and Liabilities",
          "data": [
            {
              "key": "Limitations of liability",
              "value": "In our contracts may not protect against liabilities or damages related to data protection laws."
            },
            {
              "key": "Hazardous materials",
              "value": "Our research and manufacturing involve flammable and toxic chemicals, subject to extensive regulations."
            },
            {
              "key": "Environmental liability insurance",
              "value": "We may not maintain adequate insurance for all potential claims regarding biological or hazardous materials."
            },
            {
              "key": "Impact of global developments",
              "value": "Global economic and political developments could adversely affect business operations due to inflation, war, and pandemics."
            },
            {
              "key": "COVID-19 pandemic effects",
              "value": "Work-from-home policies could disrupt business and clinical program timelines."
            },
            {
              "key": "Supplier relationships",
              "value": "Termination of supplier relationships due to COVID-19 could adversely impact operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 90,
          "title": "Impact of COVID-19 and Economic Uncertainty on Clinical Trials and Business Operations",
          "data": [
            {
              "key": "Potential Risks from COVID-19",
              "value": "Delays in clinical trials due to patient concerns and hospital prioritization of resources."
            },
            {
              "key": "Adverse Effects on Operations",
              "value": "Material adverse effects on business due to pandemic disruptions."
            },
            {
              "key": "Market Conditions",
              "value": "Increased economic uncertainty may harm results and stock price."
            },
            {
              "key": "Supply Chain Disruption",
              "value": "Potential disruptions leading to higher costs and inflation."
            },
            {
              "key": "Capital Market Volatility",
              "value": "Recent volatility may affect ability to access new capital."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 91,
          "title": "Risks Related to Our Capital Requirements and Intellectual Property",
          "data": [
            {
              "key": "Liquidity Concerns",
              "value": "Liquidity limits ability to grow, pursue acquisitions, and improve infrastructure."
            },
            {
              "key": "Future Capital Requirements",
              "value": "Future needs may differ; depend on financing unforeseen working capital, technological enhancements, and strategic relationships."
            },
            {
              "key": "Potential Limitations on Financing",
              "value": "Future debt financing may involve covenants that restrict capital raising activities."
            },
            {
              "key": "Inflation Impact",
              "value": "Rising inflation could negatively impact revenues and profitability."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Inability to protect IP rights may lead to competition from similar products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 92,
          "title": "Patent Risk Factors Discussion",
          "data": [
            {
              "key": "Patent Protection Risk",
              "value": "The text discusses potential inadequacies in patent protection for platform technologies and product candidates, highlighting that issued patents may not provide meaningful protection or competitive advantage."
            },
            {
              "key": "Cost and Complexity",
              "value": "The patent prosecution process is described as expensive, complex, and time-consuming, with associated challenges in licensing negotiations and enforcement."
            },
            {
              "key": "Enforcement and Coverage Limitations",
              "value": "Even if patents are issued, there is concern that they may not adequately cover current or future technologies, and competitors might circumvent them through alternative development paths."
            },
            {
              "key": "Legal and Procedural Uncertainties",
              "value": "The document outlines risks related to uncertainties in patent laws, prior art searches, and challenges in controlling patent filing and prosecution, which could lead to potential invalidation or reduced scope of patent claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 93,
          "title": "Risk Factor: Uncertainties in Patent Protection",
          "data": [
            {
              "key": "Key Issue",
              "value": "The document discusses uncertainties in the issuance, scope, validity, enforceability, and commercial value of patent rights."
            },
            {
              "key": "Details",
              "value": "There is significant uncertainty regarding patent protection due to non-uniform standards applied by the USPTO and foreign patent offices, potential challenges from competitors, and evolving intellectual property laws. This uncertainty could reduce competitive advantage and impact commercialization of current and future product candidates."
            },
            {
              "key": "Potential Consequences",
              "value": "Failure to secure valid and enforceable patents may allow competitors to commercialize similar products or technologies, adversely affecting the company's market exclusivity and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 94,
          "title": "Risks Related to Patent Rights and Exclusivity",
          "data": [
            {
              "key": "Patent Rights Enforcement",
              "value": "Issues with owned or in-licensed patent rights being unenforceable may lead to loss of exclusivity and allow competitors to use or commercialize similar technologies without payment."
            },
            {
              "key": "Co-ownership and Licensing Challenges",
              "value": "Co-owned patent applications with third parties may result in difficulties obtaining exclusive licenses; third parties might license these patents to competitors."
            },
            {
              "key": "Reliance on Third Parties",
              "value": "Dependence on licensors or collaborators for patent prosecution, maintenance, and enforcement may adversely impact protection and commercialization efforts."
            },
            {
              "key": "Regulatory and Jurisdictional Risks",
              "value": "Licensed European patents and patent applications could be subject to challenges under the Unified Patent Court (UPC), potentially affecting their validity across multiple countries."
            },
            {
              "key": "Overall Impact",
              "value": "These factors could have a material adverse effect on the company’s competitive position, business prospects, and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 95,
          "title": "Intellectual Property Licensing and Infringement Risks",
          "data": [
            {
              "key": "Licensing Risk",
              "value": "Potential inability to acquire or in-license essential third-party intellectual property rights necessary for product development and business operations."
            },
            {
              "key": "Infringement Proceedings",
              "value": "Licensors may initiate infringement proceedings against third-party infringers, though their actions might be less vigorous than if handled internally."
            },
            {
              "key": "Government Rights and Regulations",
              "value": "Certain technologies, particularly those developed under government-funded programs, may be subject to federal regulations such as the Bayh-Dole Act, including march-in rights that could limit exclusive rights."
            },
            {
              "key": "Competitive Disadvantage",
              "value": "More established companies may have advantages in securing licenses and capital resources, potentially leaving the company at a competitive disadvantage."
            },
            {
              "key": "Financial Impact",
              "value": "Adverse licensing terms or inability to license necessary technology could lead to injunctions, royalty obligations, and material harm to the company's business and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 96,
          "title": "Intellectual Property License Risks and Regulatory Obligations",
          "data": [
            {
              "key": "March-in Rights",
              "value": "Inventions not embodied in current product candidates are subject to march-in rights, giving the U.S. government the right to take title if disclosure or patent filing requirements are not met."
            },
            {
              "key": "Government Funding & Bayh-Dole Act",
              "value": "Intellectual property generated through government-funded programs is subject to reporting requirements and provisions of the Bayh-Dole Act, affecting ownership and commercialization."
            },
            {
              "key": "Manufacturing Preference",
              "value": "Products embodying the subject invention must be manufactured substantially in the U.S. unless a waiver is obtained, which could limit contracting with non-U.S. manufacturers."
            },
            {
              "key": "License Agreements",
              "value": "Existing and future license agreements, including those with governmental agencies like NCI, impose obligations such as development, commercialization, and patent maintenance requirements."
            },
            {
              "key": "Patent Protection Risks",
              "value": "Potential defects in patent preparation, prosecution, and enforcement, as well as limitations in controlling third-party licensed patents, may impair the company’s ability to protect its technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 97,
          "title": "License and Intellectual Property Risks",
          "data": [
            {
              "key": "Licensing Risks",
              "value": "The document explains that rights under license agreements may be adversely affected by the actions or inactions of predecessors or licensors, potentially limiting the use of acquired or licensed technology."
            },
            {
              "key": "Enforcement and Compliance",
              "value": "It describes the challenges and expenses involved in monitoring and enforcing licensing agreements, including potential breaches which could lead to damage payments or loss of intellectual property rights."
            },
            {
              "key": "Impact on Business Strategy",
              "value": "Any limitations or breaches affecting licensed technologies may impair development, out-licensing, marketing, and selling product candidates, thereby affecting profitability."
            },
            {
              "key": "Royalty and Financial Obligations",
              "value": "The text highlights uncertainty regarding future royalty obligations and the risk that infringement claims could require significant payments, impacting overall financial results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 99,
          "title": "Risk Factors - Patent Term Extension and Legal Uncertainty",
          "data": [
            {
              "key": "Patent Term Extension Risk",
              "value": "The document discusses the risk that if patent term extensions are not granted or are shorter than expected, the period during which patent rights can be enforced will be reduced, potentially allowing competitors to commercialize similar products sooner."
            },
            {
              "key": "Regulatory and Legal Uncertainties",
              "value": "It highlights uncertainties related to patent term adjustments, the Hatch-Waxman Act, and changes in U.S. patent law (including the Leahy-Smith Act), which may increase costs and delay patent prosecution."
            },
            {
              "key": "Impact on Competitive Advantage",
              "value": "The limited lifespan of patents and potential regulatory delays might weaken the company’s competitive edge, affecting revenue and market exclusivity for drug products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 100,
          "title": "Patent Law and Litigation Risk Due to Leahy-Smith Act",
          "data": [
            {
              "key": "Description",
              "value": "The document discusses the impact of the Leahy-Smith Act and its regulatory implementations on patent prosecution and enforcement. It outlines the uncertainties in patent law, including challenges related to patent validity, litigation risks through USPTO proceedings, and potential adverse impacts on the business."
            },
            {
              "key": "Patent Uncertainty",
              "value": "Changes in patent law, such as the first-to-file provisions and evolving judicial interpretations, create uncertainty regarding the scope and enforceability of patents, which may adversely affect the company's intellectual property rights and competitive position."
            },
            {
              "key": "Litigation and Cost Risks",
              "value": "There is significant risk of costly litigation or defense actions arising from third party challenges, declaratory judgments, inter partes reviews, and other legal proceedings that could weaken or invalidate patent rights."
            },
            {
              "key": "Regulatory and Legislative Impact",
              "value": "Future actions by the U.S. Congress, federal courts, and the USPTO might further modify patent law, adding to the risks and potential financial adverse effects on the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 101,
          "title": "Patent Litigation Risk and Intellectual Property Challenges",
          "data": [
            {
              "key": "Litigation Impact",
              "value": "Legal proceedings and patent litigation could materially increase operating losses and reduce resources available for development and commercialization."
            },
            {
              "key": "Patent Validity and Enforceability",
              "value": "Risks include potential challenges regarding patent validity, such as allegations of lack of novelty, indefiniteness, or non-enablement, which may result in loss of patent protection."
            },
            {
              "key": "R&D Delays",
              "value": "Uncertainty from litigation or legal proceedings could delay research and development efforts and adversely affect ongoing operations."
            },
            {
              "key": "International IP Risks",
              "value": "Challenges in protecting intellectual property globally, including issues in jurisdictions like the UPC, could impact the company's ability to maintain patent rights across multiple countries."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 102,
          "title": "Table of Contents business",
          "data": [
            {
              "key": "Risk Description",
              "value": "The text outlines significant risks associated with intellectual property, including potential invalidation of patents, narrow interpretation of patent claims, and challenges in enforcing these rights globally."
            },
            {
              "key": "Litigation Risks",
              "value": "Mentions costly litigation, third-party claims of infringement, misappropriation, and potential adverse impacts on product commercialization due to patent disputes."
            },
            {
              "key": "Competitive Impact",
              "value": "Highlights that forced licensing or litigation could impair competitive position and materially affect business prospects by diverting resources and delaying development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 103,
          "title": "Risk Factors: Intellectual Property Litigation",
          "data": [
            {
              "key": "Topic",
              "value": "Patent infringement and litigation risk"
            },
            {
              "key": "Summary",
              "value": "The document discusses the risk that third-party patents or pending patent applications may infringe on the company's technology or product candidates. It outlines potential litigation scenarios, high costs, penalties including damages and attorney fees, and possible barriers to commercialization. The text further emphasizes that even if claims are believed to be without merit, litigation could still materialize and adversely affect business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 104,
          "title": "Risk Factors – Intellectual Property and Licensing Challenges",
          "data": [
            {
              "key": "Risk Theme",
              "value": "Intellectual Property Litigation and Licensing Risks"
            },
            {
              "key": "Description",
              "value": "The text outlines potential adverse impacts on revenue and profitability due to reliance on third-party patent licenses, the possibility of expensive, prolonged litigation, and the risks associated with intellectual property infringement claims. It discusses the challenges in obtaining licenses on reasonable terms, the need to redesign technology or product candidates if licensing fails, and the potential for negative market repercussions."
            },
            {
              "key": "Potential Impact",
              "value": "Material adverse effects on commercialization, increased costs, potential damage to reputation, and a decline in market value of common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 105,
          "title": "Риски, связанные с нарушением прав интеллектуальной собственности и торговых секретов",
          "data": [
            {
              "key": "Описание риска",
              "value": "Указаны потенциальные споры по поводу нарушений патентных прав, возможные претензии со стороны третьих лиц, связанные с интеллектуальной собственностью, включая патенты, заявки на патенты, а также торговые секреты."
            },
            {
              "key": "Возможные последствия",
              "value": "В случае успешного предъявления исков компания может быть вынуждена выплачивать значительные компенсации, отказаться от технологий или продуктов, пересмотреть лицензирование, а также столкнуться с дорогостоящими судебными разбирательствами и задержками в маркетинге."
            },
            {
              "key": "Меры предосторожности",
              "value": "Использование соглашений о неразглашении и обеспечения конфиденциальности, а также применение физических и технологических мер безопасности для защиты торговых секретов и ноу-хау."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 106,
          "title": "Risk Factors: Trade Secrets, IP Litigation, and Competitive Harm",
          "data": [
            {
              "key": "Trade Secrets Disclosure Risk",
              "value": "Discussion of risks associated with trade secrets being disclosed, lawfully obtained, or independently developed by competitors, which could materially harm the competitive position."
            },
            {
              "key": "Litigation and Arbitration Risk",
              "value": "Potential for claims and disputes over wrongful use or disclosure of proprietary information, leading to litigation or arbitration and significant costs."
            },
            {
              "key": "Intellectual Property Disputes",
              "value": "Risks related to challenges on inventorship and ownership of patents and intellectual property, which could result in loss of rights or enforcement issues."
            },
            {
              "key": "Employee and Third-party Obligations",
              "value": "Concerns regarding former employees, consultants, or collaborators possessing or disclosing confidential information, leading to conflicts over IP rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 107,
          "title": "Intellectual Property and Trademark Risks",
          "data": [
            {
              "key": "Intellectual Property Assignment",
              "value": "The document outlines policies requiring employees and contractors to assign intellectual property rights, but notes the potential failure to secure such agreements, leading to disputes over IP ownership."
            },
            {
              "key": "Patent Compliance",
              "value": "Maintaining patent protection depends on timely fee payments, document submissions, and adherence to procedural requirements imposed by patent agencies (e.g., USPTO), with non-compliance risking abandonment or lapse of patents."
            },
            {
              "key": "Legal Claims and Disputes",
              "value": "There is a risk of legal action arising from breaches of assignment agreements or disputes over ownership, which could result in costly claims against third parties or the company."
            },
            {
              "key": "Trademark and Trade Name Protection",
              "value": "The document discusses the reliance on registered and unregistered trademarks and trade names for branding, noting risks of challenges, infringement, or misuse that can harm brand recognition."
            },
            {
              "key": "Competitive Impact",
              "value": "Failure to protect intellectual property and trademarks may enable competitors to enter the market with similar products, adversely affecting business prospects and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 108,
          "title": "Risks Related to Government Regulation and Intellectual Property Rights",
          "data": [
            {
              "key": "Intellectual Property Risks",
              "value": "The degree of future protection afforded by our intellectual property rights is uncertain due to various factors, including the possibility of similar technologies being developed not covered by our patents."
            },
            {
              "key": "Clinical Development Risks",
              "value": "Clinical development includes a lengthy and expensive process with an uncertain outcome, and results from earlier studies may not predict future trials' outcomes."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "All product candidates are in preclinical development, which poses a high risk of failure due to the uncertainty of achieving regulatory approval."
            },
            {
              "key": "Impact of Patent Issues",
              "value": "Other parties may independently develop similar technologies, and our patent applications may not lead to issued patents, impacting our competitiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 113,
          "title": "Regulatory Compliance and Risk Factors in Product Candidate Marketing",
          "data": [
            {
              "key": "Regulatory Authorities",
              "value": "FDA and other comparable regulatory bodies"
            },
            {
              "key": "Compliance Requirements",
              "value": "Compliance with extensive FDA requirements including manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import/export, advertising, promotion, recordkeeping, cGMP, and clinical practices"
            },
            {
              "key": "Post-Marketing Surveillance",
              "value": "Obligation for ongoing submission of safety and post-marketing information, registration, and compliance with regulatory requirements"
            },
            {
              "key": "Risks and Consequences",
              "value": "Potential restrictions on marketing/manufacturing, product recalls, fines, warning letters, trial holds/suspensions, seizures, import/export refusals, injunctions, and civil/criminal penalties"
            },
            {
              "key": "REMS Requirement",
              "value": "The FDA may require a risk evaluation and mitigation strategy (REMS) as part of the approval process"
            },
            {
              "key": "Off-Label Promotion Risks",
              "value": "Strict FDA regulations on promotion, with penalties for improper off-label promotion including adverse publicity and significant liabilities"
            },
            {
              "key": "Commercial Impact",
              "value": "Regulatory non-compliance may inhibit the ability to commercialize product candidates and generate revenue"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 114,
          "title": "Regulatory Risks and Legislative Impacts on Business Operations",
          "data": [
            {
              "key": "Regulatory Compliance Risks",
              "value": "The FDA and other regulatory authorities have required companies to enter into consent decrees or permanent injunctions, leading to changes or curtailment of promotional activities. Failure to adapt to regulatory changes could result in loss of marketing approval and adversely affect profitability."
            },
            {
              "key": "Impact of BPCIA",
              "value": "The Biologics Price Competition and Innovation Act (BPCIA) creates an abbreviated approval pathway for biosimilars with a 12-year exclusivity period. However, this exclusivity could be shortened due to legislative changes or a reclassification of product candidates, potentially allowing for earlier generic competition."
            },
            {
              "key": "Legislative and Regulatory Uncertainty",
              "value": "Ongoing and potential future changes in legislation and regulatory policies, including healthcare reforms aimed at containing costs, may limit or delay FDA approvals, reduce pricing power, and ultimately impact company revenues and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 115,
          "title": "Legislative and Regulatory Proposals and Risk Factors",
          "data": [
            {
              "key": "Capital Availability Concerns",
              "value": "Legislative proposals to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products."
            },
            {
              "key": "FDA Regulation Impact",
              "value": "Potential changes in FDA regulations, guidance, or interpretations that could affect marketing approvals of product candidates."
            },
            {
              "key": "Congressional Scrutiny",
              "value": "Increased scrutiny by Congress may delay or prevent marketing approvals and result in more stringent labeling and testing requirements."
            },
            {
              "key": "Healthcare Cost Containment",
              "value": "Efforts by governmental and third-party payors to cap or reduce healthcare costs could limit reimbursement levels, affecting future revenues."
            },
            {
              "key": "Data Protection and Legal Risks",
              "value": "Non-compliance with health and data protection laws (e.g., HIPAA, GDPR) may lead to enforcement actions, litigation, and penalties."
            },
            {
              "key": "Specialty Drug Pricing Transparency",
              "value": "Increased legislative and enforcement interest in drug pricing practices may lead to reforms impacting revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 116,
          "title": "Privacy and Data Protection Regulatory Risks",
          "data": [
            {
              "key": "Consent and Information Sharing",
              "value": "Obligations to disclose how personal data is used and shared with data subjects"
            },
            {
              "key": "Regulatory Notification",
              "value": "Requirement to notify regulators and affected individuals in the event of personal data breaches"
            },
            {
              "key": "Internal Privacy Governance",
              "value": "Extensive internal obligations to manage privacy and uphold expanded rights of data subjects"
            },
            {
              "key": "Cross-Border Data Transfers",
              "value": "GDPR restrictions and new standard contractual clauses for data transfers from the EEA, with separate UK mechanisms"
            },
            {
              "key": "Compliance Costs and Efforts",
              "value": "Transition to new transfer mechanisms will require significant effort and cost, potentially impacting business operations"
            },
            {
              "key": "Regulatory and Legal Risks",
              "value": "Risk of investigations, fines, penalties, and litigation under GDPR, CCPA, HIPAA, and other privacy laws"
            },
            {
              "key": "Business Impact",
              "value": "Non-compliance may harm business prospects, client retention, and the ability to conduct clinical trials and attract partners"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 117,
          "title": "Regulatory and Compliance Risk Factors",
          "data": [
            {
              "key": "Data Protection Compliance",
              "value": "Failure to comply with U.S. and international data protection laws and regulations could adversely affect our financial condition and restrict operations."
            },
            {
              "key": "Privacy and Cybersecurity Risks",
              "value": "Non-compliance or perceived non-compliance with privacy, data protection, and cybersecurity obligations may lead to enforcement actions, litigation, and reputational damage."
            },
            {
              "key": "Healthcare Regulatory Risks",
              "value": "Non-compliance with healthcare laws and contractual obligations can incur substantial costs, penalties, and negatively impact product development and market relationships."
            },
            {
              "key": "Enforcement and Litigation",
              "value": "Government enforcement actions, including civil or criminal penalties, and private litigation could result from violations, impacting operating results and business reputation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 118,
          "title": "Regulatory and Compliance Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The document outlines significant risk factors related to regulatory obligations and oversight. It discusses the potential imposition of corporate integrity agreements, the high costs and resource requirements tied to defending against litigation or regulatory actions, and the adverse effects on business operations if any associated allegations are proven. Additionally, the content highlights the risks arising from non-compliance with U.S. and foreign regulatory requirements, including potential penalties, restrictions on marketing approvals, and challenges in obtaining and maintaining coverage and reimbursement from third-party payors. The reliance on third-party manufacturers and the impact of post-market reviews and adverse events are also emphasized."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 119,
          "title": "Reimbursement, Pricing, and Regulatory Compliance Risks",
          "data": [
            {
              "key": "Coverage and Reimbursement Uncertainty",
              "value": "The document highlights risks that coverage and adequate reimbursement for pharmaceutical products may not be available or sufficient, which could negatively impact product commercialization and revenue generation."
            },
            {
              "key": "Government and Third-Party Controls",
              "value": "It discusses how government authorities and third-party payors control costs through limitations on drug pricing, predetermined discounts, and regulatory pricing controls that may delay product launches."
            },
            {
              "key": "Regulatory and Compliance Risks",
              "value": "The text emphasizes the potential legal and financial consequences related to anti-corruption, anti-money laundering laws, and the reliance on rigorous compliance measures, which could result in enforcement actions if violated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 120,
          "title": "Risk Factors and Share Volatility",
          "data": [
            {
              "key": "Overview",
              "value": "Business operations and financial condition could be materially harmed; management’s attention and resources may be significantly diverted."
            },
            {
              "key": "Additional Costs",
              "value": "Potential for significant defense, compliance costs, professional fees, and possible appointment of an independent compliance monitor."
            },
            {
              "key": "Stock Volatility",
              "value": "The Senti common stock price is volatile, subject to wide fluctuations due to limited trading volume and market conditions."
            },
            {
              "key": "Risk Drivers",
              "value": "Factors include progress of product candidates, preclinical study results, macroeconomic conditions including COVID-19, regulatory/legal developments, competitive pressures, and market sentiment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 122,
          "title": "Risk Factors: Litigation, Stock Volatility and Merger Activity",
          "data": [
            {
              "key": "Class Action Litigation Risk",
              "value": "The document highlights the potential for significant costs due to class action litigation arising from stock price volatility."
            },
            {
              "key": "Stock Volatility",
              "value": "It discusses various reasons for stock price fluctuations, including public announcements related to development, key personnel changes, and market valuation changes in the biopharmaceutical and biotechnology sectors."
            },
            {
              "key": "Merger and SPAC Activity",
              "value": "The text references the public announcement of the Business Combination Agreement in December 2021 and notes recent volatility involving companies that have completed a merger with a SPAC, which may lead to litigation."
            },
            {
              "key": "Emerging Growth Company Exemptions",
              "value": "Mentions that the company is an emerging growth company benefiting from reduced disclosure and reporting requirements, which might affect investor perceptions and share attractiveness."
            },
            {
              "key": "Private Placement and Share Pricing",
              "value": "There is an indication of different pricing for Founder Shares and Anchor Investors’ shares, which could impact market dynamics if significant share sales occur."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 124,
          "title": "Risk Factors and Disclosure Controls Discussion",
          "data": [
            {
              "key": "Voting Strength Impact",
              "value": "The relative voting strength of each previously outstanding share of common stock would be diminished."
            },
            {
              "key": "Market Price Risk",
              "value": "The market price of shares of common stock may decline due to various factors including mismatches between analyst projections and actual performance."
            },
            {
              "key": "Disclosure and Control Limitations",
              "value": "Disclosure controls and procedures may not prevent or detect all errors or acts of fraud due to inherent system limitations."
            },
            {
              "key": "Compliance Costs and Public Company Obligations",
              "value": "As a public company, significant legal, accounting, and compliance costs are expected due to regulatory requirements such as the Exchange Act and Sarbanes-Oxley Act."
            },
            {
              "key": "Analyst Coverage Impact",
              "value": "Analyst reports, including potential downgrades or cessation of coverage, may adversely affect the trading price and volume of the company’s common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 126,
          "title": "Forum Selection, Nasdaq Listing, and Litigation Risk",
          "data": [
            {
              "key": "Forum Selection",
              "value": "Provisions mandate that claims under the Securities Act and related matters be litigated exclusively in U.S. federal district courts, limiting alternative forums and potentially increasing litigation costs for stockholders."
            },
            {
              "key": "Nasdaq Delisting Risk",
              "value": "Failure to meet Nasdaq’s continued listing requirements, including corporate governance and minimum bid price, may result in delisting, negatively affecting security liquidity and market price."
            },
            {
              "key": "Dividend Policy",
              "value": "The company does not anticipate paying cash dividends; future earnings, if any, will be retained to finance business growth, making capital appreciation the sole source of investor gain."
            },
            {
              "key": "Securities Class Action Risk",
              "value": "There is an increased risk of securities class action litigation, especially given the stock price volatility typical in biotechnology and pharmaceutical firms, which could lead to significant costs and management distraction."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 127,
          "title": "General Risk Factors",
          "data": [
            {
              "key": "Regulatory Disruptions",
              "value": "Disruptions at the FDA and other government agencies caused by funding shortages, government shutdowns, and furloughs can delay product approvals and affect operational timelines."
            },
            {
              "key": "Government Funding and Policy",
              "value": "The FDA and similar agencies depend on fluctuating government funding and policy changes, which can lead to delays in reviews and inspections, impacting product commercialization."
            },
            {
              "key": "Operational Risks from Disasters",
              "value": "Natural disasters, pandemics, and other unplanned events (e.g., earthquakes, floods, fires) may disrupt business operations, affect facilities, and increase costs."
            },
            {
              "key": "Business Continuity Concerns",
              "value": "Inadequate disaster recovery and business continuity plans could result in significant operational interruptions and harm research and development programs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 128,
          "title": "Risk Factors Impacting Business Operations and Financial Performance",
          "data": [
            {
              "key": "Business Interruption",
              "value": "Business interruption may have a material adverse effect on our business, financial condition, results of operations and prospects."
            },
            {
              "key": "Operating Results Fluctuation",
              "value": "Quarterly operating results may fluctuate significantly and may fall below investor or analyst expectations, leading to potential declines in stock price."
            },
            {
              "key": "Expense Variations in R&D",
              "value": "Variations in expenses related to the development of product candidates, preclinical studies, and clinical trials could affect net loss and operating results."
            },
            {
              "key": "Litigation and Intellectual Property Risks",
              "value": "There is a risk of litigation arising from allegations of wrongful use or disclosure of confidential information, including potential conflicts with former employers."
            },
            {
              "key": "Strategic and Regulatory Risks",
              "value": "Strategic decisions such as acquisitions, divestitures, and changes in business strategy, along with regulatory developments, may impact business performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 135,
          "title": "Regulatory Risks Affecting Product Development",
          "data": [
            {
              "key": "Unfavorable FDA or Regulatory Inspections",
              "value": "Significant impact on costs and timing for development"
            },
            {
              "key": "COVID-19 Delays",
              "value": "Potential delays in obtaining regulatory approvals"
            },
            {
              "key": "Compliance Failures",
              "value": "Third-party contractors not complying with regulations could delay approvals"
            },
            {
              "key": "Changes in Regulatory Requirements",
              "value": "Frequent changes could affect development timelines"
            },
            {
              "key": "FDA Interpretation of Data",
              "value": "Differing interpretation could lead to non-approval of product candidates"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 196,
          "title": "Lease Grant",
          "data": [
            {
              "key": "Summary",
              "value": "This page contains a table of contents for a Lease Grant document. The table of contents outlines various sections and subsections covering topics such as Tender and Possession, Estimated Delivery Date and related delays, Landlord Delay, Confirmation Letter, Premises 'AS-IS', Rent issues including Delinquent Payment and Handling Charges, Letter of Credit requirements and its subdivisions covering general provisions, drawing, use of proceeds, additional tenant covenants, as well as sections on Services (Utilities and Common Areas), Alterations, Repairs, Maintenance, and other provisions related to the use, assignment and subletting of the property."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 209,
          "title": "Delinquent Payment, Handling Charges & Letter of Credit Provisions",
          "data": [
            {
              "key": "Default Interest Rate",
              "value": "Lesser of 10% per annum or the maximum lawful rate (referred to as the “Default Rate”)"
            },
            {
              "key": "Late Payment Fee",
              "value": "5% of the delinquent payment to reimburse Landlord for costs and inconvenience; waived for the first late payment in a 12‐month period if paid within three Business Days after written notice"
            },
            {
              "key": "Late Charge and Interest Payment",
              "value": "Payable as Additional Rent; immediately due on demand; not deemed a waiver of Tenant's default"
            },
            {
              "key": "Letter of Credit – Initial Amount",
              "value": "$[***] as collateral for Tenant’s obligations"
            },
            {
              "key": "Letter of Credit – Full Amount",
              "value": "$2,760,000.00; Tenant must provide an increased Letter of Credit by October 1, 2021 or before the first requisition for the Tenant Improvement Allowance"
            },
            {
              "key": "Letter of Credit Characteristics",
              "value": "Standby, unconditional, irrevocable, transferable (Tenant bears any transfer fee), callable at sight, permits partial draws and multiple presentations"
            },
            {
              "key": "Governing Standards",
              "value": "Subject to International Standby Practices (ISP 98), International Chamber of Commerce Publication #590, and California law"
            },
            {
              "key": "Draw Locations",
              "value": "San Francisco, CA or Manhattan, NY (or via acceptable alternative methods such as overnight courier or facsimile)"
            },
            {
              "key": "Default Consequence",
              "value": "Failure to increase the Letter of Credit by the specified deadline may be deemed an Event of Default under the Lease"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 213,
          "title": "Utilities and Common Areas Provisions",
          "data": [
            {
              "key": "Utilities Procurement",
              "value": "Tenant must obtain all water, electricity, sewerage, gas, telephone and other utilities directly from the public utility company and is responsible for installation of any meters and payment of deposits, fees, and monthly service charges."
            },
            {
              "key": "Cost Allocation",
              "value": "If utilities are not separately metered on the Commencement Date, Tenant pays an equitable share of the cost. In cases of shared metering among several tenants, costs are allocated among them."
            },
            {
              "key": "Common Areas Responsibility",
              "value": "Tenant remains liable for its proportionate share of any utilities or services provided to the Common Areas as defined in the lease and related exhibits."
            },
            {
              "key": "Interruption and Liability",
              "value": "Landlord is not liable for temporary interruptions or failures. However, if a utility interruption due to landlord negligence persists for over three business days and materially affects Tenant’s business, rent abatement will commence on the fourth business day."
            },
            {
              "key": "Exclusion of Equipment Overload",
              "value": "Tenant is prohibited from installing equipment that exceeds the capacity of the utility facilities serving the Premises."
            },
            {
              "key": "Definition of Common Areas",
              "value": "Common Areas include shared spaces such as parking, private streets, landscaping, loading areas, and other communal facilities, excluding spaces designated for commercial rental."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 217,
          "title": "Lease Provisions on Repairs, Liability, and Mold Prevention",
          "data": [
            {
              "key": "Tenant Repair Option",
              "value": "Tenant may, at its option, make repairs without liability to Landlord for any resulting loss or damage to its stock or business, but must reimburse Landlord for the repair costs plus interest at the Default Rate."
            },
            {
              "key": "Landlord Emergency Repairs",
              "value": "Landlord has the right to make repairs without notice in an actual or apparent emergency or when repairs relate to the exterior of the Premises."
            },
            {
              "key": "Premises Condition at Lease Expiration",
              "value": "At lease expiration, Tenant must surrender the Premises in good condition, accounting for reasonable wear and tear and required restorations."
            },
            {
              "key": "Personal Property Risk",
              "value": "All personal property, including goods, merchandise, inventory, and trade fixtures, is stored at Tenant's sole risk with no liability on the part of Landlord."
            },
            {
              "key": "Liability Disclaimer",
              "value": "Landlord and its agents are not liable for loss or damage due to fire, explosion, falling plaster, water intrusion, or other causes, including acts or negligence by other tenants or their agents."
            },
            {
              "key": "Mold and Moisture Control",
              "value": "Tenant acknowledges the ubiquitous nature of mold spores and is required to practice good housekeeping and moisture control. Tenant must inspect for mold upon lease signing, notify Landlord if mold or moisture issues arise, and adhere to prescribed mold prevention guidelines."
            },
            {
              "key": "Contractor and Insurance Requirements",
              "value": "All repairs must be performed by contractors approved in writing by Landlord, who must maintain specified insurance coverages including Commercial General Liability, workers’ compensation, and Business Automobile Liability."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 218,
          "title": "Insurance Coverage Requirements and Contractor Obligations",
          "data": [
            {
              "key": "Insurance Types",
              "value": "Umbrella/Excess Liability, Contractors Pollution Liability, Professional Liability, and Property Insurance"
            },
            {
              "key": "Minimum Coverage Limits",
              "value": "Not less than $1,000,000 per occurrence/claim and $1,000,000 annual aggregate; higher limits required for Moderate/High Risk work under Umbrella/Excess Liability"
            },
            {
              "key": "Additional Insureds",
              "value": "Landlord, Landlord’s property management company, and Invesco"
            },
            {
              "key": "Policy Conditions",
              "value": "Policies must be excess to primary coverages, written in follow form (or equivalent), provide waiver of subrogation, and be supported by insurance certificates prior to work commencement"
            },
            {
              "key": "Mechanic's Liens",
              "value": "Tenant must ensure no mechanic’s liens are filed; final lien waivers from contractors required upon completion"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 236,
          "title": "Sections 20 & 21: Landlord’s Lien and Surrender of Premises",
          "data": [
            {
              "key": "Collateral and Security Interest",
              "value": "Tenant grants Landlord a security interest in all tenant property on or used in connection with the Premises or Project as collateral for performance of obligations, excluding merchandise sold in the ordinary course of business."
            },
            {
              "key": "Perfection of Lien",
              "value": "Landlord may file any necessary financing statements under the UCC, with Tenant authorizing such filings via a power of attorney, to perfect the security interest."
            },
            {
              "key": "Event of Default and Notice",
              "value": "Upon an Event of Default, Landlord can exercise rights under the UCC with five days' prior written notice when required, without additional demand."
            },
            {
              "key": "Surrender of Premises",
              "value": "Upon termination or expiration of the Lease, Tenant must deliver the Premises in specified condition, and may remove certain items subject to Landlord’s restrictions and repair obligations for any removal damage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 258,
          "title": "Removal of Laboratory Equipment and Hazardous Materials Definitions",
          "data": [
            {
              "key": "Removal of Laboratory Equipment",
              "value": "Tenant is required to remove all laboratory-related equipment, fixtures, and furnishings (including laboratory benches and vented fume hoods) upon expiration or early termination of the lease, in addition to removal of any required Tenant Improvements."
            },
            {
              "key": "Biohazardous Materials",
              "value": "Defined as substances or materials referred to as 'medical waste', 'biological waste', 'biohazardous waste', or similar under relevant Hazardous Materials Laws, including specific California Health & Safety Code sections."
            },
            {
              "key": "Environmental Condition",
              "value": "Refers to the release of any Hazardous Materials in, over, on, under, through, from or about the Complex, including the Premises."
            },
            {
              "key": "Environmental Damages",
              "value": "Covers claims, losses, penalties, fines, liabilities, and remedial costs arising out of any Environmental Condition, including costs for investigations, remediation, and legal fees."
            },
            {
              "key": "Handling",
              "value": "Encompasses the receipt, storage, use, generation, release, transportation, treatment, or disposal of any hazardous substance or material."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 259,
          "title": "Hazardous Materials and Laws Definitions",
          "data": [
            {
              "key": "Hazardous Materials",
              "value": "means any and all chemical, explosive, biohazardous, radioactive or otherwise toxic or hazardous materials or hazardous wastes, including without limitation any asbestos-containing materials, PCB’s, CFCs, petroleum and derivatives thereof, Radioactive Materials, Biohazardous Materials, Hazardous Wastes, any other substances defined or listed as or meeting the characteristics of a hazardous substance under any Hazardous Materials Laws, hazardous material, Hazardous Waste, toxic substance, toxic waste, biohazardous material, biohazardous waste, biological waste, medical waste, radiation, radioactive substance, radioactive waste, or other similar term, as applicable, under any law, statute, ordinance, code, rule, regulation, directive, order, condition or other written requirement enacted, promulgated or issued by any public officer or governmental or quasi-governmental authority, whether now in force or hereafter in force at any time or from time to time to protect the environment or human health, and/or any mixed materials, substances or wastes containing more than one of the foregoing categories of materials, substances or wastes."
            },
            {
              "key": "Hazardous Materials Laws",
              "value": "means, collectively, (A) the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Sections 9601-9657, (B) the Hazardous Materials Transportation Act of 1975, 49 U.S.C. Sections 1801-1812, (C) the Resource Conservation and Recovery Act of 1976, 42 U.S.C. Sections 6901-6987 (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, “RCRA”), (D) the Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 U.S.C. §1251 et seq., (E) the Toxic Substances Control Act of 1976, 14 U.S.C. §2601 et seq., (F) the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §11001 et seq., (G) the Clean Air Act, 42 U.S.C. §§ 7401 et seq., (H) the Safe Drinking Water Act, 42 U.S.C. §§ 300f et seq., (I) the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. §§ 136 et seq., (J) the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health & Safety Code Sections 25300 et seq., (K) the Hazardous Materials Release Response Plans and Inventory Act, California Health & Safety Code Sections 25500 et seq., (L) the California Hazardous Waste Control Law, California Health & Safety Code Sections 25100 et seq. (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, the “CHWCL”), (M) California Health & Safety Code Sections 25015-25027.8, (K) the Medical Waste Management Act, California Health & Safety Code Sections 117600 et seq., (N) any amendments to or successor statutes to any of the foregoing, as adopted or enacted from time to time, (O) any regulations or amendments thereto promulgated pursuant to any of the foregoing from time to time, (P) any laws relating to Biohazardous Materials, including (but not limited to) any regulations or requirements with respect to the shipping, use, decontamination and disposal thereof, and (Q) any other law now or at any time hereafter in effect regulating, relating to or imposing liability or standards of conduct concerning any Hazardous Materials, including (but not limited to) any requirements or conditions imposed pursuant to the terms of any orders, permits, licenses, registrations or operating plans issued or approved by any governmental or quasi-governmental authority from time to time in connection with any Handling of Hazardous Materials in, on or about the Premises or the Complex."
            },
            {
              "key": "Hazardous Wastes",
              "value": "means (A) any waste listed as or meeting the identified characteristics of a “hazardous waste” or terms of similar import under RCRA, (B) any waste meeting the identified characteristics of a “hazardous waste”, “extremely hazardous waste” or “restricted hazardous waste” under the CHWCL, and/or (C) any and all 4"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 260,
          "title": "Определения и обязательства по работе с опасными материалами",
          "data": [
            {
              "key": "Hazardous Waste",
              "value": "Определяется как иные вещества и материалы, обозначенные как «опасные отходы» или аналогичный термин по любым законам об опасных материалах."
            },
            {
              "key": "Radioactive Materials",
              "value": "Любые вещества и материалы, для обращения с которыми требуется разрешение, лицензия или иной нормативный акт от Комиссии по ядерному регулированию или аналогичного органа (например, от штата Калифорния), включая определения «излучения», «радиоактивного материала» или «радиоактивных отходов»."
            },
            {
              "key": "Release",
              "value": "Любое случайное или умышленное пролитие, утечка, выброс или иное освобождение опасных материалов в окружающую среду, за исключением случаев, не вызванных действиями или бездействием арендатора или связанных с ним сторон."
            },
            {
              "key": "Tenant’s Contamination",
              "value": "Любое освобождение опасного материала на объекте или его части, осуществлённое Арендатором или его представителями."
            },
            {
              "key": "Handling of Hazardous Materials",
              "value": "Обязательство арендатора и его представителей всегда соблюдать все применимые законы об опасных материалах при работе на объекте и в комплексе, включая соблюдение условий государственных лицензий и разрешений."
            },
            {
              "key": "Disposition of Hazardous Materials",
              "value": "Запрет на размещение или самостоятельную утилизацию опасных материалов на объекте; необходима организация вывозной утилизации за счет арендатора с соблюдением всех нормативных требований."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 273,
          "title": "HAZARDOUS MATERIALS DISCLOSURE CERTIFICATE",
          "data": [
            {
              "key": "Certificate Type",
              "value": "Hazardous Materials Disclosure"
            },
            {
              "key": "Document Title",
              "value": "Exhibit H"
            },
            {
              "key": "Description",
              "value": "Disclosure related to hazardous materials"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 281,
          "title": "EXHIBIT L MOISTURE AND MOLD CONTROL INSTRUCTIONS",
          "data": [
            {
              "key": "Guideline 1",
              "value": "Report any maintenance problems involving water, moist conditions, or mold to the Property Manager promptly and conduct required activities to prevent unusual moisture conditions or mold growth."
            },
            {
              "key": "Guideline 2",
              "value": "Do not block or inhibit the flow of return or make-up air into the HVAC system. Maintain a consistent temperature and humidity level in accordance with the Property Manager’s instructions."
            },
            {
              "key": "Guideline 3",
              "value": "Regularly perform janitorial activities, especially in bathrooms, kitchens, and janitorial spaces, to remove mildew and correct moist conditions."
            },
            {
              "key": "Guideline 4",
              "value": "Maintain water in all drain taps at all times."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Table of Contents - Forward Looking Statements",
          "data": [
            {
              "key": "Statement_Type",
              "value": "Forward Looking Statements Disclaimer"
            },
            {
              "key": "Company",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Purpose",
              "value": "Provides forward-looking statements regarding business strategies, financial estimates, research and development activities, clinical trials, and potential regulatory approvals."
            },
            {
              "key": "Key_Projections",
              "value": "Estimates and projections of financial information, capital requirements, cash utilization, research and development progress, clinical trials initiation and outcomes, and strategic plans execution."
            },
            {
              "key": "Risk_Disclosure",
              "value": "Statements are subject to risks, uncertainties, and assumptions; forward-looking statements are not guarantees of future performance."
            },
            {
              "key": "Referenced_Products_or_Plans",
              "value": "Focus on SENTI-202, SENTI-401, and gene circuit platform technologies for current and future product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 13,
          "title": "Smart Sensors for Gene Circuits",
          "data": [
            {
              "key": "Description",
              "value": "Smart Sensors are designed to detect cell type or disease environments, and respond to specific therapeutic conditions."
            },
            {
              "key": "Key Features",
              "value": "Can sense diverse biomarkers specific to disease or cell states; respond dynamically to internal control mechanisms."
            },
            {
              "key": "Need for Novel Sensors",
              "value": "Current gene therapies often lack specificity in targeting gene expression for diseased cells."
            },
            {
              "key": "Solution",
              "value": "Constructing Smart Sensors that are selectively activated by cell type or cell state."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 20,
          "title": "EMCN Target Antigen Research and Development",
          "data": [
            {
              "key": "EMCN Expression in Healthy HSCs",
              "value": "70.2%"
            },
            {
              "key": "EMCN Expression in AML LSCs",
              "value": "0%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 26,
          "title": "Table of Contents and Findings on VSIG2 iCARs",
          "data": [
            {
              "key": "Observation",
              "value": "Table of Contents is only expressed in healthy colon epithelium."
            },
            {
              "key": "Findings",
              "value": "VSIG2 iCARs showed selective NOT GATE functions in vitro."
            },
            {
              "key": "Protection",
              "value": "Nearly 100% protection observed when model healthy cells expressing both VSIG2 and CEA were exposed to CAR-NK cells."
            },
            {
              "key": "Cancer Cells",
              "value": "Killing of CEA+ cancer cells unimpaired in the presence of iCAR."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 36,
          "title": "NCI CD33 Agreement and Spark Therapeutics, Inc. Agreement Overview",
          "data": [
            {
              "key": "NCI CD33 Agreement Fee",
              "value": "$150,000 one-time, non-refundable license issue fee"
            },
            {
              "key": "NCI Minimum Annual Royalty",
              "value": "Minimum flat annual royalty fee in the low five digits"
            },
            {
              "key": "NCI Milestone Payments",
              "value": "Aggregate of $3.5 million for the first licensed product"
            },
            {
              "key": "NCI Royalties on Net Sales",
              "value": "Low single-digit percentages on net sales"
            },
            {
              "key": "NCI Agreement Expiry",
              "value": "Expiration expected in 2039"
            },
            {
              "key": "Termination by Licensee",
              "value": "Can terminate with 60 days' written notice"
            },
            {
              "key": "Termination by NCI Conditions",
              "value": "Breach of obligations, commercial development plan issues, false statements"
            },
            {
              "key": "Spark Agreement Purpose",
              "value": "Collaborative research on synthetic promoters"
            },
            {
              "key": "Spark Reimbursement",
              "value": "Spark will reimburse costs and expenses"
            },
            {
              "key": "Optioned Promoters",
              "value": "Spark has the right for exclusive royalty-bearing licenses"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 42,
          "title": "Clinical Trials and FDA Submission Process",
          "data": [
            {
              "key": "key_points",
              "value": "Submission of an IND to the FDA is mandatory before starting human clinical trials. The IND must include results of preclinical testing, including toxicity studies."
            },
            {
              "key": "importance",
              "value": "Approval of IND is crucial for testing biological products in humans."
            },
            {
              "key": "timeline",
              "value": "The IND becomes effective 30 days after receipt by the FDA unless safety concerns arise."
            },
            {
              "key": "oversight",
              "value": "Certain clinical trials must comply with NIH Guidelines and may require review by institutional biosafety committees."
            },
            {
              "key": "regulatory_requirements",
              "value": "Compliance with federal regulations, including GLPs, cGMP, and Good Clinical Practices (GCPs), is essential throughout the process."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 98,
          "title": "Intellectual Property Disputes and Licensing Agreements",
          "data": [
            {
              "key": "Intellectual Property Disputes",
              "value": "Disputes may arise with present and future licensors regarding the scope and terms of intellectual property licensing agreements."
            },
            {
              "key": "Impact on Business",
              "value": "Disputes may impair the ability to maintain licensing arrangements, affecting business, financial condition, and prospects."
            },
            {
              "key": "Current Licensing Agreements",
              "value": "The agreements with National Cancer Institute and third parties are complex and could have multiple interpretations."
            },
            {
              "key": "Potential Future Issues",
              "value": "Potential for taking possession of intellectual property used as collateral for loans."
            },
            {
              "key": "Patent Lifespan",
              "value": "Patents have a limited lifespan of 20 years from the earliest filing date, with uncertain extensions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.INS*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Instance Document — the instance document does not appear the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document."
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.SCH*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Taxonomy Extension Schema Document"
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.CAL*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Taxonomy Extension Calculation Linkbase Document"
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.DEF*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Taxonomy Extension Definition Linkbase Document"
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.LAB*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Taxonomy Extension Label Linkbase Document"
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "101.PRE*"
            },
            {
              "key": "Number Description",
              "value": "Inline XBRL Taxonomy Extension Presentation Linkbase Document"
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "104*"
            },
            {
              "key": "Number Description",
              "value": "The cover page for the Company's Annual Report on Form 10-K has been ormatted in Inline XBRL and contained in Exhibit 101."
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "* —"
            },
            {
              "key": "Number Description",
              "value": "Filed herewith."
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "A' Item"
            },
            {
              "key": "Number Description",
              "value": "Certain ex! hibits and schedules to this Exhibit have been omitted in accordance with 601(b)(2). The Company agrees to furnish supplementally a copy of all omitted schedules to the Securities and Exchange Commission upon its request."
            },
            {
              "key": "Schedule/Form",
              "value": "Regulation S-K exhibits and"
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "tT"
            },
            {
              "key": "Number Description",
              "value": "Portions 0: this exhibit (indicated by asterisks) have been omitted because the registrant determined that the information is both not material and is the type that the registration private or confidential."
            },
            {
              "key": "Schedule/Form",
              "value": "has treats as"
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 187,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Exhibit",
              "value": "+"
            },
            {
              "key": "Number Description",
              "value": "Indicates management contract or compensatory plan."
            },
            {
              "key": "Schedule/Form",
              "value": ""
            },
            {
              "key": "File No.",
              "value": ""
            },
            {
              "key": "Exhibit_2",
              "value": ""
            },
            {
              "key": "Filing Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 211,
          "title": "Use of Proceeds by Landlord",
          "data": [
            {
              "key": "Unused Proceeds Definition",
              "value": "The proceeds from any draw upon the Letter of Credit not used to pay for damages actually suffered by Landlord."
            },
            {
              "key": "Tenant's Property Interest",
              "value": "Tenant has no property interest whatsoever in the proceeds from any such draw."
            },
            {
              "key": "Security Deposit Treatment",
              "value": "Such proceeds shall not be deemed to be or treated as a 'security deposit'."
            },
            {
              "key": "Payment Conditions for Unused Proceeds",
              "value": "Payments of Unused Proceeds are contingent upon receipt of a replacement Letter of Credit or within thirty days after Final LC Expiration Date."
            },
            {
              "key": "Bankruptcy Provision",
              "value": "Landlord shall not be obligated to pay Unused Proceeds if Tenant files for bankruptcy or an involuntary petition is filed."
            },
            {
              "key": "Replacement of Letter of Credit Requirements",
              "value": "Replacement is required if the Issuing Bank is closed, downgraded, or no longer well-capitalized."
            },
            {
              "key": "Events of Default",
              "value": "Failure to deliver a replacement Letter of Credit on time is deemed an Event of Default."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 212,
          "title": "Letter of Credit Agreement Terms",
          "data": [
            {
              "key": "Tenant Responsibilities",
              "value": "Provide additional Letter(s) of Credit in the amount of the deficiency."
            },
            {
              "key": "Event of Default",
              "value": "Failure to comply with the terms shall constitute an Event of Default without additional notice."
            },
            {
              "key": "Nature of Letter of Credit",
              "value": "The Letter of Credit is not treated as a security deposit under any applicable laws."
            },
            {
              "key": "Reduction Conditions",
              "value": "Conditions under which the Letter of Credit amount may be reduced."
            },
            {
              "key": "Reduction Date",
              "value": "Last day of the month that completes a 48-month period from the Rent Commencement Date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 224,
          "title": "Tenant’s Insurance Policies",
          "data": [
            {
              "key": "Insurance Type",
              "value": "Commercial General Liability (CGL) Insurance"
            },
            {
              "key": "CGL Insurance Minimum Coverage",
              "value": "$5,000,000 per occurrence"
            },
            {
              "key": "CGL Coverage Includes",
              "value": "premises/operations liability, products/completed operations liability, personal and advertising injury liability, independent contractors liability, broad form contractual liability"
            },
            {
              "key": "Automobile Liability Insurance Required",
              "value": "Yes"
            },
            {
              "key": "Automobile Liability Insurance Minimum Coverage",
              "value": "$1,000,000 per accident"
            },
            {
              "key": "Additional Insureds",
              "value": "Landlord, Landlord’s property management company, Invesco"
            },
            {
              "key": "Terrorism Coverage",
              "value": "Included"
            },
            {
              "key": "Exclusions",
              "value": "No exclusion for explosion, collapse and underground (XCU)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 229,
          "title": "Tenant's Lease Agreement Terms",
          "data": [
            {
              "key": "Loan Proceeds",
              "value": "The application of the proceeds of any loan and agreements set forth shall not be impaired."
            },
            {
              "key": "Current Holder",
              "value": "PGIM Real Estate"
            },
            {
              "key": "SNDA",
              "value": "Landlord will use good faith efforts to obtain a subordination, non-disturbance and attornment agreement for Tenant."
            },
            {
              "key": "Rules and Regulations",
              "value": "Tenant must comply with rules and regulations as attached in Exhibit F."
            },
            {
              "key": "Total Taking",
              "value": "Lease terminates if the entire Building is taken by eminent domain."
            },
            {
              "key": "Partial Taking - Tenant's Rights",
              "value": "Tenant can terminate lease within 30 days if business is significantly affected."
            },
            {
              "key": "Partial Taking - Landlord's Rights",
              "value": "Landlord can terminate lease if material portion is taken within 30 days."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 245,
          "title": "Indemnification Provisions and Lease Execution",
          "data": [
            {
              "key": "Exhibit E",
              "value": "Additional Use Provisions - Laboratory Use"
            },
            {
              "key": "Exhibit F",
              "value": "Building Rules and Regulations"
            },
            {
              "key": "Exhibit G",
              "value": "Form of Confirmation of Commencement Date Letter"
            },
            {
              "key": "Exhibit H",
              "value": "Hazardous Materials Disclosure Certificate"
            },
            {
              "key": "Exhibit I",
              "value": "Form of Tenant Estoppel Certificate"
            },
            {
              "key": "Exhibit J",
              "value": "Renewal Options"
            },
            {
              "key": "Exhibit K",
              "value": "Right of First Refusal"
            },
            {
              "key": "Exhibit L",
              "value": "Moisture and Mold Control Instructions"
            },
            {
              "key": "Exhibit M",
              "value": "Approved Form of Letter of Credit"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 265,
          "title": "Environmental Obligations of Tenant and Cleanup Procedures",
          "data": [
            {
              "key": "Obligations of Tenant",
              "value": "Tenant is responsible for reimbursement of costs incurred by Landlord due to Tenant's breaches."
            },
            {
              "key": "Clean Up Responsibilities",
              "value": "Tenant must remediate any hazardous material release in compliance with laws."
            },
            {
              "key": "Deadline for Reporting",
              "value": "Tenant must report within 30 days of discovering a breach."
            },
            {
              "key": "Environmental Study Requirement",
              "value": "Tenant must deliver an environmental study 30 days before lease term expiration."
            },
            {
              "key": "Remediation Plan",
              "value": "If remediation is needed, Tenant must provide a plan and execute remedial actions."
            },
            {
              "key": "Cost of Remediation",
              "value": "All costs of remediation are to be covered by Tenant."
            },
            {
              "key": "Rent During Remediation",
              "value": "Tenant must continue to pay rent during cleanup efforts."
            },
            {
              "key": "Failure to Remediate",
              "value": "If remediation is not initiated, Landlord can remediate and recover costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 276,
          "title": "Renewal Options",
          "data": [
            {
              "key": "Lease Tenant",
              "value": "Senti Biosciences, Inc."
            },
            {
              "key": "Renewal Term Length",
              "value": "two (2) additional periods of five (5) years"
            },
            {
              "key": "Notice Period for Renewal Election",
              "value": "not earlier than twelve (12) months nor later than nine (9) months before the expiration"
            },
            {
              "key": "Prevailing Rental Rate Determination",
              "value": "Landlord to deliver written notice within 30 days of Tenant's renewal notice"
            },
            {
              "key": "Tenant's Response Time After Prevailing Rental Rate Notice",
              "value": "10 days"
            },
            {
              "key": "Conditions for Renewal Acceptance",
              "value": "Tenant must accept Prevailing Rental Rate to execute extension amendment"
            },
            {
              "key": "Adjustment of Base Rent",
              "value": "Base Rent shall be adjusted to the Prevailing Rental Rate"
            },
            {
              "key": "Further Renewal Options",
              "value": "No further renewal option after the second renewal unless granted in writing by Landlord"
            },
            {
              "key": "Parking Spaces Payment",
              "value": "Tenant shall pay for parking spaces at rates charged during the extended Term"
            },
            {
              "key": "Negotiation Period for Prevailing Rental Rate",
              "value": "30 days after rejection to agree upon the Prevailing Rental Rate"
            },
            {
              "key": "Arbitration Procedure",
              "value": "If no agreement reached, Prevailing Rental Rate will be determined by arbitration procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 278,
          "title": "Adjustment of Base Rent Overpayment",
          "data": [
            {
              "key": "context",
              "value": "Discussion of rent adjustments related to overpayment."
            },
            {
              "key": "overpayment_policy",
              "value": "Overpayment of Base Rent will be credited against future installments."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 41,
          "title": "Table of Contents and Patent Regulation Overview",
          "data": [
            {
              "key": "Patent Term Adjustment (PTA)",
              "value": "Compensates for administrative delays by the USPTO."
            },
            {
              "key": "Patent Term Extension (PTE)",
              "value": "Eligible for FDA-approved drugs."
            },
            {
              "key": "Duration of Patents",
              "value": "Typically 20 years from earliest filing date."
            },
            {
              "key": "Trademark Protection",
              "value": "Registered trademarks include SENTI and its logo."
            },
            {
              "key": "Regulatory Authorities",
              "value": "FDA and other agencies regulate biologics."
            },
            {
              "key": "Approval Process",
              "value": "Involves preclinical tests and IND submission."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 45,
          "title": "FDA Approval Process and Expedited Development Programs",
          "data": [
            {
              "key": "CRL Process",
              "value": "Describes that the FDA may issue a Complete Response Letter (CRL) without required inspections, testing, or review of proposed labeling, and that the sponsor must resubmit the BLA addressing deficiencies or withdraw the application."
            },
            {
              "key": "BLA Approval Conditions",
              "value": "Indicates that regulatory approval of a Biologics License Application (BLA) is granted with specific indications, limitations, or with conditions such as requiring a Risk Evaluation and Mitigation Strategy (REMS)."
            },
            {
              "key": "Expedited Programs",
              "value": "Outlines various FDA expedited development and review programs including fast track designation, breakthrough therapy designation, priority review, and rolling review to facilitate timely evaluation."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Mentions requirements for Phase 4 post-market studies and surveillance to monitor safety and efficacy, and the possibility of product approval withdrawal if compliance is not maintained."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 46,
          "title": "Overview of FDA Accelerated Approval, RMAT and Orphan Drug Designations",
          "data": [
            {
              "key": "FDA Priority Review Timeline",
              "value": "FDA aims to act on marketing applications within six months from the 60-day filing date, compared to ten months under standard review."
            },
            {
              "key": "Accelerated Approval Conditions",
              "value": "Approval may be granted based on surrogate or clinical endpoints with the condition that post-marketing clinical studies are conducted to verify long-term clinical benefits."
            },
            {
              "key": "FDORA Provisions",
              "value": "Under FDORA, the FDA has increased authority to require that post-marketing studies be underway pre-approval or within a specified period after accelerated approval, with expedited procedures to withdraw approval if necessary."
            },
            {
              "key": "RMAT Designation",
              "value": "Introduced in 2017 for regenerative medicine advanced therapies including cell therapies and therapeutic tissue engineering products; offers benefits such as frequent FDA meetings, rolling and priority review, and potential eligibility for accelerated approval."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "Granted for biologics intended to treat rare diseases (fewer than 200,000 patients in the US, or more if cost recovery is unlikely), with no shortening of regulatory review timelines."
            },
            {
              "key": "Advertising and Promotional Materials",
              "value": "For accelerated approval candidates, all materials intended for dissemination within 120 days of marketing approval must be submitted to the FDA for review during the pre-approval period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "FDA Regulatory Enforcement and Compliance Risks",
          "data": [
            {
              "key": "Enforcement Actions",
              "value": "Fines, warning letters, clinical holds, product seizures, suspensions, and revocations of approvals"
            },
            {
              "key": "Regulatory Compliance",
              "value": "Mandated modifications of promotional materials, labeling changes, and compliance with approved claims"
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Phase 4 testing, safety alerts, corrective advertising, and communications with healthcare providers"
            },
            {
              "key": "Legal and Sanction Risks",
              "value": "Consent decrees, injunctions, debarment, and potential civil or criminal penalties"
            },
            {
              "key": "Biosimilars Guidance",
              "value": "Abbreviated approval pathways under the BPCIA and requirements for biosimilarity and interchangeability"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 50,
          "title": "Regulatory Challenges in Drug Pricing",
          "data": [
            {
              "key": "Drug Company Discounts and Prices",
              "value": "Drug companies are required to provide predetermined discounts and are challenged on prices charged for medical products."
            },
            {
              "key": "Reimbursement Availability",
              "value": "Uncertainty exists regarding the availability and level of reimbursement for product candidates."
            },
            {
              "key": "Price Reporting to Government",
              "value": "Pharmaceutical manufacturers must calculate and report price metrics to the government, with penalties for inaccuracies."
            },
            {
              "key": "Legislative and Regulatory Proposals",
              "value": "Proposals have been made to expand post-approval requirements and restrict sales/promotional activities."
            },
            {
              "key": "Foreign Pricing Approval",
              "value": "Pricing for drugs may require prior approval in some foreign countries."
            },
            {
              "key": "Historical Pricing Differences",
              "value": "Products launched in the EU usually have significantly lower prices compared to the US."
            },
            {
              "key": "Healthcare Reform Initiatives",
              "value": "Legislative initiatives in the US have aimed to contain healthcare costs, impacting the pharmaceutical industry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 51,
          "title": "Regulatory and Legislative Measures Impacting Healthcare",
          "data": [
            {
              "key": "American Rescue Plan Act of 2021",
              "value": "Estimated budget deficit increases resulting from the act, affecting Medicare payments"
            },
            {
              "key": "American Taxpayer Relief Act of 2012",
              "value": "Reduced Medicare payments to providers and extended the statute of limitations for recovery of overpayments"
            },
            {
              "key": "CMS Final Rule (April 13, 2017)",
              "value": "Provided states with greater flexibility in setting benchmarks for insurers in individual and small group marketplaces, potentially affecting ACA essential health benefits"
            },
            {
              "key": "Right to Try Act (May 30, 2018)",
              "value": "Established a federal framework allowing certain patients access to investigational new drug products without FDA permission under expanded access program"
            },
            {
              "key": "CMS Final Rule (May 23, 2019)",
              "value": "Permitted Medicare Advantage Plans to use step therapy for Part B drugs beginning January 1, 2020, alongside growing legislative and enforcement focus on drug pricing"
            },
            {
              "key": "Inflation Reduction Act of 2022 (IRA)",
              "value": "Introduced provisions reducing Medicare Part D out-of-pocket caps, imposing new manufacturer liabilities, enabling government negotiation of drug prices, and modifying rebate rules; includes conditions for orphan drug exemptions"
            },
            {
              "key": "HHS Proposal (February 2023)",
              "value": "Proposed prescription drug pricing model in response to prior executive orders to incentivize confirmatory trials for FDA accelerated approval drugs"
            },
            {
              "key": "State-level Legislative Initiatives",
              "value": "Aggressive state measures aimed at controlling pharmaceutical and biological product pricing, including transparency and reimbursement reforms"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 52,
          "title": "Healthcare Laws and Regulations Impacting Pharmaceutical Sales",
          "data": [
            {
              "key": "Reimbursement Constraints",
              "value": "Measures that could reduce demand for products and impact pricing."
            },
            {
              "key": "Healthcare Reform Measures",
              "value": "Potential future legislation that could limit payments by federal and state governments."
            },
            {
              "key": "Impact of Medicare Denials",
              "value": "Denial in coverage could affect revenue generation."
            },
            {
              "key": "U.S. Healthcare Laws Overview",
              "value": "Role of healthcare providers, physicians, and payors in product prescription and recommendations."
            },
            {
              "key": "Federal Anti-Kickback Statute",
              "value": "Prohibits soliciting payment in exchange for referrals related to federal healthcare programs."
            },
            {
              "key": "False Claims Act",
              "value": "Imposes penalties against providing false or fraudulent claims."
            },
            {
              "key": "HIPAA Violations",
              "value": "Specifies liabilities for healthcare fraud and misleading information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Table of Contents – Regulatory Framework and Compliance",
          "data": [
            {
              "key": "HIPAA Amendments",
              "value": "HIPAA, as amended by the HITECH Act and its implementing regulations, imposes obligations on covered healthcare entities regarding the safeguarding, privacy, and security of individually identifiable health information."
            },
            {
              "key": "HITECH Act and Final Omnibus Rule",
              "value": "The HITECH Act created new civil and criminal penalties, extended enforcement to business associates, and introduced the Final Omnibus Rule (January 2013) with mandatory contractual terms and breach notification requirements."
            },
            {
              "key": "Federal False Statements Statute",
              "value": "Prohibits knowingly falsifying, concealing, or misrepresenting material facts in connection with healthcare benefits, services, or payments."
            },
            {
              "key": "Federal Price Reporting Laws",
              "value": "Require manufacturers to calculate and report complex pricing metrics that are used in reimbursement and discount calculations."
            },
            {
              "key": "Federal Consumer Protection and Unfair Competition Laws",
              "value": "Broadly regulate marketplace activities to prevent harm to consumers and ensure fair competition."
            },
            {
              "key": "Physician Payment Transparency ('Sunshine Act')",
              "value": "Mandates the reporting of transfers of value made to physicians and other healthcare practitioners, including details on ownership and investment interests."
            },
            {
              "key": "Local, State, and Foreign Regulations",
              "value": "Encompass a range of laws including anti-kickback, false claims, transparency, and marketing expenditure reporting requirements that may differ significantly and complicate compliance efforts."
            },
            {
              "key": "International Regulatory Compliance",
              "value": "Outside the United States, regulations require obtaining necessary approvals for clinical studies and commercial activities, with specific restrictions on biologically sourced raw materials and additional local compliance requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 62,
          "title": "Tax Liabilities and NOL Utilization Risks",
          "data": [
            {
              "key": "Management Experience",
              "value": "Members of our management team have limited experience in managing day-to-day operations of a public company."
            },
            {
              "key": "Compliance Costs",
              "value": "Additional costs for compliance with SEC reporting requirements may negatively affect financial condition."
            },
            {
              "key": "NOL Limitations",
              "value": "NOLs could expire unused and may be subject to limitations under Section 382 if ownership changes."
            },
            {
              "key": "Tax Law Changes",
              "value": "Changes in tax laws could adversely affect the company and its shareholders."
            },
            {
              "key": "Research and Development Expenses",
              "value": "Under new tax laws, R&D expenses will be capitalized and may adversely affect cash flow."
            },
            {
              "key": "Consulting Advisers",
              "value": "Investors are urged to consult with legal and tax advisers regarding tax law changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 88,
          "title": "Potential Regulatory and Litigation Risks Due to Security and Data Breaches",
          "data": [
            {
              "key": "Material Adverse Effects",
              "value": "Imposition of significant criminal, civil and administrative fines or other sanctions, including monetary penalties, damages, fines."
            },
            {
              "key": "Operational Dependencies",
              "value": "Dependence on sophisticated information technology systems and data processing."
            },
            {
              "key": "Security Risks",
              "value": "Vulnerability to cyber-attacks, data privacy breaches, and other unauthorized access."
            },
            {
              "key": "Liabilities and Business Disruption",
              "value": "Costs, significant liabilities, and harm to brand may occur due to security incidents."
            },
            {
              "key": "Cyber-Threat Landscape",
              "value": "Evolving threats including phishing, ransomware, and nation-state attacks."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Increased risks due to remote working and technology reliance."
            },
            {
              "key": "Failure Consequences",
              "value": "Potential claims, regulations, and significant financial and reputational harm."
            },
            {
              "key": "Regulatory Compliance Costs",
              "value": "Costs of notifying stakeholders in case of security breaches."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 110,
          "title": "Regulatory and Clinical Trial Risks",
          "data": [
            {
              "key": "Delay of Clinical Trials",
              "value": "Delays may occur due to unresolved ethical issues or regulatory authority actions impacting clinical trials."
            },
            {
              "key": "Potential for Termination",
              "value": "Clinical trials may be suspended or terminated by various authorities due to compliance and safety concerns."
            },
            {
              "key": "Compensation Conflicts",
              "value": "Principal investigators receiving compensation could present conflicts of interest impacting trial integrity."
            },
            {
              "key": "Regulatory Approval Denials",
              "value": "Delays in trials might lead to regulatory approval denials, preventing product commercialization."
            },
            {
              "key": "Cost and Time Implications",
              "value": "Delays increase costs and slow product development, affecting revenue generation."
            },
            {
              "key": "Regulatory Variability",
              "value": "Changing standards and regulations create unpredictability in securing approvals."
            },
            {
              "key": "Impact of New Regulations",
              "value": "Unexpected delays and costs may result from new governmental regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 111,
          "title": "Regulatory Approval Risks",
          "data": [
            {
              "key": "delay_or_failure",
              "value": "Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenue from the particular product candidate."
            },
            {
              "key": "approval_restrictions",
              "value": "The approval may be for targets, disease indications, or patient populations that are not as broad as desired or required labeling that includes restrictions or safety warnings."
            },
            {
              "key": "post_approval_requirements",
              "value": "Numerous post-approval requirements apply, including periodic monitoring, reporting obligations, and inspections."
            },
            {
              "key": "revocation_risks",
              "value": "Approvals may be withdrawn or revoked due to safety or effectiveness concerns."
            },
            {
              "key": "regulatory_compliance",
              "value": "Failure to comply with regulatory requirements may result in warnings, fines, recalls, or other sanctions."
            },
            {
              "key": "impact_on_business",
              "value": "Failure to obtain or maintain regulatory approvals will negatively impact our business."
            },
            {
              "key": "foreign_regulatory_requirements",
              "value": "We will be subject to numerous foreign regulatory requirements governing clinical trials, manufacturing, and marketing."
            },
            {
              "key": "jurisdictional_challenges",
              "value": "Obtaining regulatory approval in one jurisdiction does not guarantee approval in others."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 112,
          "title": "Regulatory Issues with Clinical Trials Outside of the US",
          "data": [
            {
              "key": "Risks",
              "value": "If the FDA does not accept data from clinical trials of product candidates, it may require additional trials."
            },
            {
              "key": "Conditions for FDA Data Acceptance",
              "value": "Data from foreign trials must meet conditions set by the FDA."
            },
            {
              "key": "Foreign Regulatory Bodies",
              "value": "Acceptance of data may vary by foreign regulatory authorities."
            },
            {
              "key": "Additional Risks",
              "value": "Cultural differences, compliance issues, intellectual property protection."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 129,
          "title": "Legal Proceedings and Property Overview",
          "data": [
            {
              "key": "Litigation Risks",
              "value": "The document highlights that any litigation or the threat of litigation may adversely affect the company's reputation, strategic alliances, sublicensing arrangements, and could distract management while incurring substantial costs."
            },
            {
              "key": "Legal Proceedings Status",
              "value": "The company is not currently a party to any material legal proceedings, though it acknowledges potential future involvement in claims arising in the ordinary course of business."
            },
            {
              "key": "Property Leases and Facilities",
              "value": "Details provided include leased office and research space in South San Francisco (approximately 40,000 square feet, lease from April 25, 2019 to April 30, 2027 with an eight-year extension option) and in Alameda (approximately 92,000 square feet, lease from June 3, 2021 to September 30, 2032 with two five-year extension options). A cell therapy manufacturing facility is being built within the Alameda space."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 181,
          "title": "Evaluation of Disclosure Controls and Procedures",
          "data": [
            {
              "key": "Main Findings",
              "value": "The company evaluated its disclosure controls and procedures and found material weaknesses."
            },
            {
              "key": "Material Weakness Description",
              "value": "Lack of sufficient resources in finance and accounting, resulting in inadequate risk assessments and ineffective controls."
            },
            {
              "key": "Remediation Actions",
              "value": "Hired experienced personnel, engaged accounting services firm, implemented risk assessments and new software."
            },
            {
              "key": "Current Status",
              "value": "Not fully remediated as of December 31, 2022."
            },
            {
              "key": "Conclusion on Effectiveness",
              "value": "Disclosure controls and procedures were not effective as of December 31, 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 185,
          "title": "Legal Documents and Agreements Register",
          "data": [
            {
              "key": "document_id",
              "value": "0.8+"
            },
            {
              "key": "description",
              "value": "Employment Agreement, by and between Curt Herberts III and Senti Biosciences, Inc., dated April 28, 2018."
            },
            {
              "key": "form_type",
              "value": "S-4"
            },
            {
              "key": "filing_number",
              "value": "333-262707"
            },
            {
              "key": "exhibit",
              "value": "10.8"
            },
            {
              "key": "filing_date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 185,
          "title": "Legal Documents and Agreements Register",
          "data": [
            {
              "key": "document_id",
              "value": "0.9+"
            },
            {
              "key": "description",
              "value": "Employee Offer Letter, by and between Deborah Knobelman and Senti Biosciences, Inc., dated May 13, 2021."
            },
            {
              "key": "form_type",
              "value": "S-4"
            },
            {
              "key": "filing_number",
              "value": "333-262707"
            },
            {
              "key": "exhibit",
              "value": "10.9"
            },
            {
              "key": "filing_date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 185,
          "title": "Legal Documents and Agreements Register",
          "data": [
            {
              "key": "document_id",
              "value": "0.10"
            },
            {
              "key": "description",
              "value": "Lease, by and between Britannia Biotech Gateway Limited Partnership and Senti Biosciences, Inc., dated July 17, 2018."
            },
            {
              "key": "form_type",
              "value": "S-4"
            },
            {
              "key": "filing_number",
              "value": "333-262707"
            },
            {
              "key": "exhibit",
              "value": "10.1"
            },
            {
              "key": "filing_date",
              "value": "February 14, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 194,
          "title": "Choice of Forum Provision",
          "data": [
            {
              "key": "Forum Selection",
              "value": "Unless we consent in writing to an alternate forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for certain actions under Delaware law."
            },
            {
              "key": "Applicable Actions",
              "value": "Derivative actions, claims for breach of fiduciary duty by directors, officers, or employees, claims under the DGCL, Charter or Bylaws, and claims governed by the internal affairs doctrine."
            },
            {
              "key": "Exceptions",
              "value": "The exclusive forum provision does not apply to actions under the Securities Act of 1933, the Securities Exchange Act of 1934, or other claims where federal courts have exclusive jurisdiction."
            },
            {
              "key": "Alternate Forum for Securities Act Claims",
              "value": "For claims under the Securities Act, the United States federal district courts shall be the sole and exclusive forum."
            },
            {
              "key": "Stockholder Consent",
              "value": "Purchasers or acquirers of shares are deemed to have notice of and to have consented to these exclusive forum provisions."
            },
            {
              "key": "Litigation Impact",
              "value": "The provisions may limit stockholders' ability to litigate in a favorable forum and may impose additional litigation costs."
            },
            {
              "key": "Transfer Agent",
              "value": "Continental Stock Transfer & Trust Company"
            },
            {
              "key": "Trading Information",
              "value": "The common stock is listed on the Nasdaq Global Market under the symbol “SNTI”."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 197,
          "title": "Lease Agreement Section Index",
          "data": [
            {
              "key": "(h)",
              "value": "Waiver"
            },
            {
              "key": "(60)",
              "value": "Permitted Transfer"
            },
            {
              "key": "Insurance;",
              "value": "Waivers; Subrogation; Indemnity."
            },
            {
              "key": "(a)",
              "value": "Tenant's Insurance"
            },
            {
              "key": "(b)",
              "value": "Landlord's Insurance"
            },
            {
              "key": "(c)",
              "value": "Waiver of Subrogation"
            },
            {
              "key": "(d)",
              "value": "Indemnity"
            },
            {
              "key": "",
              "value": "Subordination; Attornment; Notice to Landlord's Mortgagee."
            },
            {
              "key": "(a)",
              "value": "Subordination"
            },
            {
              "key": "(b)",
              "value": "Attornment"
            },
            {
              "key": "(c)",
              "value": "Notice to Landlord's Mortgagee"
            },
            {
              "key": "(d)",
              "value": "Landlord's Mortgagee's Protection Provisions"
            },
            {
              "key": "(e)",
              "value": "SNDA"
            },
            {
              "key": "Rules",
              "value": "and Regulations"
            },
            {
              "key": "",
              "value": "Condemnation."
            },
            {
              "key": "(a)",
              "value": "Total Taking"
            },
            {
              "key": "(b)",
              "value": "Partial Taking - Tenant's Rights"
            },
            {
              "key": "(c)",
              "value": "Partial Taking - Landlord's Rights"
            },
            {
              "key": "(d)",
              "value": "Award"
            },
            {
              "key": "(e)",
              "value": "Repair"
            },
            {
              "key": "(f)",
              "value": "Waiver"
            },
            {
              "key": "Fire",
              "value": "or Other Casualty."
            },
            {
              "key": "(a)",
              "value": "Repair Estimate"
            },
            {
              "key": "(b)",
              "value": "Tenant's Rights"
            },
            {
              "key": "(c)",
              "value": "Landlord's Rights"
            },
            {
              "key": "(d)",
              "value": "Repair Obligation"
            },
            {
              "key": "(e)",
              "value": "Abatement of Rent"
            },
            {
              "key": "(f)",
              "value": "Waiver"
            },
            {
              "key": "Other",
              "value": "Taxes Payable by Tenant"
            },
            {
              "key": "Events",
              "value": "of Default"
            },
            {
              "key": "(a)",
              "value": "Payment Default"
            },
            {
              "key": "(b)",
              "value": "Abandonment"
            },
            {
              "key": "(c)",
              "value": "Estoppel/Financial Statement/Commencement Date Letter"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 219,
          "title": "Lease Obligations: Lien, Indemnity and Signage Provisions",
          "data": [
            {
              "key": "Lien Resolution",
              "value": "Tenant must either pay and release any lien or contest it with a bond or security acceptable to Landlord to avoid forfeiture of the Premises or fines."
            },
            {
              "key": "Reimbursement Obligation",
              "value": "If Landlord pays the lien, Tenant must reimburse all amounts, including expenses and interest, within ten days of invoicing."
            },
            {
              "key": "Contractual Relationship",
              "value": "The relationship is strictly landlord-tenant, excluding any owner-contractor or similar relations; contractors and subcontractors must look solely to Tenant for payment."
            },
            {
              "key": "Indemnification Clause",
              "value": "Tenant shall indemnify and hold Landlord and associated parties harmless from all claims related to non-payment for work or materials by Tenant parties."
            },
            {
              "key": "Signage Restrictions",
              "value": "Tenant requires Landlord’s prior written approval for exterior or roof signage, must adhere to the Business Park's Signage Program, and is responsible for sign removal and related restoration costs if required."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 220,
          "title": "Use and Permitted Use Provisions",
          "data": [
            {
              "key": "Tenant_Obligation",
              "value": "Tenant must continuously occupy and use the Premises solely for the Permitted Use as defined in the lease, and comply with all applicable laws."
            },
            {
              "key": "Compliance_Requirements",
              "value": "Tenant must adhere to all easements, covenants, conditions, restrictions, and obtain all necessary permits, licenses, and authorizations."
            },
            {
              "key": "ADA_Compliance",
              "value": "Tenant bears the risk of compliance with Title III of the Americans With Disabilities Act and other relevant state laws for the Premises, while Landlord is responsible for Common Areas."
            },
            {
              "key": "Insurance_Risk",
              "value": "Tenant is liable for any increase in insurance rates resulting from activities that may invalidate coverage or require additional premiums."
            },
            {
              "key": "Use_Restrictions",
              "value": "The Premises must not be used for activities creating offensive odors, harmful emissions, excessive noise, or any use that could damage the Premises or the Project."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 222,
          "title": "Lease Transfer, Subletting and Attornment Provisions",
          "data": [
            {
              "key": "attorneys_fees",
              "value": "Up to $5,000 per request for consent to Transfer; fees subject to change if material modifications or negotiations occur"
            },
            {
              "key": "transfer_conditions",
              "value": "Proposed transferee must assume Tenant’s obligations in writing; Tenant remains liable and both Tenant and transferee are jointly and severally liable"
            },
            {
              "key": "event_of_default",
              "value": "If an Event of Default occurs while the Premises are under Transfer, Landlord may collect rents directly from the transferee and apply against Rent"
            },
            {
              "key": "subtenant_attornment",
              "value": "Subtenants are automatically bound by the lease terms and must attorn to Landlord upon default, without additional instruments"
            },
            {
              "key": "improvement_costs",
              "value": "Tenant bears cost for demising walls or other improvements required by subletting or assignment"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 223,
          "title": "Lease Cancellation and Permitted Transfer Provisions",
          "data": [
            {
              "key": "Cancellation Provision",
              "value": "Landlord may cancel the lease for the portion of the Premises proposed to be sublet or assigned within 30 days after Tenant’s written request. If canceled and Tenant does not revoke the proposed transfer, the lease ceases for that portion and Rent is adjusted accordingly."
            },
            {
              "key": "Additional Compensation",
              "value": "Tenant must pay Landlord 50% of the excess of all compensation received for a Transfer over the Rent allocable to the affected portion."
            },
            {
              "key": "Waiver",
              "value": "Tenant waives any suretyship defenses to actions brought by Landlord under specified sections of the California Civil Code."
            },
            {
              "key": "Permitted Transfer",
              "value": "Tenant may assign the lease or sublet (to an Affiliate or Successor) without prior consent provided specific conditions are met, including prior notice, financial disclosures, assumption of obligations, and maintained use of the Premises."
            },
            {
              "key": "Tangible Net Worth Requirement",
              "value": "A Transferee or Successor must have a Tangible Net Worth at least equal to that of the Tenant as of the Lease Date or as otherwise defined in the transfer conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 225,
          "title": "Commercial Property and Liability Insurance Requirements",
          "data": [
            {
              "key": "Property Covered",
              "value": "inventory, FF&E, alterations, improvements, betterments, other property retained by Tenant"
            },
            {
              "key": "Insurance Coverage Includes",
              "value": "coverage against special causes of loss, business income coverage, agreed amount endorsement, loss payable endorsement"
            },
            {
              "key": "Full Replacement Value Definition",
              "value": "cost of repairing, replacing, or reinstating property without depreciation"
            },
            {
              "key": "Builders’ Risk Insurance",
              "value": "on an all risk form, includes flood, earthquake, and terrorism coverage"
            },
            {
              "key": "Workers Compensation Insurance",
              "value": "covering statutory benefits, includes employer’s liability coverage"
            },
            {
              "key": "Environmental Clean-Up Insurance",
              "value": "covers third party bodily injury, property damage, remediation costs, limits of $2,000,000 per occurrence"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 226,
          "title": "Insurance Requirements",
          "data": [
            {
              "key": "narrative",
              "value": "Such other insurance or any changes or endorsements to the insurance required herein, including increased limits of coverage, as Landlord, or any mortgagee or lessor of Landlord, may reasonably require from time to time."
            },
            {
              "key": "Tenant's insurance obligations",
              "value": "Tenant’s commercial general liability insurance, automobile liability insurance and all other insurance policies shall provide primary coverage to Landlord."
            },
            {
              "key": "Certificates of insurance",
              "value": "Tenant shall furnish to Landlord certificates of such insurance and notify Landlord at least thirty (30) days before cancellation, non-renewal or a material change."
            },
            {
              "key": "Landlord's insurance policies",
              "value": "Landlord shall maintain property and commercial general liability insurance with specified coverage amounts."
            },
            {
              "key": "Tenant's share of costs",
              "value": "Tenant shall pay its Proportionate Share of the cost of all insurance carried by Landlord with respect to the Project or Complex."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 227,
          "title": "Indemnity and Waiver of Subrogation",
          "data": [
            {
              "key": "Waiver of Subrogation",
              "value": "Both parties waive the right to recover claims against each other regarding insurance."
            },
            {
              "key": "Indemnity Responsibilities",
              "value": "Tenant indemnifies Landlord against claims, even if caused by Landlord's negligence, except for gross negligence."
            },
            {
              "key": "Indemnification Scope",
              "value": "Covers claims relating to injury or damage in the premises and Tenant’s obligations."
            },
            {
              "key": "Survival of Indemnity",
              "value": "Indemnity provisions survive Lease termination."
            },
            {
              "key": "Legal Proceedings",
              "value": "Indemnifying party must defend the other in proceedings if requested."
            },
            {
              "key": "Subordination",
              "value": "This Lease is subordinate to various financial instruments and leases."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 230,
          "title": "Condemnation and Casualty Repair Obligations",
          "data": [
            {
              "key": "Taking Award",
              "value": "Landlord shall receive the entire award or compensation for the Land, Building, and improvements taken; Tenant may pursue claims against the condemner."
            },
            {
              "key": "Repair Obligation",
              "value": "Landlord shall restore the remaining Premises and Building substantially to former condition."
            },
            {
              "key": "Casualty Repair Estimate",
              "value": "Landlord to deliver estimate within 60 days of Casualty."
            },
            {
              "key": "Tenant's Termination Rights",
              "value": "Tenant may terminate Lease if repair takes more than 180 days."
            },
            {
              "key": "Landlord's Termination Rights",
              "value": "Landlord may terminate Lease under certain damage conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 233,
          "title": "18. Remedies",
          "data": [
            {
              "key": "Event of Default",
              "value": "Triggers various remedies available to the Landlord under the lease"
            },
            {
              "key": "Termination of Lease",
              "value": "Landlord may terminate the lease by written notice; Tenant must surrender the Premises and compensate for unpaid Rent and losses, computed based on the 'worth at the time of award' method including default interest or discounted at the Fed Bank of San Francisco rate plus 1%"
            },
            {
              "key": "Compensation for Rent Loss",
              "value": "Includes unpaid Rent earned up to termination, amounts for future Rent loss that could not be avoided, and additional amounts to cover all detriment due to Tenant's non-performance (including Section 19(a) amounts)"
            },
            {
              "key": "Termination of Possession",
              "value": "Landlord may also terminate Tenant's right to possession without terminating the Lease; Tenant must pay accrued Rent, other sums per Section 19(a), and future net sums diminished by reletting proceeds"
            },
            {
              "key": "Interest Computation",
              "value": "The 'worth at the time of award' is determined by applying interest at the Default Rate (or discounting at the relevant Federal Reserve rate plus 1%)"
            },
            {
              "key": "Waiver of Redemption Rights",
              "value": "Tenant waives all rights to redeem occupancy by court order or legal process after termination"
            },
            {
              "key": "Forbearance Clause",
              "value": "Forbearance by Landlord in enforcing remedies does not constitute a waiver of Tenant's default"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 234,
          "title": "Section 18(b) Lease Enforcement Provisions",
          "data": [
            {
              "key": "Removal of Tenant Property",
              "value": "Landlord may remove all Tenant’s property from the Premises and store it at Tenant’s expense without liability for loss or damage."
            },
            {
              "key": "Reletting Terms",
              "value": "Landlord is not obligated to spend funds on reletting, may set new leasing terms at its discretion, and need not accept Tenant-proposed buyers unless they meet leasing criteria."
            },
            {
              "key": "Tenant's Ongoing Liability",
              "value": "Tenant remains liable for rent and other obligations even after reentry or property removal; any excess consideration from reletting is not applied to rent."
            },
            {
              "key": "Legal Remedies and Attorney Fees",
              "value": "Landlord may pursue legal action on behalf of Tenant for collection of amounts due, including recovery of attorney fees and court costs as determined by the court."
            },
            {
              "key": "Alteration of Locks",
              "value": "Landlord may alter locks or access control devices to restrict Tenant’s access without obligation to provide a new key."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 235,
          "title": "Lease Default Remedies and Legal Costs",
          "data": [
            {
              "key": "Attorney Fees",
              "value": "Landlord is entitled to recover reasonable attorneys’ fees incurred for preparing and serving default notices and consultations."
            },
            {
              "key": "Court Costs",
              "value": "Costs including court costs incurred in obtaining possession of the Premises and related legal actions."
            },
            {
              "key": "Remedies Provided",
              "value": "Upon an Event of Default, Tenant must pay all actual costs incurred by Landlord, including expenses for tenant property removal, repairs, restoration, reletting, and enforcement of lease terms."
            },
            {
              "key": "Non-Waiver & Cumulative Remedies",
              "value": "Landlord’s acceptance of rent or partial payments does not constitute a waiver of rights; remedies are cumulative and may be pursued concurrently."
            },
            {
              "key": "Jurisdiction",
              "value": "Federal and state courts of the state where the Premises are located have exclusive jurisdiction over matters related to this Lease."
            },
            {
              "key": "Payment Application",
              "value": "Tenant waives the right to designate payment allocation; Landlord may apply payments as it sees fit."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 238,
          "title": "Tenant's Obligations Regarding Hazardous Materials",
          "data": [
            {
              "key": "Access",
              "value": "Landlord may enter the Premises at reasonable hours to perform repairs, show to prospective purchasers, lenders, or tenants."
            },
            {
              "key": "Hazardous Materials Disclosure Certificate",
              "value": "Tenant must deliver an executed initial Hazardous Materials Disclosure Certificate to the Landlord."
            },
            {
              "key": "Covenant",
              "value": "Tenant assures the information in the Certificate is true and correct."
            },
            {
              "key": "Annual Certificate Requirement",
              "value": "Tenant must provide an updated HazMat Certificate upon Landlord's demand."
            },
            {
              "key": "Landlord's Responsibility",
              "value": "Landlord is responsible for removal and remediation of existing Hazardous Materials as of Lease Date."
            },
            {
              "key": "Tenant's Responsibility",
              "value": "Tenant is responsible for any Hazardous Materials they bring onto the Premises."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 241,
          "title": "Litigation Waiver and Financial Reporting Requirements",
          "data": [
            {
              "key": "Litigation Waiver",
              "value": "Written consent to waiver of trial by jury, includes claims related to lease."
            },
            {
              "key": "Governing Law",
              "value": "Lease governed by laws of the state where the premises are located."
            },
            {
              "key": "Recording",
              "value": "Tenant cannot record lease without Landlord's consent."
            },
            {
              "key": "Joint and Several Liability",
              "value": "Multiple parties as tenants are jointly and severally liable."
            },
            {
              "key": "Financial Reports Requirement",
              "value": "Tenant must provide audited financial statements or other financial information upon Landlord's request."
            },
            {
              "key": "Confidentiality of Financial Statements",
              "value": "Landlord must keep financial statements confidential except under specified conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 242,
          "title": "Confidentiality and Landlord’s Fees Terms",
          "data": [
            {
              "key": "Landlord’s Fees",
              "value": "Tenant will reimburse Landlord for reasonable, out-of-pocket costs for actions not required and any consents requested."
            },
            {
              "key": "Reimbursement Limit",
              "value": "Tenant’s obligation shall not exceed $5,000 for each request unless material modifications are needed."
            },
            {
              "key": "Telecommunications Services",
              "value": "Tenant cannot access the Building for telecommunications without Landlord’s written consent."
            },
            {
              "key": "Telecommunications Compliance",
              "value": "All providers must comply with Building rules and applicable laws."
            },
            {
              "key": "Anti-Terrorism Laws",
              "value": "Tenant must not violate laws related to terrorism or money laundering during the Term."
            },
            {
              "key": "Prohibited Person Definition",
              "value": "Defined as persons or entities listed under Anti-Terrorism measures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 243,
          "title": "Lease Compliance and Legal Provisions",
          "data": [
            {
              "key": "ExecutiveOrder",
              "value": "Subject to the provisions of the Executive Order and related regulatory directives"
            },
            {
              "key": "SanctionsAndAntiTerrorism",
              "value": "Prohibits dealing with persons or entities listed in the Annex or under Anti-Terrorism Laws, including the USA Patriot Act"
            },
            {
              "key": "OFACDesignation",
              "value": "Reference to specially designated nationals and blocked persons per the U.S. Treasury Department’s OFAC list"
            },
            {
              "key": "CertificationRequirement",
              "value": "Tenant must provide written certification evidencing compliance with these regulatory provisions within 10 days upon request"
            },
            {
              "key": "Confidentiality",
              "value": "Lease terms are confidential and require Landlord’s written consent for any disclosure"
            },
            {
              "key": "AuthorityRepresentation",
              "value": "Tenant represents it is duly formed, qualified to do business, and that signatories have appropriate authority"
            },
            {
              "key": "AdjacentExcavation",
              "value": "If adjacent excavation occurs, the Tenant must allow access to protect the Building without claims for damages"
            },
            {
              "key": "OnSiteRefueling",
              "value": "Refueling on the Premises requires prior written consent from Landlord and adherence to applicable laws and regulations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 244,
          "title": "Environmental Compliance and Spill Management Requirements",
          "data": [
            {
              "key": "Regulation Reference",
              "value": "40 CFR Part 112 (SPCC)"
            },
            {
              "key": "Insurance Requirements",
              "value": "Environmental clean-up and liability insurance and pollution liability insurance with a minimum of $2,000,000 per occurrence"
            },
            {
              "key": "Additional Insured Entities",
              "value": "Landlord, Landlord’s property management company, Invesco"
            },
            {
              "key": "Contractor Requirements",
              "value": "Contractors and subcontractors must maintain required insurance coverages and provide certificates prior to commencement of refueling activities"
            },
            {
              "key": "Spill Management Plan (SMP) Requirements",
              "value": "SMP must include fuel types/amounts, details on refueled equipment/vehicles, contractor names with contract copies, contractor insurance certificates for pollution liability, refueling schedule and location, list of containment supplies, and a contingency plan for spills"
            },
            {
              "key": "Refueling Conditions",
              "value": "Refueling must occur over diesel resistive substrate (e.g., concrete) with run-off control measures in accordance with SPCC and the approved SMP; must not jeopardize any stormwater permit"
            },
            {
              "key": "Notification Requirement",
              "value": "Tenant must immediately notify Landlord in writing in the event of any spill related to Tenant or its contractors"
            },
            {
              "key": "Liability Provisions",
              "value": "Outlines obligations including removal and remedial actions, losses, claims, suits, judgments, liabilities, penalties, and damages (including consequential and punitive damages)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 246,
          "title": "Consent to Electronic Signature Technology in Lease Agreement",
          "data": [
            {
              "key": "Parties Consent",
              "value": "The parties consent to the use of electronic signature technology."
            },
            {
              "key": "Validity of Electronic Signatures",
              "value": "Electronic signatures will be treated the same as hand-written signatures for validity and enforceability."
            },
            {
              "key": "Method of Signing",
              "value": "Signing electronically via DocuSign or similar technology is permitted."
            },
            {
              "key": "Acknowledgment of Electronic Signing",
              "value": "By clicking 'Sign', the party acknowledges signing electronically."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 254,
          "title": "Common Area Maintenance Costs Audit Provisions",
          "data": [
            {
              "key": "auditor agreement clauses",
              "value": "Landlord shall engage a third auditor if agreement cannot be reached between Tenant's auditor and Landlord’s auditor."
            },
            {
              "key": "rebates on overcharges",
              "value": "If overcharges are found, appropriate rebates will be made to Tenant."
            },
            {
              "key": "final findings",
              "value": "The third auditor will issue a final report determining which auditor's findings are valid."
            },
            {
              "key": "costs associated with audits",
              "value": "If Landlord overstated costs by more than 5%, they will pay audit costs and reimburse Tenant up to $7,500."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 261,
          "title": "Hazardous Materials Disclosure Requirements",
          "data": [
            {
              "key": "Lease Section",
              "value": "25(a)"
            },
            {
              "key": "Required Certificate",
              "value": "Hazardous Materials Disclosure Certificate"
            },
            {
              "key": "Documentation Requirements",
              "value": "Inventory of Hazardous Materials, Permits, SDS, Hazardous Waste Manifests, Hazardous Materials Business Plan"
            },
            {
              "key": "Regulatory Compliance",
              "value": "California Health & Safety Code Sections 25500 et seq."
            },
            {
              "key": "Landlord Notice Requirements",
              "value": "Deliver documentation upon demand or any Material Change in inventory"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 262,
          "title": "Contingency Plans and Emergency Procedures",
          "data": [
            {
              "key": "Contingency Plans Requirement",
              "value": "Landlord may prepare coordinated emergency response plan."
            },
            {
              "key": "Applicable Laws",
              "value": "California Code of Regulations, Title 22, Section 66264.50 and 66264.70."
            },
            {
              "key": "Reports to California Department",
              "value": "Biennial or other periodic reports on Hazardous Materials."
            },
            {
              "key": "Permit Requirements",
              "value": "Copies of industrial wastewater discharge permits."
            },
            {
              "key": "FDA and Regulatory Submissions",
              "value": "Reports filed with FDA related to Biohazardous Materials."
            },
            {
              "key": "Additional Information Requests",
              "value": "Landlord may request additional information regarding compliance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 263,
          "title": "Material Change and Hazardous Materials Indemnification",
          "data": [
            {
              "key": "Material Change Definition",
              "value": "Any change in the use, presence or Handling of Hazardous Materials by Tenant."
            },
            {
              "key": "Significant Effects",
              "value": "Expected to have a significant effect on the Premises or the Complex."
            },
            {
              "key": "Compliance Violations",
              "value": "Would violate compliance with any existing permits, licenses, registrations."
            },
            {
              "key": "Indemnification Responsibility",
              "value": "Tenant shall indemnify, defend and hold Landlord harmless from Environmental Damages."
            },
            {
              "key": "Notification Obligations",
              "value": "Tenant must notify Landlord of material claims relating to Hazardous Materials."
            },
            {
              "key": "Exclusion of Routine Spills",
              "value": "Tenant is not obligated to report routine spills handled without Environmental Damage."
            },
            {
              "key": "Landlord's Indemnification",
              "value": "Landlord must indemnify Tenant for Hazardous Materials present before Commencement Date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 264,
          "title": "Liabilities and Governmental Notices Related to Hazardous Materials",
          "data": [
            {
              "key": "assessments",
              "value": "Liabilities, costs, disbursements, expenses, or fees related to Hazardous Materials."
            },
            {
              "key": "responsibility",
              "value": "Landlord or Tenant responsibilities concerning Hazardous Materials before Tenant’s occupancy."
            },
            {
              "key": "negligence",
              "value": "Negligence or willful misconduct of Landlord regarding Hazardous Materials."
            },
            {
              "key": "governmental_notices",
              "value": "Tenant must provide Landlord with governmental authority notices regarding actual, threatened or alleged releases of Hazardous Materials."
            },
            {
              "key": "inspection",
              "value": "Landlord's rights to inspect handling of Hazardous Materials by Tenant."
            },
            {
              "key": "monitoring",
              "value": "Landlord's right to monitor Tenant's compliance at Tenant's cost regarding handling of Hazardous Materials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 266,
          "title": "Handling of Radioactive Materials and Hazardous Materials Provisions",
          "data": [
            {
              "key": "Tenant's Obligation Regarding Radioactive Materials",
              "value": "Provide Landlord with licenses or permits for handling radioactive materials and radiation protection programs."
            },
            {
              "key": "Compliance with Landlord's Rules",
              "value": "Tenant must comply with rules regarding radioactive materials issued by Landlord."
            },
            {
              "key": "Remediation and Clean-Up Requirements",
              "value": "Tenant must complete remediation/clean-up before lease expiration and provide a Closure Letter from governmental authority."
            },
            {
              "key": "Deemed Holdover Occupancy",
              "value": "Tenant's failure to remove hazardous materials may result in holdover occupancy without Landlord's consent."
            },
            {
              "key": "Survival of Obligations",
              "value": "Tenant's obligations under this section survive lease expiration or termination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 268,
          "title": "Building Rules and Regulations",
          "data": [
            {
              "key": "General Regulations",
              "value": "Sidewalks, doorways, vestibules, halls, stairways, and other similar areas shall not be obstructed by tenants."
            },
            {
              "key": "Plumbing Use",
              "value": "Plumbing, fixtures and appliances shall be used only for the purposes for which designed."
            },
            {
              "key": "Signage Restrictions",
              "value": "No signs, advertisements or notices shall be painted or affixed without written consent of Landlord."
            },
            {
              "key": "Door Locks",
              "value": "Landlord shall provide all door locks; tenants may not add locks without consent."
            },
            {
              "key": "Heavy Equipment Movement",
              "value": "Movement of furniture or bulky materials must be conducted under Landlord’s supervision."
            },
            {
              "key": "Weight Limitations",
              "value": "Landlord may prescribe weight limitations and locations for safes and heavy items."
            },
            {
              "key": "Corridor Usage",
              "value": "Corridor doors shall be kept closed; no birds or animals allowed besides seeing-eye dogs."
            },
            {
              "key": "Occupancy Restrictions",
              "value": "No portion of premises used as sleeping or lodging quarters."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 272,
          "title": "Ratification and Binding Effect of Lease Agreement",
          "data": [
            {
              "key": "Tenant",
              "value": "SENTI BIOSCIENCES, INC."
            },
            {
              "key": "Landlord",
              "value": "1430 HARBOR BAY PKWY LLC"
            },
            {
              "key": "Governing Law",
              "value": "Laws of the state in which the Premises are located"
            },
            {
              "key": "Obligations",
              "value": "Tenant confirms obligations under the Lease"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 274,
          "title": "Tenant Estoppel Certificate",
          "data": [
            {
              "key": "Summary",
              "value": "The document is an Exhibit I form of a Tenant Estoppel Certificate related to a lease agreement for premises in a research and development building. It summarizes key lease provisions (e.g. lease effective date, lease term, amendments, occupancy, and absence of transfer or subletting). Note: This document is contractual in nature and does not correspond directly to any of the predefined business report metadata categories. In the absence of a perfectly matching category, 'regulatory_litigation' is selected as a default placeholder."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 275,
          "title": "Estoppel Certificate – Lease Compliance",
          "data": [
            {
              "key": "Lease Payment Compliance",
              "value": "All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid when due."
            },
            {
              "key": "Landlord Obligations",
              "value": "All conditions required for the enforceability of the Lease by Landlord have been satisfied; Tenant is not aware of any default by Landlord."
            },
            {
              "key": "Tenant Default Notice",
              "value": "Tenant has not delivered any notice regarding a default by Landlord."
            },
            {
              "key": "Advance Rental Payment Limit",
              "value": "No rental has been paid more than 30 days in advance."
            },
            {
              "key": "Security Deposit Provision",
              "value": "No security deposit has been delivered except as provided in the Lease."
            },
            {
              "key": "Tenant Entity Status",
              "value": "If Tenant is a corporation, partnership or other business entity, it is duly formed and existing with proper authority to execute this certificate."
            },
            {
              "key": "Bankruptcy Actions",
              "value": "There are no actions pending against Tenant under any bankruptcy or similar laws."
            },
            {
              "key": "Hazardous Substances Usage",
              "value": "No hazardous substances have been used or stored in the Premises except as approved and in compliance with applicable laws."
            },
            {
              "key": "Tenant Improvement Allowances",
              "value": "All reimbursements and allowances due under the Lease in connection with tenant improvement work have been paid in full."
            },
            {
              "key": "Recipient Awareness",
              "value": "Tenant acknowledges that this Estoppel Certificate may be delivered to Landlord, its Mortgagee, or prospective mortgagee/purchaser, and relied on for disbursing loan advances or property acquisition."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 277,
          "title": "Tenant’s Rights and Arbitration Procedures",
          "data": [
            {
              "key": "Termination Conditions",
              "value": "Tenant's rights terminate under various conditions including lease termination, unauthorized assignment or subletting, failure to exercise options, and deterioration of financial condition."
            },
            {
              "key": "Arbitration Procedure",
              "value": "Describes the arbitration process for determining the Prevailing Rental Rate including submission of Estimates, selection of brokers, and binding determinations."
            },
            {
              "key": "Broker Qualifications",
              "value": "Brooks must have 10 years’ experience in leasing similar type properties in Alameda."
            },
            {
              "key": "Cost Sharing for Arbitrator",
              "value": "Costs of the Arbitrator are shared equally between Landlord and Tenant."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 284,
          "title": "Letter of Credit Transfer Instructions",
          "data": [
            {
              "key": "Facsimile Presentations",
              "value": "Permitted; Transmissions at (408) 496-2418 or (408) 969-6510"
            },
            {
              "key": "Telephone Advice",
              "value": "Call (408) 450-5001 or (408) 654-7176, Attention: GLOBAL TRADE FINANCE"
            },
            {
              "key": "Transferability",
              "value": "Letter of Credit is transferable in whole but not in part, one or more times, to a single beneficiary as transferee for the then available amount"
            },
            {
              "key": "Compliance",
              "value": "Transfers must comply with applicable law and regulation including U.S. Department of Treasury and U.S. Department of Commerce regulations"
            },
            {
              "key": "Transfer Fee",
              "value": "1% of the transfer amount (Minimum US $250.00); fee payment is not a condition to transfer"
            },
            {
              "key": "Evidence of Transfer",
              "value": "Either by endorsement on the reverse of the Letter of Credit (with original forwarded) or by issuing a replacement Letter of Credit on substantially the same terms"
            },
            {
              "key": "Payment Instruction",
              "value": "If instructions require transfer to an account with another bank, payment will be effected by FedWire to a U.S. regulated bank"
            },
            {
              "key": "Governing Rules",
              "value": "Subject to International Standby Practices (ISP98), ICC Publication No. 590"
            },
            {
              "key": "Issuer",
              "value": "SILICON VALLEY BANK"
            },
            {
              "key": "Authorized Signature",
              "value": "Present with signature block and reference '4'"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 289,
          "title": "Side Letter Agreement – Breach, Destruction, and Dispute Resolution Clauses",
          "data": [
            {
              "key": "Trigger Event Conditions",
              "value": "The agreement specifies that a breach—including failure to meet Section 10.3 terms, failure to achieve certain benchmarks, or non-exercise of an Option by BlueRock—constitutes a 'BlueRock Triggering Event'."
            },
            {
              "key": "Obligations upon Trigger Event",
              "value": "In the event of a BlueRock Triggering Event, BlueRock (and the counterparty) must promptly destroy all material, data, and results generated under the Agreement and certify the destruction in writing."
            },
            {
              "key": "Dispute Resolution",
              "value": "All disputes related to the Side Letter will be governed by the laws of the Commonwealth of Massachusetts, with no third-party rights conferred by the agreement."
            },
            {
              "key": "Execution",
              "value": "The Side Letter may be signed in multiple counterparts, each deemed an original, collectively forming one agreement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 292,
          "title": "Independent Contractor and Confidentiality Provisions",
          "data": [
            {
              "key": "Contractor Status",
              "value": "Advisor is designated as an independent contractor, not an employee or agent, and is responsible for his/her own taxes."
            },
            {
              "key": "Authority Limitations",
              "value": "Advisor has no authority to obligate the Company by contract or otherwise."
            },
            {
              "key": "Employee Benefits",
              "value": "Advisor is not eligible for any employee benefits; no tax deductions will be made from Advisor’s fees."
            },
            {
              "key": "Institutional Affiliation",
              "value": "Advisor is a professor at Massachusetts Institute of Technology and must comply with the Institute’s policies regarding consulting, conflicts of interest, and intellectual property."
            },
            {
              "key": "Confidentiality and Non-Disclosure",
              "value": "Advisor must maintain strict confidentiality regarding the Company’s proprietary information and any third party information, and is restricted from disclosing or using such data except as necessary for performing services."
            },
            {
              "key": "Indemnity Provision",
              "value": "Advisor agrees to indemnify the Company against losses arising from breaches of third-party agreements."
            },
            {
              "key": "Conflict of Interest and Third-Party Obligations",
              "value": "Advisor must notify the Company of any conflicts arising from obligations to the Institute or other third parties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 293,
          "title": "Контракт: Конфиденциальность, Правовая Защита и Интеллектуальная Собственность",
          "data": [
            {
              "key": "HIPAA Compliance",
              "value": "Advisor and Company must comply with HIPAA regulations regarding the privacy and security of Protected Health Information."
            },
            {
              "key": "Confidentiality Obligations",
              "value": "Advisor is required to maintain the confidentiality of medical and financial records and may only disclose such records as required by law, court order, or with Company approval."
            },
            {
              "key": "Trade Secret Disclosure Exception",
              "value": "Advisor will not be held criminally or civilly liable under trade secret law when disclosing trade secrets under specified conditions (e.g., disclosure to government officials or in sealed legal filings)."
            },
            {
              "key": "Intellectual Property Rights",
              "value": "All inventions, discoveries and related intellectual property developed by the Advisor during the term of the Agreement belong exclusively to the Company, with an assignment of rights and a power of attorney granted to the Company."
            },
            {
              "key": "Noncompetition Clause",
              "value": "During the term of the Agreement, Advisor must not engage in any competitive commercial activities without prior consent from the Company's Board of Directors, with certain exceptions for academic or non-commercial work."
            },
            {
              "key": "Non-solicitation of Employees",
              "value": "During the Agreement and for one year thereafter, Advisor may not recruit or induce any employee of the Company to leave their employment."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 83,
          "title": "Supply Chain and Manufacturing Risks Overview",
          "data": [
            {
              "key": "Risk Factors Identified",
              "value": "Discusses potential supply chain failures and delays due to the COVID-19 pandemic and other events. Highlights issues such as limited on-site staff availability, shortages of qualified personnel, and key contractors impacting production and delivery of laboratory equipment, materials, and supplies."
            },
            {
              "key": "Impact on Manufacturing",
              "value": "Potential delays in manufacturing processes, production halts, and requirement to alter manufacturing methods which may lead to additional costs, extra clinical trials, and setbacks in commercialization plans."
            },
            {
              "key": "Workforce Concerns",
              "value": "Mentions workforce reductions, employee absenteeism, and attrition as contributing factors to supply chain and production challenges."
            },
            {
              "key": "Material and Equipment Availability",
              "value": "Emphasizes risk of inability to obtain necessary rights, materials, or supplies on commercially reasonable terms, possibly affecting product candidate development and market launch."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 14,
          "title": "Smart Sensor Proof-of-Concept and Applications",
          "data": [
            {
              "key": "Gene Circuits Applicability",
              "value": "Broad applicability across treatment modalities and disease areas."
            },
            {
              "key": "Treatment Modalities",
              "value": "Includes NK cells, T cells, TILs, stem cells, in vivo gene therapy and mRNA."
            },
            {
              "key": "Disease Areas",
              "value": "Address aspects of disease biology in oncology, immunology, genetic diseases, neurology, cardiology, metabolic diseases, ophthalmology, and regenerative medicine."
            },
            {
              "key": "Chart Title",
              "value": "Smart Sensor Promotor Data"
            },
            {
              "key": "Chart Type",
              "value": "scatter plot"
            },
            {
              "key": "Key Features",
              "value": "Iterative performance optimization, constitutive control promoter, maximum performance over CAG promoter."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 38,
          "title": "BlueRock Collaboration Agreement",
          "data": [
            {
              "key": "Development Focus",
              "value": "cell therapy products containing applicable gene circuits"
            },
            {
              "key": "Obligation",
              "value": "work exclusively with BlueRock"
            },
            {
              "key": "Collaboration Duration",
              "value": "until specified negotiations or option exercise periods end"
            },
            {
              "key": "Termination Conditions",
              "value": "material breach, bankruptcy or insolvency, patent validity challenges"
            },
            {
              "key": "Expiration Date",
              "value": "no later than January 2026"
            },
            {
              "key": "Funding Source",
              "value": "National Cancer Institute (NCI)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 54,
          "title": "Regulatory Approval and Market Exclusivity for Orphan Medicinal Products",
          "data": [
            {
              "key": "Clinical Trial Application (CTA)",
              "value": "Must be submitted to national health authority and ethics committee prior to clinical studies."
            },
            {
              "key": "Market Exclusivity in EU",
              "value": "New chemical entities receive eight years of data exclusivity and an additional two years of market exclusivity."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "Ten years of market exclusivity for orphan medicinal products."
            },
            {
              "key": "Criteria for Orphan Status",
              "value": "Product intended for life-threatening or chronically debilitating conditions affecting fewer than five in 10,000 persons."
            },
            {
              "key": "Financial Incentives",
              "value": "Reduction of fees for orphan drug designation."
            },
            {
              "key": "Market Exclusivity Reduction",
              "value": "May be reduced to six years if product no longer meets orphan designation criteria."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 267,
          "title": "Hazardous Materials Laws and Compliance",
          "data": [
            {
              "key": "Laws",
              "value": "Hazardous Materials Laws"
            },
            {
              "key": "Conditions",
              "value": "Environmental Conditions"
            },
            {
              "key": "Compliance",
              "value": "Compliance with federal, state, or local laws"
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 20,
    "EUR": 20,
    "AUD": 9,
    "CAD": 3
  },
  "sha1": "6159f86f38ec4f82453d99a01c22f1847de133c6"
}